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ABSTRACT 
Adoptive cell transfer of T cell receptor (TCR) gene-modified T cells targeting 
specific tumor antigens is currently in clinical trials for patients with advanced 
malignancies. Despite the clinical responses, there are still hurdles to be overcome in 
achieving an effective and safe therapy. One of the limitations in the success of this 
type of therapy is the potential for cross-reactivity and unanticipated off-target reactivity 
which could lead to autoimmunity. Adverse events encompassing these “off-target, off-
tumor” cross-reactivities leading to autoimmunity have been seen in patients in different 
clinical trials. Here, we demonstrate a novel approach to improve antigen specific 
reactivity and to reduce off-target cross-reactivity by modifying the TCR using structure-
guided mutations. This strategy combines mutations that alter the TCR to enhance 
antigen specificity with mutations that alter the TCR/MHC contact residues to reduce 
TCR binding with the MHC. Using the DMF5 TCR that targets the melanoma associated 
antigen MART-1, we examined HLA-A2 restricted cross-reactivity by measuring the 
polyfunctional T cell response by T cells transduced with strategically mutated DMF5 
TCRs against a panel of MART-1 homologs. We further investigated how structure-
guided mutations in the DMF5 TCR affected tumor lysis, processed antigen recognition, 
and 3D vs. 2D affinity. We demonstrate that while modified DMF5 TCRs can enhance 
on-target specificity, they can also lead to unexpected off-target cross-reactivity. Our 
data fully supports the notion that affinity is not always an accurate predictor of T cell 
function and cross reactivity. Moreover, we highlight the importance of rigorous pre- 
 xxi 
clinical testing to examine the potential for new specificities and reactivities of modified 
TCRs. By determining how various TCR mutations can alter functional T cell 
phenotypes and on-target responses, we can gain a better understanding of the biology 
of the TCR/pMHC (peptide-MHC) interface and thus how to maximize the efficacy and 
safety of TCRs to be used in gene-modified T cell in adoptive cell transfer. 
 1 
CHAPTER ONE 
REVIEW OF LITERATURE 
Introduction 
T cells play a vital role in adaptive immunity in fighting microbial and viral 
infections as well as malignancies. The initiation and the specificity of T cell immunity 
lies within the T cell receptor (TCR). Consequently, understanding the different 
mechanisms associated with TCR antigen recognition, T cell activation, and T cell 
function that are involved in the adaptive immune response is critical for the success of 
treatments or therapies that utilize T cells. 
Over recent years, immunotherapy has become increasing prevalent and 
promising as an instrument to utilize the power of the immune system to fight cancer 
and disease. Even though the adaptive immune response is capable of recognizing 
infections and malignancies, the response is not always efficient enough for clearance. 
Some of the advances in cancer immunotherapy are the result of a variety of different 
strategies focused on enhancing the immune response via tumor infiltrating 
lymphocytes (TILs), gene-modified T cells, cytokines, chemokines, mono-clonal 
antibodies (mAb), and vaccines [1]. Adoptive T cell transfer therapy has been shown to 
have clinical success in treating melanoma and other malignancies [1]. This process 
commonly involves isolating TILs, ex vivo expansion, and subsequent administration 
back into the patient [2]. Albeit, the isolation and further expansion of these TILs can be 
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difficult and is not always possible in a wide variety of cancers [3].  One alternative 
strategy that has been clinically successful is the use of genetically modified T cells for 
adoptive cell transfer. The transduction of T cells or NK (natural killer) cells with 
chimeric antigen receptors (CARs) or TCRs has demonstrated the ability to redirect the 
specificity of these cells to recognize tumor and/or viral associated antigens of choice 
[4]. It is possible to isolate tumor reactive T cell clones from TIL or peripheral blood 
lymphocyte (PBL) derived T cells and further identify and clone the TCR genes that 
mediate recognition of tumor associated antigens or viral antigens. In this dissertation 
we will exclusively study TCR biology by using a retroviral vector encoding TCR genes 
to redirect the specificity of T cells to recognize a specific tumor antigen. TCR gene-
modified T cells for adoptive T cell transfer is a form of a more personalized medicine, 
since its procedure is unique for each individual patient. As personalized medicine is 
becoming a more attractive treatment strategy and the methodologies used in this 
therapy can be applied to a variety of cancers and viral infections, it is imperative to 
concentrate on making this therapy as clinically efficient and safe as possible.  
 One of the challenges in using TCR gene-modified T cells that target self-
antigens for therapy, is that the TCRs generally harbor a lower affinity. This is a result of 
negative selection in the thymus during development. Negative selection is critical in 
order to eliminate potentially autoreactive T cells. Strategies to enhance TCR affinity 
commonly include yeast and phage display. Affinity enhancement through random TCR 
mutation can allow for potential unpredicted cross-reactivity. Adverse events, even 
patient deaths, have been reported where affinity enhanced TCRs were used [5, 6]. 
Therefore, there is a rising concern in the field in regards to the safety associated with 
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using TCRs that target self-antigens, and this concern is even further amplified when 
TCR modifications come in to play. In this dissertation, we have developed a novel 
strategy to modify the TCR in order to enhance antigen specificity while simultaneously 
reducing potential cross-reactivity. The structural explanation and further implications on 
T cell function and therapeutic efficacy of TCR gene-modified T cells will be discussed 
in this dissertation.  
TCR Diversity 
 This dissertation focuses on TCR gene-modified T cells, therefore, it is important 
to understand T cell development, T cell biology, and T cell genetics. The initiation and 
the specificity of T cell immunity lies within the TCR. TCR diversity is imperative for 
responses against a large number and a diverse group of antigens. Consequently, TCR 
diversity allows for an expansive immune response. TCRs are heterodimers expressed 
on the T cell surface as either αβ or γδ heterodimers. The extensive repertoire of TCRs 
is a result of somatic gene rearrangement of the TCR gene loci to allow for recognition 
of roughly 1018 epitopes [7]. The TCR gene segments are comprised of the following 
regions: variable (V), diversity (D), joining (J), and constant (C). Only the TCR beta and 
delta chains contains the D region [8]. V(D)J recombination occurs in the thymus and is 
vital for the generation TCRs with diverse recognition. The process of recombination is 
site-specific and occurs between TCR gene segments that are flanked by recombination 
signal (RS) sequences. Recombination activating genes-1 and -2 (RAG-1 and RAG-2) 
bind to the RS sequences and make single strand nicks in the DNA to initiate 
recombination. First, D-J gene rearrangements occur in the TCR beta or delta chain, 
followed by V-DJ gene rearrangements [9]. The TCR beta chain will assemble with the 
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pre-T alpha chain to form a pre-TCR. The TCR alpha chain is subsequently rearranged. 
Specifically, V-J gene rearrangements occur and are mediated by RAG-1 and RAG-2 
[10]. During recombination, diversity is also enhanced at junctional regions via the 
incorporation of “P” nucleotides and “N” nucleotides and deletion of nucleotides [11-13]. 
Nonhomologous DNA end-joining (NHEJ) proteins function to then join the rearranged 
gene fragments [9, 14]. In summary, this recombination is essential for the generation of 
a large and diverse TCR repertoire in order to allow for the recognition of many 
pathogens. 
T cell Development 
T cells arise from hematopoietic stems cell progenitors derived from the bone 
marrow that home to the thymus. Commitment to the T cell lineage occurs upon Notch 
signaling [15]. This is critical, as mice generated with neonatally induced loss of Notch1 
exhibited austere deficiency in thymocyte development [16]. For these studies we focus 
only on the αβ TCR and thus, we will further describe T cell development and T cell 
function in regards to the αβ TCR. T cells begin as TCR-, CD4-, and CD8- and are 
therefore termed double negative (DN). CD4 and CD8 are co-receptors are found on 
the surface of T cells and they play an important role in T cell activation. CD4 and CD8 
will be described in more detail in a later section. There are four differentiation stages 
which are classified by various markers on the T cell surface. In the stages DN2 through 
DN4, the developing T cell expresses a pre-TCR [17]. This pre-TCR consists of a fully 
rearranged TCR beta chain and a non-rearranged pre-TCR alpha chain in association 
with the CD3 signaling complex. The pre-TCR induces T cell survival, expansion, and 
differentiation. The pre-TCR also functions to control allelic exclusion of the TCR beta 
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locus as well as permitting TCR alpha chain rearrangement [18, 19]. With a fully 
rearranged αβ TCR on the T cell surface, the T cell becomes double positive (DP), 
expressing both CD4 and CD8 co-receptors, and will move onto the next step in T cell 
development [17].  
 The next step in T cell development consists of positive and negative selection of 
the T cells, which occurs in the thymic cortex and medullar, respectively. The TCR 
expressed on a T cell recognizes peptide-MHC complexes on stromal or dendritic cells. 
If there is no, or weak, recognition by the TCR of MHC and self-antigen, death by 
neglect will occur. If the TCR binds too strongly to the MHC and self-antigen, the T cell 
is negatively selected and apoptosis occurs [17]. High affinity TCRs can result in 
autoreactive T cells and autoimmunity. Thus, negative selection serves to avoid 
potential autoimmunity and to establish central tolerance. The TCR must recognize self-
antigen in the context of MHC via a weak interaction to be positively selected [17]. 
However, it is critical that non-thymus related antigens are presented in the thymus to 
prevent autoimmunity in other tissues. The transcription factor encoded by the 
autoimmune regulator (AIRE) gene has been identified and is critical for the expression 
of other tissue-restricted antigens [20-23]. Mutations in the human AIRE gene can result 
in multiple different autoimmune diseases [24-26]. Therefore, AIRE is important for 
promoting negative selection of T cells with TCR specific for peripheral antigens. 
Following positive and negative selection, T cells migrate to the medulla and become 
single positive, expressing either the CD4 or CD8 co-receptor, depending upon the 
initial TCR signal [27]. Upon selection, these T cells will migrate into the periphery to 
elicit an immune response. How TCRs recognize numerous antigens, both self and non-
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self, is discussed in a later section. First, it is important to understand how a TCR 
recognizes its ligand to initiate T cell activation. 
MHC Restriction 
 In 1974, Peter Doherty and Rolf Zinkernagel demonstrated the concept of MHC 
restriction where T cell activation required two concurrent factors, foreign antigen in the 
context of self-MHC [28]. It was later determined through the crystallization of HLA-A2 
by Bjorkman and colleagues, that the MHC presented peptides [29, 30]. This has since 
been well appreciated as a hallmark in T cell-mediated immunity, as well a unique 
receptor-ligand interaction. Accordingly, two models have been proposed regarding the 
drivers of the MHC restriction of TCRs.  
The germline-encoded model suggests the TCR genes have co-evolved with the 
MHC and thus, are selected for inherent motifs important for recognition of the MHC 
molecules [31]. This model theorizes that multiple “interaction codons” exist and are 
evolutionarily conserved in the TCR V region and MHC molecules to drive their 
interaction [32]. The second model, the selection model, suggests that positive selection 
during development in the thymus imposes MHC reactivity, not intrinsic reactivity to 
MHC [33]. Specifically, this model suggests MHC restriction is driven by CD4 or CD8 
co-receptor binding to the MHC for initiation of TCR signaling through localization of Lck 
[34, 35]. Structural and functional studies have provided evidence for both of these 
models and do not exclude the possibility for either. 
 There are a few pieces of evidence that support the notion that TCRs have 
evolved to intrinsically recognize MHC molecules. First, TCR complementarity-
determining regions (CDRs) are more evolutionarily conserved among species than 
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immunoglobulin [36]. CDRs are regions of the TCR, specifically in the variable region, 
that bind pMHC. Studies examining TCR/pMHC crystal structures have revealed 
evolutionarily conserved residues in the TCR V genes that contact MHC. Results 
concluded that TCRs frequently utilize amino acids at positions 28, 29, and 31 of the 
CDR1α chain, positions 50, 51, and 52 of the CDR2α chain, positions 28 and 29 of the 
CDR1β chain, and position 48 of the CDR2β chain to bind the MHC molecule. For 
example, position 31 in the TCR CDR1α chain frequently binds at position 155 in the α2 
helix of MHC class I or position 70 in the β helix of MHC class II [37]. Also, around 40% 
of human and mouse TCRs have a tyrosine or phenylalanine at position 31 in the TCR 
alpha chain [37]. The most conserved residue in published TCR structures is a serine at 
position 51 in the CDR2α chain. This residue makes contacts with the conserved 
residues at positions 158 and 151 in the MHC class I α helix [38, 39]. One last example 
in the TCR alpha chain is position 50 (a tyrosine in 16% of sequenced TCRs) in the 
CDR2 region. Residues at this TCR position contact position 158 of MHC class I or 
position 73 of the β helix in MHC class II [37]. In the TCR beta chain, a tyrosine or 
asparagine at position 29 in the CDR1β often contacts the MHC class I α1 helix [37]. 
Most notable in the TCR beta chain is a conserved tyrosine at position 48 in the CDR2β 
that contacts the MHC class I α1 helix. This residue appears to be critical for anchoring 
the TCR to the MHC [37, 40]. There are numerous other specific examples of 
conserved residues in TCRs that frequently contact residues in the MHC. Lastly, up to 
30% of TCRs display intrinsic reactivity for MHC before completing positive and 
negative selection in the thymus [41]. In summary, numerous examples of conserved 
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interactions between TCRs and the MHC molecule suggests that TCRs have evolved to 
intrinsically recognize MHC molecules. 
 Another concept that supports the germ-line encoded model is the fact that TCRs 
generally bind pMHC in the same angled orientation across the MHC. Specifically, the 
TCR alpha chain lies over the α2 helix or β helix in MHC class I or II, respectively, and 
the TCR beta chain lies over the α1 or α helix of MHC class I or II, respectively [41]. 
Furthermore, the pivot point of the TCR centered over the peptide on the MHC is 
generally the same. In MHC class I, this is positions 4 through 6 of the peptide versus 
position 5 of the peptide in MHC class II [37]. If recognition of MHC was due to positive 
selection (hypothesis of the selection model) you might question why the orientation is 
not commonly reversed. It has been proposed that conserved residues in the CDR1 and 
CDR2 regions of the TCR are responsible for determining the angle and orientation of 
the TCR on pMHC, because these conserved interactions occur diagonally and 
opposite of each other on the helices [37]. In summary, there are numerous features of 
the TCR/pMHC interaction that suggest TCRs have evolved to intrinsically recognize 
MHC molecules. 
 Conversely, there is evidence that also suggests TCRs have not co-evolved to 
recognize the MHC molecules. First, TCR genes and MHC genes are found on different 
chromosomes, and no mechanism appears to control co-expression of the proteins [37]. 
Furthermore, studies have demonstrated cases of antigen recognition in a MHC 
independent manner [42, 43]. In mice, the deletion of MHC class I, MHC class II, CD4, 
and CD8 resulted in the expression of TCRs with the ability to recognize epitopes in an 
MHC independent manner [33]. Lastly, examples of reversed docking of the TCR over 
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the MHC has been reported [44, 45]. Collectively, studies that analyzed the TCR/pMHC 
crystal structure and the pre-selection TCR repertoire have resulted in conclusions that 
provided evidence to support both the germline-encoded model and the selection model 
for MHC restriction by TCRs. While the concept of MHC restriction is fundamental in 
immunology, it is also important to understand how antigen is associated with the MHC 
molecule in a process called antigen presentation. 
Antigen Presentation 
Activation of a T cell requires the engagement of the TCR with peptide in the 
context of either MHC class I or MHC class II. MHC class I is expressed on all 
nucleated cells, while MHC class II expression is limited to antigen presenting cells 
(APCs) such as dendritic cells, macrophages, or B cells. The MHC class I α chain, MHC 
class II α chain, and MHC class II β chains are each encoded by three genes in 
humans. The classical MHC genes include HLA-A, -B, and -C for MHC class I and HLA-
DR, -DQ, and -DP for MHC class II [46]. MHC is inherited as a haplotype from each 
parent. Thus, two siblings have a 50% chance of sharing one haplotype, and a 25% 
chance of being genotypically identical [47]. An exception to this is the possibility of 
recombination [48]. The two inherited MHC alleles are co-dominantly expressed [49]. 
MHC genes are extremely polymorphic, with humans having over 800 MHC class I and 
over 600 MHC class II alleles [50]. MHC genetic variation is proposed to be important 
for fighting pathogens and overall survival and fitness [51-53]. This polymorphism allows 
for genetic variation within the MHC region that binds antigen, known as the peptide 
binding groove, and thus, affects the potential peptide presentation [54, 55]. In 
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summary, the extremely polymorphic and co-dominantly expressed MHC genes, are 
critical for the activation of a T cell-mediated immune response. 
Peptides presented in the context of the MHC class I molecule and the MHC 
class II molecule are derived from two distinct proteolytic mechanisms [46]. For MHC 
class I peptide binding, proteins in the cytoplasm undergo degradation by the 
proteasome and are transported to the endoplasmic reticulum (ER) by the transporter 
associated with antigen processing protein (TAP). Peptides in the ER are loaded onto 
the MHC class I molecule in the peptide loading complex and then the complex is 
transported through the Golgi to the cell surface [46, 56]. Alternatively, peptides 
presented on MHC class II are generally exogenous antigens from outside the cell that 
are endocytosed. These exogenous antigens are delivered to late endosomes and are 
processed by cathepsins. At this point, the MHC class II protein and the chaperone 
HLA-DM protein have passed through the Golgi and into the late endosome [46]. The 
class II-associated invariant chain peptide (CLIP) plays an important role in stabilizing 
the peptide free complex, but must be removed to allow peptide loading [57, 58]. 
Peptides are loaded onto the MHC by HLA-DM and subsequently transported to the cell 
surface [46]. In summary, antigen presentation occurs via two distinct pathways for 
MHC class I and MHC class II. 
 In these studies we focus on TCRs that recognize peptides in the context of MHC 
class I. Therefore, for the remainder of this dissertation, we will focus exclusively on 
peptides presented in the context of the MHC class I molecule. MHC class I molecules 
are comprised of an alpha chain (three extracellular domains - α1, α2, and α3) that is 
non-covalently associated with β2 microglobulin. The alpha chain is commonly referred 
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to as the heavy chain and the β2 microglobulin is commonly referred to as the light 
chain. The β2 microglobulin lies next to the α3 domain and under the α1 domain [59]. 
The peptide binding groove is formed by the α1 and α2 domains. These regions are 
highly polymorphic to allow for the allele specific peptide presentation [60, 61]. The 
membrane-proximal α3 domain is the binding site for the CD8 co-receptor (conserved 
among all MHC class I molecules) [62, 63]. MHC class I generally presents peptides of 
eight to ten amino acids in length [64]. The interactions between the peptide and the 
MHC are dependent upon charge distribution, geometry, and hydrophobicity of the 
peptide binding groove [65]. In the heavy chain, six pockets (A-F pockets) in the MHC 
peptide binding groove exist to accommodate peptide side chains. Specifically, the B-
pocket accommodates the N-terminal anchor of the peptide and the F-pocket 
accommodates the C-terminal anchor of the peptide [65-67]. Most anchor residues are 
generally considered to be hydrophobic residues, but this can vary depending upon the 
MHC class I allele. It is possible that antigen presentation favors more hydrophobic 
regions of proteins, as a correlation has been observed between the immunogenicity 
and the hydrophobicity of peptides [68]. Previous studies suggested that the exposed 
hydrophobic domains in proteins significantly enhanced the rate of proteasomal 
degradation and MHC presentation [69]. This correlation between immunogenicity and 
hydrophobicity could be of importance when addressing the cross-reactivity of TCRs, a 
major topic in this dissertation, and will be discussed in future sections.  
pMHC Recognition by the TCR 
The TCR/pMHC interaction is like any other protein-protein interaction in that it is 
mainly governed by hydrogen bonds and charges, or van der Waals interactions [70]. 
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The individual van der Waals interactions are often weak, but in combination across the 
whole TCR/pMHC interface can equate to considerable binding energies. The specificity 
of the TCR/pMHC interaction is dependent upon, and can be enhanced by hydrogen 
bonds and salt bridges [71]. On a more macro level, these interactions between the 
TCR/pMHC are reliant on the CDRs of the TCR. As mentioned previously, CDRs are 
regions of the TCR, specifically in the variable region, that bind pMHC. In summary, the 
TCR/pMHC interaction consists of numerous van der Waals interactions and the TCR 
CDR loops are critical for recognition of the pMHC. 
The diversity of the TCR repertoire is critical for an inclusive T cell-mediated 
immune response. The diversity found in the TCR repertoire is due to the six CDR loops 
in the αβ TCR. CDR1, CDR2, and CDR3 loops are present in both the TCR alpha chain 
and the TCR beta chain. The CDR1 and CDR2 loops are germline-encoded versus the 
hypervariable CDR3 loop [8]. It has been estimated that 75-80% of the TCR/pMHC 
interaction occurs between the CDR1 and CDR2 regions of the TCR and the MHC 
helices [71]. As mentioned previously, TCRs generally bind the pMHC class I complex 
in the same angled orientation across the MHC α helices [37]. The Vα domain generally 
lies over the amino-end of the peptide and the α2 helix of MHC class I, whereas the Vβ 
domain generally lies over the carboxyl-end of the peptide and the α1 helix of MHC 
class I. More specifically, the most variable region of the TCR, the CDR3 region, is 
positioned in the center of the binding interface in order to make contact with the 
peptide. It was previously mentioned that antigen presentation favors hydrophobic 
regions of proteins. Furthermore, peptides with a hydrophobic core are favorable for 
TCRs to recognize because there is less precise geometry for the CDR loops to match 
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or engage [72]. The more conserved regions of the TCR, the CDR1 and CDR2 regions, 
are positioned over the tops of the MHC helices. However, it is still entirely possible for 
the CDR3 loops to contact the MHC and the CDR1 and CDR2 loops to contact the 
peptide [71, 73]. The TCR CDR loops are capable of conformational shifts to 
accommodate the pMHC via their intrinsic flexibility. This has been demonstrated by 
different TCR conformations in free and bound states, and with the same TCR binding 
different ligands [74-79]. In summary, the CDR loops of the TCR orient over the pMHC 
in a conserved manner and dictate any potential binding with the pMHC. TCR binding 
with the pMHC is the first step for inducing subsequent T cell activation. 
T cell Activation 
 T cell activation occurs when a TCR engages with a peptide in the context of the 
MHC molecule. This TCR/pMHC engagement causes a conformational change in the 
CD3 signaling complex [80, 81]. The CD3 signaling complex consists of ε, γ, δ, and ζ 
subunits. These subunits form a CD3εγ heterodimer, a CD3εδ heterodimer, and a 
CD3ζζ homodimer [82]. Upon antigen recognition via the TCR, the Src-family kinase, 
Lck, is recruited to the CD3 complex and phosphorylates the immunoreceptor tyrosine-
based activation motifs (ITAMS) of the CD3ζ chain [83]. The related Src kinase Fyn also 
can phosphorylate the CD3 ITAMs [84-88]. Zap-70 is then recruited to the 
phosphorylated ITAMS, is phosphorylated by Lck or itself, and propagates a cascade of 
downstream signaling pathways [81, 89, 90]. Through a manifold of signaling pathways, 
changes in gene expression occur and result in the production of cytokines and T cell 
proliferation, among other factors involved in a pro-inflammatory response. A majority of 
these changes in gene expression are initiated by the transcription factors NFAT, NF-
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κB, and AP-1 [83]. Overall, TCR/pMHC engagement induces T cell activation through 
the CD3 complex, signaling, and a pro-inflammatory response. 
CD4 and CD8 co-receptors can affect TCR/pMHC engagement and T cell 
activation. Although not always the case, it is typically appreciated that CD8+ T cells 
mediate a cytotoxic T cell response through recognition of peptide in the context of 
MHC class I, while CD4+ T cells mediate a helper T cell response through recognition of 
peptide in the context of MHC class II [80]. The CD4 and CD8 glycoproteins play an 
important role in T cell activation. These co-receptors function by stabilizing the 
interaction between the T cell and antigen presenting cell via the MHC on the antigen 
presenting cell [85]. This stabilization can also have an impact on the affinity of the 
interaction. Additionally, it has been demonstrated that the cytoplasmic tails of CD4 and 
CD8 help recruit Lck to the CD3 signaling complex [91, 92]. Therefore, CD4 and CD8 
are important co-receptors in T cell activation due to their dual functions.  
 The CD3 signaling complex is important for both TCR expression and T cell 
function. T cell activation and further TCR signaling in response to antigen recognition is 
essential to initiate an immune response. However, there are numerous factors within 
the TCR/pMHC interface that can impact the downstream T cell response. These 
factors and their potential impact on T cell function will be described in the next section. 
T cell Function 
 T cells play a critical role in the adaptive immune response and cell-mediated 
immunity. T cells differentiate into a variety of subtypes dependent upon their function. 
These subtypes commonly include: effector, cytotoxic, helper, memory, regulatory, 
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natural killer, mucosal associated invariant, and gamma delta. Cytotoxic and helper T 
cells are the focus of this dissertation and therefore, will be discussed in further detail. 
The two major T cell subtypes examined in this dissertation are helper T cells and 
cytotoxic, or killer T cells [93]. CD4+ T cells are generally classified as helper T cells 
although, but they have been shown to have cytotoxic abilities [94, 95]. Helper T cells 
are important for directing an effector response and immune cell differentiation [96]. 
Secreted cytokine patterns further categorize T helper cells into two major categories, 
either Th1 or Th2, but the production of these cytokines are not mutually exclusive [95]. 
Other categories include Th17, Th22, and Th9. Cytokines important to the studies 
completed in this dissertation and their basic function are shown in Table 1. Th1 
responses are important for cell-mediated immunity and are generally classified by IFN-
γ and TNF-α secretion. Th2 responses are important for humoral-mediated immunity 
and are generally classified by IL-4, IL-5, and IL-13 secretion [96]. IL-2 has been shown 
to be produced in both Th1 and Th2 responses [97]. In summary, T cells are capable of 
secreting numerous different cytokines that affect an immune response and the patterns 
of cytokine secretion can categorize T cells into various T cell subclasses. 
CD8+ T cells are generally classified as cytotoxic or killer T cells. These cells are 
important for the clearance of cells infected with intracellular pathogens as well as 
cancers [98]. Upon engaging with pMHC on a target cell, CD8+ T cells secrete large 
amounts of IFN-γ and TNF-α [99]. Secretory vesicles within the T cell, release perforin 
and granzyme which mediate death of the target cell [100]. Cell-mediated targeted cell 
death can also occur via the Fas/Fas ligand pathway.  
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Cytokine Function 
IFN-γ 
Activates T cells, NK cells, and macrophages, increase HLA 
expression on tumors, increases chemokine secretion [1, 96] 
IFN-α 
Involved in viral infections, increases HLA class I expression on 
tumors, enhances dendritic cell maturation [1, 101] 
TNF-α 
Initiates pro-inflammatory innate immune response, induces fever, 
cell death, and hemorrhagic necrosis of tumors [1, 102] 
IL-2 
Stimulates T cell proliferation, activation, and memory 
differentiation [97] 
IL-4 
Induces expansion of Th2 cells, activates B cells, enhances IgG 
and IgE production [96, 103] 
IL-5 
Stimulates antibody production, enhances proliferation of 
eosinophils, drives allergic type inflammatory responses [96, 104] 
IL-6 
Enhances antibody production and cytotoxic T cell differentiation, 
inhibit T regulatory differentiation [105-107] 
IL-12 
Induces expansion of Th1 cells, enhances CD8+ T cell activation, 
proliferation, and survival [1, 108] 
IL-13 
Facilitates B cell activation, promotes mucus production, mediator 
of allergic asthma, can inhibit production of pro-inflammatory 
cytokines [96, 109] 
IL-15 
Stimulates T cell and NK cell activation and proliferation, enhances 
survival of memory T cells [1, 110] 
IL-17 
Promotes recruitment and activation of innate cells, enhances B 
cell function, induces pro-inflammatory cytokine production [96, 
111] 
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Table 1. Cytokines Discussed in this Dissertation and their Basic Function.  
 
Herein, Fas ligand, expressed on activated T cells, binds to Fas expressed on the target 
cell and causes cell death through initiated signaling cascades [114]. Following antigen 
encounter, T cells can expand and differentiate into effector and memory cells [115]. 
Additional T cell subclasses are characterized by their level of differentiation. Naïve T 
cells differentiate into stem cell memory T cells; central memory T cells; effector 
memory T cells; and effector T cells. Memory and proliferation decrease with 
differentiation, while effector function increases with differentiation [93]. These T cell 
subsets are commonly distinguishable by different surface markers. In CD8+ T cells, 
these surface markers include L-selectin (CD62L), CCR-7, CD45RO, and CD45RA 
[116, 117]. Specifically, naïve T cells are CD62L+CCR7+CD45RA-CD45RO-, stem cell 
memory T cells are CD62L+CCR7+CD45RA+CD45RO+, central memory T cells are 
CD62L+CCR7+CD45RA-CD45RO+, effector memory T cells are CD62L-CCR7-CD45RA-
CD45RO+, and effector T cells are CD62L-CCR7-CD45RA+CD45RO- [93]. In CD4+ T 
cells, these surface markers include CD25, CD45RA, CD45RO, and CD127. 
Specifically, naïve T cells are CD25-CD127+CD45RA+CD45RO-, central memory T cells 
are CD25+CD127+CD45RA-CD45RO+, effector memory T cells are CD25-
CD127+CD45RA-CD45RO+, and effector T cells are CD25+CD127-CD45RA+/-CD45RO+/- 
IL-22 
Regulates autoantibody production, promotes tissue regeneration 
[96, 112] 
GM-CSF 
Stimulates stem cells to produce granulocytes, increases dendritic 
cell and macrophage activation [1, 113] 
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[93]. Many different factors have been described to be important in inducing memory 
differentiation such as strength and duration of TCR/pMHC interaction [118], help from 
CD4+ T cells and dendritic cells [119-121], natural killer group 2 member D (NKG2D) 
expression [122], and various cytokines and chemokines [123-127]. Memory T cells 
have been shown to rapidly re-express cytokines and lytic machinery. This hyper-
responsive state allows them to rapidly respond to re-encountered antigen, which differs 
from naïve T cells [128-130]. More recently, tissue resident memory T cells have been 
identified and are characterized by their non-circulating nature and remain in peripheral 
tissue sites [116]. Central memory T cells continuously recirculate throughout the blood 
and lymphoid organs, such as the spleen and lymph nodes. Conversely, effector 
memory T cells generally traffic to non-lymphoid tissues [131]. These different memory 
T cells and further, memory subtypes, have been implicated to be important in 
immunotherapy. For instance, CD4+ and CD8+ central memory T cell subsets have 
been demonstrated as superior to effector memory T cell subsets in terms of activation, 
expansion, and persistence in vivo [132-135]. Strategies for generating these T cell 
subsets include purification on surface markers and modulation with cytokines [93, 132, 
136, 137]. In conclusion, numerous T cell subsets exist and demonstrate unique 
functional phenotypes to elicit a critical role in adaptive immunity.  
TCR Affinity 
 Affinity is a significant factor that shapes an immune response both in regards to 
antibodies and TCRs. One way in which TCRs and antibodies differ, is the fact that 
antibodies can undergo affinity maturation. Affinity maturation is the process in which 
antibodies increase their affinity throughout an immune response [138, 139]. Gene 
rearrangement of immunoglobulin V, D, and J segments occurs during B cell 
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development to generate a repertoire of B cells that express diverse antigen receptors. 
However, upon recognition of antigen, B cells undergo clonal expansion and affinity 
maturation [140]. B cells traffic to the germinal centers of lymphoid follicles and where 
they undergo somatic hypermutation in the CDR regions of the immunoglobulin genes 
which introduces single nucleotide substitutions to enhance antibody affinity, sometimes 
up to 100-fold higher, reaching the nM-pM range [141]. In summary, this process is 
imperative for antibody-mediated responses, however, affinity maturation does not exist, 
or is not required for T cell responses via their TCR. 
 TCRs do not undergo affinity maturation, nonetheless, TCR affinity has been 
implicated to have importance in a T cell response. Affinity is generally reported by the 
dissociation constant, KD, a measurement used to describe the strength of the 
interaction between a TCR and a given pMHC complex [142]. Generally speaking, 
weakly self-reactive TCRs harbor affinities in the 10-100 μM range and high affinity 
TCRs that recognize foreign peptide fall in the 1-10 μM range [142, 143]. It has been 
generally appreciated that a higher affinity TCR will elicit a more robust T cell response; 
but more recently it is becoming increasing apparent that TCR affinity is not always a 
direct correlate or adequate predictor of T cell function [144]. Higher affinity TCRs do 
not always elicit the most robust T cell response, as it has been demonstrated that 
TCRs with affinities around 1 μM or less result in decreased TCR signaling and T cell 
function [142, 145, 146]. Src homology 2 domain-containing phosphatase 1 (SHP-1) is 
an important negative regulator in TCR signaling by inactivating Lck. Studies show that 
SHP-1 is upregulated in an affinity dependent manner [142]. Overall, TCR affinity has 
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been demonstrated to be an important factor in T cell function and antigen recognition 
and is a key element of this dissertation. 
The interaction between the TCR/pMHC impacts numerous kinetic parameters in 
addition to affinity. Another parameter is the dissociation rate (koff) or half-life (t1/2). Serial 
triggering is important to allow one pMHC complex to trigger multiple TCRs. It is 
estimated that one pMHC can trigger up to 200 TCRs [147]. Therefore, the optimal 
dissociation rate will be short enough to allow for other TCRs to bind the same pMHC, 
but long enough to allow for complete signaling [148]. This is critical in order to induce T 
cell activation despite the presence of very few pMHC complexes [149]. Evidence 
suggest that the t1/2 can affect if the TCR behaves as an agonist, partial agonist, or 
antagonist [147]. This has been shown to alter patterns of ITAM phosphorylation and 
ZAP-70 activation. For example, lower affinity interactions may act as partial agonists 
and induce cytokine production but no proliferation [150, 151]. However, maximum 
cytokine production requires maintenance of the TCR and APC synapse while the 
release of cytotoxic granules is estimated to only require 1 to 3 pMHC complex 
interactions [151, 152]. In summary, the affinity of a TCR takes into account, as well as 
affects, multiple biophysical variables that successively influence the T cell response.  
Methods of Measuring TCR Affinity 
There are multiple methods that have been used to quantify TCR binding affinity. 
Some of these methods include surface plasmon resonance (SPR) [153], isothermal 
titration calorimetry (ITC) [154, 155], fluorescence resonance energy transfer (FRET) 
[156-158], fluorescence anisotropy [154, 159], the thermal fluctuation assay [160-162], 
tetramer off-rates [163-165], and the micropipette adhesion frequency assay [166]. 
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Since SPR and the micropipette adhesion frequency assay are used in these studies, 
we will focus more in detail on these two methods for measuring TCR affinity. 
The “gold standard” for measuring TCR binding affinity is generally via SPR. 
Briefly, either soluble TCR or pMHC, is secured to the sensor surface and the binding 
partner, either soluble TCR or pMHC, flows over the bound molecule. As binding 
occurs, mass accumulates on the sensor surface and increases the signal. When using 
SPR with immobilized TCR, the KD is equal to the concentration of free unbound pMHC 
when 50% of the immobilized TCR is bound [167]. TCR affinity and kinetic properties 
between soluble TCR and pMHC have most frequently been measured via SPR 
technology. These measurements provide information about the physical chemistry of 
the TCR/pMHC binding interaction. However, because three-dimensional (3D) 
measurements via SPR require soluble TCR and pMHC, they fail to account for aspects 
unique to membrane-bound proteins. The affinity measurement is limited to and 
dependent upon only the ligand-binding site. Therefore, TCR/pMHC binding kinetics 
measured via 3D SPR are advantageous for observing molecular TCR/pMHC 
properties, however, they have been demonstrated to be subpar for predicting T cell 
functional activities [168]. 
 Systems have consequently been developed to study these membrane-bound 
interactions in a two-dimensional (2D) manner, and have been demonstrated to be 
better predictors of functional T cell outcomes. Unlike in SPR, these are cell to cell 
interactions. In one of these systems, the micropipette adhesion frequency assay, a red 
blood cell (RBC) serves as the APC and can be coated with pMHC via biotin-
streptavidin coupling [169, 170]. Using a micropipette, a T cell and the pMHC coated 
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RBC are brought together and pulled apart via micromanipulation. Multiple parameters 
can be measured such as affinity, adhesion frequency, force, off-rate, and on-rate [162, 
171]. Kinetic parameters of the TCR/pMHC measured in 2D have been shown in both 
CD4+ and CD8+ T cells to better correlate to T cell function than when measured in 3D 
[170, 172]. Specifically, one study using the 42F3 TCR (alloreactive TCR that 
recognizes HD-Ld presenting the peptide p2Ca933-940 of mouse 2-oxoglutarate 
dehydrogenase), demonstrated that 2D micropipette affinity measurements with multiple 
altered-peptide ligands better correlated to T cell potency than 3D SPR measurements. 
However, 3D SPR measurements better correlated with tetramer binding, eluting to the 
differences in TCR affinity using purified proteins or membrane-bound interactions 
[173]. In conclusion, due to the intrinsic factors of 3D and 2D affinity measurements, 
they can differentially correlate with T cell function. Affinity measurements obtained via 
SPR (3D) and via the micropipette adhesion frequency assay (2D) are included in this 
dissertation. Furthermore, how these measurements correlate to T cell function and 
cross-reactivity will be discussed in later chapters.  
T cell Cross-Reactivity 
 Understanding T cell cross-reactivity is essential for my studies. The clonal 
selection theory suggested that B cells and T cells have specificity for only one antigen 
and it was doubtful they could recognize alternative ligands [174]. It was not until the 
1990s that this paradigm was questioned and suggested highly improbable [175, 176]. 
The need for T cells to be inherently cross-reactive is now a fundamental concept in 
adaptive immunity and the idea of TCR binding degeneracy is well appreciated [177]. It 
has been estimated that there are less than 108 unique TCRs in the naïve T cell 
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population of humans [178]. Albeit, it has been estimated that an effective T cell 
repertoire must be capable of recognizing up to 1015 potential foreign antigens [177]. 
Therefore, the number of potential antigenic peptides exponentially surpasses the 
number of potential TCRs. Furthermore, estimations suggest a T cell clone must be 
able to recognize at least one million different peptides [176]. There are multiple 
reasons as to why a cross-reactive T cell population is advantageous. First, a cross-
reactive T cell population allows for proficient immunity against an unlimited number of 
antigens via a limited number of T cells. Secondly, cross-reactivity reduces the potential 
for immune escape by pathogens because escape of recognition by one TCR may be 
recognized by another TCR. Thirdly, with cross-reactive T cells, fewer T cells are 
needed to scan for foreign antigen, which is both temporally and spatially advantageous 
[177]. Overall, it is well appreciated that T cells are cross-reactive and they need to be 
in order to maintain a comprehensive immune system and provide protection against 
the diverse pathogens we encounter. 
 The cross-reactivity of a T cell can be influenced by its TCR’s affinity with various 
ligands. Although exceptions exist, it is generally appreciated that higher affinity TCRs 
are more cross-reactive [179, 180]. It is believed that higher affinity TCRs can better 
withstand changes in the peptide structure and still allow for T cell activation. 
Conversely, in a lower affinity TCR, these changes in the peptide structure could result 
in reduced binding energy and thus, yield an interaction that is below the threshold of T 
cell activation [148]. How TCR affinity affects T cell cross-reactivity will be further 
discussed throughout this dissertation. In summary, T cells are cross-reactive and the 
level of cross-reactivity can be influenced by TCR affinity. 
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The Immune System and Cancer 
 The immune system is essential for controlling many malignant cells. It is 
estimated that a cell can experience over 20,000 DNA damaging events a day, but 
these are normally repaired [181, 182]. A malignant cell can have more than an 
estimated 11,000 mutations [183]. The immune system can detect and kill these 
malignant cells. This was first described by Burnet and Thomas in the cancer 
immunosurveillance hypothesis [184-186]. When a tumor grows to more than 2-3 mm, 
blood supply and stromal remodeling induces proinflammatory cytokines and initiates 
the recruitment of innate cells, such as dendritic cells, macrophages, and NK cells, to 
the tumor where they produce IFN-γ [187]. The recruited dendritic cells then take up 
tumor associated antigens and cross-prime T cells in lymph nodes [188]. Tumor 
associated antigens can include viral, mutated, differentiation, cancer germline, or 
overexpressed antigens [189]. Conveniently, the “Cancer Antigenic Peptide Database” 
provides a regularly updated list and characterization of numerous different tumor 
antigens [190]. Tumor antigen specific T cells then traffic to the tumor site and eliminate 
the tumor cells [191]. Overall, both innate and adaptive immune cells are important for 
the control of malignant cells.  
 The idea of cancer immunoediting was subsequently described to include the 
immune system’s role in both host protection and tumor sculpting. The immunoediting 
process has been further described in three phases: elimination, equilibrium, and 
escape [192]. After elimination, as described above, the equilibrium phase consists of 
continuous elimination of the tumor, while selecting for tumor cell variants that can 
evade the immune response. Escape occurs when the tumor cell variants expand 
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and/or metastasize due to loss of control by the host immune system [191]. Cancers 
have developed numerous mechanisms to escape recognition by the immune system 
[191]. Mainly, this is achieved by creating a “cold” immunosuppressive tumor 
microenvironment [193]. To name a few of these mechanisms, tumors can 
downregulate MHC expression, mutate antigen processing pathways, or lose 
expression of, or mutate, the targeted antigen [194]. Tumors can express checkpoint 
molecules to suppress T cell function. To generate an immunosuppressive environment, 
tumors can recruit regulatory T cells, myeloid-derived suppressor cells, and type II 
macrophages [195]. Overall, identification of these numerous immunosuppressive 
mechanisms elicited by tumor cells, has been important in expanding the field of tumor 
immunology [196].  
History of Immunotherapy 
 Scientists have been searching for decades to find new ways in which the host’s 
immune system can be exploited to treat cancer. In the 19th century, it was first 
observed that erysipelas infection aided tumor regression [197]. By 1959, it was shown 
that Bacillus Calmette-Guerin (BCG), an attenuated live bovine tubercle Bacillus-based 
vaccine for tuberculosis, could inhibit tumor growth in mice [198]. This was the first 
immunotherapy based treatment utilized for cancer treatment in 1970 [199]. 
Subsequently, IL-2 was discovered upon its ability to activate and expand T cells [200]. 
It was further demonstrated that administration of recombinant IL-2 (rIL-2) to tumor 
bearing mice elicited regression of pulmonary metastases and subcutaneous tumors 
[201]. These exciting results were quickly translated into the clinic. In the first six cancer 
patients treated with high dose IL-2, three patients had objective responses [202]. 
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However, since not all patients responded, the combination of cellular immunotherapy 
and IL-2 treatment was investigated. It was demonstrated that peripheral blood 
mononuclear cells (PBMCs) cultured with IL-2 could generate lymphocyte-activated 
killer (LAK) cells and could then kill tumor cells in vitro [203-205]. In vivo models 
combining rIL-2 treatment with adoptive transfer of LAK cells into tumor bearing mice 
demonstrated antitumor activity if treated prior to tumor vascularization [206, 207]. 
Following these results, the first cellular immunotherapy combined high dose IL-2 with 
LAK cells [208]. LAK cells are made up of NK cells and NK T cells, however, their anti-
tumor efficacy with high dose IL-2 was as effective as high dose IL-2 alone [209-211]. 
Since then, IL-2 has been and is currently used in combination with many forms of 
immunotherapies in many clinical trials [212].  
 TIL was an attempt to improve upon the responses obtained with IL-2 or LAK 
cells in cancer therapies. TIL have been found in melanoma lesions for over forty years 
[213]. It was later demonstrated that culturing TIL ex vivo in high amounts of IL-2 could 
restore their proliferation and lytic function [214]. Objective responses were observed in 
about 31% of melanoma patients receiving autologous cell transfer of ex vivo TIL 
expansions and IL-2 treatment [215]. To improve upon this, these therapies were given 
in conjunction with lymphodepletion, where objective responses rose to 55% in 
melanoma patients [212, 215-218]. Host lymphodepletion has been demonstrated to be 
important to enhance the efficacy of adoptively transferred cells for a few reasons. 
Specifically, lymphodepletion can create space for the transferred cells and deplete 
regulatory T cells [219, 220]. A 72% response rate was later observed in metastatic 
melanoma patients treated with 12 Gy of total-body irradiation prior to TIL and IL-2 
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treatment [221]. In summary, the observation of TILs present in the tumor lesions has 
eventually supported the notion of utilizing T cells for cancer targeted therapies [222].  
Aside from IL-2, LAK, and TIL, numerous other forms immunotherapies have 
subsequently been investigated. These include cytokines, chemokines, dendritic cell-
based vaccines, antibodies, and gene-modified cells. Other cytokines used in clinical 
trials include TNF-α, IFN-γ, IFN-α, IL-15, and GM-CSF [1]. Efficacies of single agent 
cytokine therapies ranged between 5% and 43% of patients exhibiting partial responses 
and 13% and 42% of patients exhibiting complete response, however, many treatments 
exhibited toxicities [1]. One open clinical trial is treating patients with TIL transduced to 
express CXCR2, with the expectation that CXCR2 will enhance T cell trafficking to the 
tumor [1, 223]. Peptide and peptide pulsed dendritic cell vaccination strategies have not 
been successful in melanoma, with only 2.6% of patients having an objective response 
[224, 225]. This was most likely due to the observed functional inabilities of melanoma 
reactive T cells in patients [226]. Albeit, Sipuleucel-T, a dendritic cell vaccine, has been 
FDA approved for treatment of castrate-resistant metastatic prostate cancer [227]. 
Furthermore, vaccinations targeting patient specific neo-antigens induced expansion of 
neo-antigen specific T cells and protected against tumor reoccurrences [228-230]. Neo-
antigens have become an attractive focus for research, as it has been demonstrated 
that tumor mutation burden can be a strong determinant of responses with 
immunotherapies [231-235]. Targeting neo-antigens is advantageous due to their 
exclusive expression on tumor cells, and thus, could reduce the potential for on-target, 
off-tumor cross-reactivity [236, 237]. Overall, ongoing research may provide evidence 
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on the role of vaccination in T cell responses and anti-tumor immunity, especially in the 
targeting of neo-antigens. 
In the last three decades, advancements have been made in identifying 
suppressive receptors that inhibit T cell responses. These receptors are classified as 
checkpoints and include programmed cell death protein 1 (PD-1), cytotoxic T-
lymphocyte associated protein 4 (CTLA-4), T-cell immunoglobulin and mucin-domain 
containing-3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). CTLA-4 was first 
identified in 1988 and by 1996 it was demonstrated that blocking CTLA-4 could enhance 
anti-tumor responses in mice [238-240]. In subsequent clinical trials, response rates 
ranged from 16.2% to 28.5% of patients and responses were often durable, lasting 
more than 34 months [241-243]. The checkpoint blockade mAb targeting CTLA-4 was 
the first immunotherapy drug to become FDA approved in 2011 for the treatment of 
melanoma [240, 244-247]. Overall, CTLA-4 mAb has demonstrated success as a single 
agent in immunotherapy.  
The second checkpoint, PD-1, was identified and cloned in 1992 and 1994, 
respectively [248, 249]. It was later demonstrated that PD-1 ligand (PDL-1) expression 
on tumor cells promoted tumor escape via T cell suppression in mice [250, 251]. 
Furthermore, in mouse models, tumor growth could be suppressed using an anti-PD-L1 
mAb [251, 252]. In subsequent clinical trials, up to 40% of patients had objective 
responses and responses were durable, lasting more than one year [245, 253, 254]. 
Consequently, the checkpoint blockade mAb targeting PD-1 or PD-L1 has also been 
FDA approved [253, 255]. Overall, checkpoint blockade antibodies demonstrated 
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success as single agent therapies and thus, remain a promising area of research for 
combination immunotherapies. 
A robust T cell response is important for the success of cancer immunotherapies. 
Therefore, further improvements in T cell therapies have been developed using TCR or 
CAR gene-modified T cells to redirect the specificity of T cells. In the 1980’s, scientists 
explored methods of combining the functional response of a T cell with the diversity of 
antibody recognition. As a result, CARs were developed to consist of an extracellular 
single chain variable fragment linked to an intracellular signaling domain [256]. The first 
described CAR contained the Fc receptor (FcR) γ chain signaling domain, and 
subsequent CARs contained the zeta chain of the CD3 signaling complex [256, 257]. 
The CD3ζ chain contains three ITAMs compared to FcRγ’s single ITAM. Succeeding 
CARs have been developed over the years with varying signaling and stimulatory 
components. Specifically, in addition to the CD3ζ domain, second generation CARs 
implemented another costimulatory domain (such as CD28, 4-1BB, or OX40) and third 
generation CARs implemented two additional costimulatory domains [257-261]. A 
schematic of the different generations of CARs is depicted in Figure 1. CAR genes (and 
also TCR genes) are commonly inserted into T cells via viral vectors. Numerous 
different viral vectors have been utilized to insert genes into T cells. Some of these 
include adenoviral, retroviral, lentiviral (technically retroviral), and poxviral [262]. 
Retroviruses are commonly used due to their ability to integrate into the host cell’s 
genome [263, 264]. Specifically, lentiviral vectors and γ-retroviruses, generally based on 
murine leukemia virus (MLV), are frequently used in gene therapy [262].  
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Figure 1. Generations of CARs. CARs include an extracellular single chain variable 
fragment comprised of variable light (VL) and heavy (VH) chains linked via hinge. 
Intracellular domains, linked via hinge, in first generations CARs included either FcRγ or 
CD3ζ chain signaling domains. Second generation CARs included an additional 
costimulatory domain. Third generation CARs included two costimulatory domains.  
 
In summary, various viral vectors have been utilized to introduce various generations of 
CARs into T cells to redirect T cell specificity towards the antigen of choice.  
A wide variety of CARs have been developed to target an array of antigens both 
in vitro and in vivo. Some of these targets include antigens expressed on glioblastoma, 
neuroblastoma, melanoma, hematologic malignancies, prostate cancer, breast cancer, 
colorectal cancer, and ovarian cancer [258]. CARs are advantageous due to their ability 
to recognize antigen in an MHC independent manner. However, adverse events in 
clinical trials have been documented due to “on-target, off-tumor” reactivity, tumor lysis 
syndrome, and cytokine storm [258]. CAR T cells have exhibited varying levels of 
clinical success, albeit, the greatest success with CAR T cells has been exhibited in 
recent years with the treatment of refractory B-cell leukemia [265, 266]. The first clinical 
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trial using the CD19-targeting CAR resulted in objective responses in 57% of patients 
[265, 266]. These rates have since increased up to almost 80% complete response 
rates in patients [267, 268]. Consequently, the use of autologous CAR T cells for the 
treatment of large B-cell lymphoma was FDA approved in 2017 [265, 269, 270]. Overall, 
the use CAR T cells for treatment of B-cell malignancies has been a significant 
breakthrough in the field of immunotherapy and CAR T cells remain a promising area of 
research in terms of gene-modified T cells. 
 TCR gene-modified T cells have also shown success in the clinic and remain a 
significant area of research in addition to CAR T cells. TCR gene-modified T cells are 
the focus of this dissertation and thus, will be described in more detail. As TIL therapies 
exhibited success in many patients, researchers began to identify and isolate tumor-
reactive TCRs. The first melanoma specific TCRs were cloned in 1994 and 1995 [271, 
272]. Subsequently, the use of TCR gene-modified T cells for adoptive cell transfer 
moved into clinical trials. A graphical schematic of the process of using TCR gene-
modified T cells for adoptive T cell transfer therapy is depicted in Figure 2 (this process 
is the same for CAR T cells, except CAR genes are inserted into a viral vector instead 
of TCR genes). In the first clinical trial, using a TCR targeting a melanoma associated 
antigen, 2/15 patients had objective clinical responses and engraftment of the 
introduced T cells [273]. In clinical trials thus far, the use of TCR gene-modified T cells 
has yielded efficacies in up to 55% of treated patients [1, 274, 275]. Overall, the use of 
TCR gene-modified T cells has become increasingly widespread in immunotherapies, 
with advancements in utilization as a single agent therapy, as well as in combination 
therapies.   
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Figure 2. Graphical Representation of Generating TCR Gene-Modified T cells for 
Adoptive T cell Transfer Therapy. Tumor reactive T cell clones are isolated and 
expanded from the PBMCs or TIL of a patient with cancer. TCR alpha and beta chain 
genes that are reactive against tumor associated or viral antigens are identified and 
cloned into a viral vector. Packaging and producer cell lines are utilized to make high 
titer virus. Patient activated peripheral blood T cells are transduced with viral 
supernatant, expanded, and administered back to the patient. The specificity of these 
circulating T cells is now redirected toward the specific tumor or viral antigen resulting in 
anti-tumor immunity. 
 
Adoptive T cell therapy and the use of TCR gene-modified T cells have 
revolutionized the field of immunotherapy through their ability to target specific tumor or 
viral antigens of choice [276]. With all the success of this treatment, there are also 
potential drawbacks in utilizing TCR gene-modified T cells. First, introduction of another 
TCR into the T cell allows for the potential of αβ TCR chain mispairing between the 
introduced and endogenous TCR chains. The formation of mixed dimers can lead to 
new TCR specificities and result in autoimmunity. This phenomenon has been 
demonstrated in murine models [277, 278], but has never been proven to have occurred 
in clinical trials. Strategies have been implemented to enhance proper TCR chain 
pairing by making modifications to the TCR genes. These strategies include: addition of 
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another disulfide bond, replacing human constant regions with murine constant regions, 
codon optimization, leucine zipper fusion proteins, and single chain TCRs [94, 279-286]. 
In vitro evidence suggested modifying the TCR genes to express murine constant 
regions or leucine zipper fusion proteins resulted in enhanced proper TCR chain pairing 
and T cell function [94]. Overall, one of the challenges associated with the introduction 
of a new TCR is TCR chain mispairing. TCR chain mispairing has the potential to cause 
autoimmunity, and strategies to enhance proper TCR chain pairing have been 
investigated. 
Properly paired introduced TCRs can also cause potential cross-reactivity of the 
TCR gene-modified T cells. Specifically, TCR gene-modified T cells can recognize the 
on-target antigen on normal tissue or an off-target antigen on normal tissue [287]. On-
target, off-tumor antigen recognition has been described in clinical trials using non-
modified TCRs. Specifically, this occurred where the TCR target was a melanoma 
antigen that is also expressed in the ear, eye, and normal melanocytes, and where the 
TCR target was a colorectal cancer antigen that is also expressed in epithelial cells 
throughout the gastrointestinal tract [288-290]. The clinical implications of this 
drawback, moreover when modifying the TCR, will be discussed in the next section. The 
focus of this dissertation will include a novel strategy proposed to enhance the efficacy 
and safety of TCR gene-modified T cells for adoptive T cell transfer.  
Adverse Events Observed in Clinical Trials using Affinity Enhanced TCRs 
 Despite the success seen in clinical trials, the use of TCR gene-modified T cells 
does not elicit an anti-tumor response in every patient. TCRs that target self-antigens 
generally harbor a low affinity as a result of negative selection in the thymus. Therefore, 
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TCR affinity enhancement has been utilized as a strategy to enhance the anti-tumor 
efficacy of TCR gene-modified T cells. Specifically, yeast or phage display is frequently 
utilized as a method for affinity enhancement [291-296]. However, random mutation 
through yeast or phage display can lead to unanticipated off-target cross-reactivity 
[142]. Adverse events have been observed in clinical trials where autologous affinity 
enhanced TCR gene-modified T cells were used and have been attributed to cross-
reactivity. In summary, TCR affinity enhancement can augment the anti-tumor 
response, but also has the potential to cause off-target autoimmunity in patients. 
There are two clinical trials where affinity enhanced TCRs were utilized in TCR 
gene-modified T cells and resulted in unexpected patient deaths. An affinity enhanced 
HLA-A2 restricted TCR that targeted MAGE-A3 was used to treat nine cancer patients. 
This TCR was previously affinity enhanced by mutating a residue that improved T cell 
reactivity in CD8+ T cells and allowed for recognition in CD4+ T cells. This TCR was 
chosen from 85 variant TCRs containing single or multiple amino acid substitutions in 
the CDR3 region of the TCR alpha chain [297]. 4/9 patients exhibited neurological 
toxicity and two of these patients subsequently died. Further investigation indicated that 
MAGE-A12 and possibly MAGE-A1, MAGE-A8, and MAGE-A9 were expressed in the 
brain. In this case, the reactivity against these other MAGE-A targets was known, but 
their expression in the brain was not. It is unclear as to if the WT TCR would have 
resulted in the same observed neurological toxicity. These adverse events can be 
attributed to an on-target, off-tumor cross-reactivity of the introduced TCR gene-
modified T cells [5]. 
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In the second case, an affinity enhanced HLA-A1 restricted TCR that targeted 
MAGE-A3 was affinity enhanced via phage display through four substitutions in the 
CDR2 region of the TCR alpha chain. Herein, 2/2 treated patients died from cardiac 
toxicity four or five days after TCR transduced T cell infusion, respectively. Further 
analysis indicated that the TCR gene-modified T cells had trafficked to the heart and 
histological results were consistent with immunologically mediated damage. This is an 
example of off-target, off-tumor cross-reactivity [6]. It was later determined that the 
affinity enhanced TCR recognized the Titin protein expressed on cardiomyocytes, 
whereas recognition of Titin was not conferred in T cells expressing the WT TCR. The 
MAGE-A3 and Titin peptides differ in sequence in four of nine residues, including the 
core, yet the affinity enhanced TCR recognized both peptides in the context of MHC 
with almost identical conformation of the CDR loops [298, 299]. This is an example of 
how high affinity TCRs can tolerate alterations in the peptide structure [148]. Pre-clinical 
screening for potential cross-reactivity of the affinity enhanced TCR was completed 
using only a limited number of off-target tissues. However, Titin is only expressed in 
beating cardiomyocytes derived from induced pluripotent stem cells and the epitope is 
not homologous in the mouse [298, 299]. These results exemplify the potential dangers 
of non-specifically affinity enhancing a TCR without extensive pre-clinical screening.  
Both of these described clinical trials demonstrated the potential dangers in using 
affinity enhanced TCRs, especially non-specific enhancement, even when done so with 
an originally low affinity TCR. However, despite the risks involved in using an affinity 
enhanced TCR, one affinity enhanced TCR was used in patients that did not result in 
adverse events [300-304]. This NY-ESO-1 targeting TCR contained two mutations in 
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the CDR3 region of the TCR alpha chain that enhanced T cell reactivity [304]. Overall, 
these results indicated that TCR affinity enhancement does not always lead to off-target 
cross-reactivity. 
Even though affinity enhanced TCRs did not result in adverse events in every 
clinical trial, it is evident that we need more advanced and meticulous strategies in order 
to enhance the anti-tumor responses of TCR gene-modified T cells while still sustaining 
safety for treated patients. The purpose of this dissertation is to address that current 
obstacle in the field.  
MART-1 and DMF5 TCR 
One subclass of tumor associated antigens includes differentiation antigens. 
Many differentiation antigens have been identified for their frequent expression in 
melanomas. Some of these include tyrosinase [305, 306], premelanosome protein 
(PMEL or gp100) [307-309], and tyrosinase related protein 1 and 2 (TRP1 and TRP2) 
[310, 311]. Herein, we focus on the melanoma differentiation antigen, melanoma 
antigen recognized by T cells 1 (MART-1). MART-1 is lineage-specific protein found in 
melanocytes and is important for melanosome maturation [312].  
MART-1 was first identified in 1994 by cDNA expression cloning [313]. It was 
recognized by a melanoma patient’s HLA-A2 restricted TIL. MART-1 mRNA was found 
in 11 out of 14 melanoma lines. Furthermore, expression of MART-1 was confirmed in 
retinal tissue, but no other normal tissue lines [313]. Subsequent studies show MART-1 
expression in up to 90% of melanomas [314]. MART-1 epitopes have been recognized 
in the context numerous different HLAs, expressed on both MHC class I and MHC class 
II [315-320]. Expression of this tumor associated antigen has been linked to significantly 
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longer overall survival in melanoma patients [321]. In summary, MART-1 has been a 
frequently targeted melanoma antigen for therapy due to its recurrent, and sole 
expression on melanocytes and melanomas. 
MART-1 is a unique antigen because high frequencies of MART-1 reactive T 
cells are found in both cancer patients and normal donors [322-324]. Both the MART-
1(27-35), nonameric, and MART-1(26-35), decameric, peptides are recognized by MART-1 
reactive T cells [324, 325]. The MART-1(27-35) epitope (AAGIGILTV) has been regarded 
as an immunodominant epitope [326]. MART-1 anchor modified epitopes have been 
generated and are discussed in further detail in Chapter Three. It has been 
hypothesized that the high frequency of MART-1 reactive T cells in the blood of normal 
donors and cancer patients is due to epitope mimicry. This is a result of T cells being 
primed by a foreign or pathogen derived antigen and subsequently reacting with a 
formerly ignored self-antigen [327]. The MART-1 nonameric epitope is extremely 
hydrophobic, with only one neutral threonine at position eight. Transmembrane domains 
and leader peptides of proteins are also very hydrophobic. Furthermore, studies show 
that cytosolic proteins with central hydrophobic core are the major substrates of 
proteasomal degradation. Hence, why it is well appreciated that hydrophobicity is 
strongly correlated to immunogenicity [68]. It has been shown that MART-1 derived TIL 
cultures and MART-1 specific T cell clones can lyse peptides in the context of HLA-A2 
that have some degree of homology with MART-1 [327, 328]. Since MART-1 reactive T 
cells are uniquely found in healthy donors, most likely due to epitope mimicry, we 
thought it would be an interesting antigen to target while studying the cross-reactive 
properties of TCRs.  
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 Multiple MART-1 reactive TCRs have been used in clinical trials. With the use of 
autologous PBMCs engineered to express a MART-1 reactive TCR (unnamed), 2/15 
patients demonstrated sustained objective responses [329]. Intra-tumoral injections of 
allogeneic T cells expressing the MART-1 reactive TCR, TIL 5 [271, 330], resulted in 
1/15 patients demonstrating a partial response [331]. The use of another MART-1 
reactive TCR, DMF4, resulted in objective responses in 13% of the patients and none of 
the patients exhibited normal melanocyte destruction in the ear or eye [329, 332]. 
Additionally, the MART-1 reactive TCR, DMF5, was used in a clinical trial where 
objective responses were observed [288, 332]. This HLA-A2 restricted DMF5 TCR was 
utilized in the studies completed in this dissertation and thus, will be described in further 
detail.  
The DMF5 TCR was isolated from a MART-1 reactive TIL clone from a 
melanoma patient, the same patient from which the DMF4 TCR was cloned. This TCR 
is classified as a high affinity/avidity and CD8 independent TCR [332]. The DMF5 TCR 
was utilized in a clinical trial using autologous TCR gene-modified T cells for adoptive 
cell transfer in 20 melanoma patients. Objective responses were seen in 30% of the 
patients. Albeit, 17/20 patients exhibited melanocyte destruction in off-tumor tissues, 
specifically the eye, ear, and skin. Some of the patients experienced these adverse 
events up to grade 3 toxicities. This is an example of an on-target but off-tumor cross-
reactivity of the introduced TCR gene-modified T cells. Additionally, some of the 
patients exhibited off-tumor melanocyte destruction in the absence of any tumor 
rejection. The DMF5 TCR has a higher affinity than the DMF4 TCR. This possibly 
explains why the percentages of objective clinical responses were higher with the DMF5 
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TCR. Furthermore, this possibly explains the observation of off-tumor melanocyte 
destruction with the DMF5 TCR, but not the DMF4 TCR. This clinical trial indicated that 
T cells expressing the DMF5 TCR can have a therapeutic anti-tumor response in 
melanoma patients [288]. Overall, due to the high level of epitope mimicry observed 
with MART-1 “like” epitopes and the clinical relevance of the DMF5 TCR, we believed 
the MART-1/DMF5 TCR model was fitting for understanding TCR specificity and cross-
reactivity. 
Novel Structure-Guided Approach 
 As mentioned previously, one of the strategies for enhancing the anti-tumor 
response of TCR gene-modified T cells is by TCR affinity enhancement via yeast or 
phage display. It is possible that use of an affinity enhanced TCR can result in 
unanticipated cross-reactivity or recognize unpredicted targets, and thus, modified 
TCRs for adoptive transfer of TCR gene-modified T cells need to be addressed more 
carefully.  
 The process of introducing mutations into TCRs to alter affinity and T cell 
specificity is not a new concept. There are many examples in different TCRs where 
introduced mutations affected affinity, binding kinetics, antigen specificity, and cross-
reactivity. For example, CDR1, CDR2, and CDR3 substitutions in the 2C (alloreactive 
TCR that recognizes alpha-ketoglutarate dehydrogenase in the context of H-2Ld and 
syngeneic recognition of SIYR peptide in the context of H2-Kb) TCR’s alpha and beta 
chains resulted in varying levels of altered-peptide ligand recognition and tetramer 
binding. TCR mutations also altered the recognition of the targeted peptide in CD4+ and 
CD8+ T cells [333, 334]. More specifically, high affinity mutant TCRs demonstrated 
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higher binding to altered-peptide ligands compared to the WT TCR [335]. One TCR 
mutation enhanced affinity for the targeted ligand 1,000-fold higher than the WT TCR. 
There was a 5- to 10-fold increase in T cell potency against the targeted ligand, but 
CD8+ T cells expressing this high affinity 2C TCR were autoreactive [179, 333]. In 
another example, high affinity 3.L2 TCR (HI-Ek restricted, recognizes β-chain of mouse 
hemoglobin) variants were also more degenerate in their recognition of altered-peptide 
ligands, both in potency and in the number of recognized targets, compared to the WT 
TCR [336]. In a third example, single CDR3 TCR alpha and beta chain mutations were 
introduced into the 1MOG9 TCR (HI-Ab restricted, recognizes myelin oligodendroglial 
glycoprotein) based on the importance of TCR CDR3 loops in peptide binding [337-
340]. Herein, high affinity TCRs did enhance targeted antigen potency and confer co-
receptor independence compared to the WT TCR. However, the introduction of 
mutations in the 1MOG9 TCR also led to new recognition of self-peptides [341]. Lastly, 
yeast libraries have been utilized as a strategy in in vitro directed evolution, specifically, 
for intentionally changing the antigen specificity of the A6 TCR (HLA-A2 restricted, 
recognizes Tax) [342]. Other studies have claimed to have enhanced targeted antigen 
specificity with TCR mutants generated via phage display, but an examination of cross-
reactivity and T cell recognition of altered-peptide ligands was marginal or absent [343, 
344]. Despite the many examples of high affinity TCR variants resulting in new 
recognition of altered-peptide ligands, this is not always the case. For example, using a 
WT1-specific TCR, two high affinity TCR clones with CDR3 TCR alpha chain mutations 
were selected from yeast display libraries. The affinity enhanced TCRs demonstrated 
enhanced targeted T cell reactivity in CD4+ and CD8+ T cells compared to the WT TCR. 
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Additionally, mice that were injected with T cells expressing the WT or affinity enhanced 
TCRs with irradiated peptide pulsed splenocytes, exhibited no signs of autoimmunity, 
and expansion of TCR transduced T cells was similar among the different groups. 
Pathology after two to three weeks indicated no T cell-mediated tissue damage within 
the different treatment groups. These results provided further evidence that not all 
affinity enhanced TCRs will cause autoimmunity in vivo [345]. In another example, 
single and dual mutations in the CDR3 TCR alpha chain and CDR2 TCR beta chain of 
the 1G4 TCR (HLA-A2 restricted, recognizes NY-ESO-1) enhanced affinity and targeted 
antigen potency compared to the WT TCR, but cross-reactivity or recognition of altered-
peptide ligands was not addressed in these studies [304]. However, one of these 
modified 1G4 TCRs was safe when used in patients [300, 302]. In summary, many 
studies suggest TCR mutations in the CDR1, CDR2, and CDR3 regions impact TCR 
affinity and T cell specificity. Specifically, TCR mutations can alter binding kinetics, 
antigen recognition in CD4+ and CD8+ T cells, and cross-reactivity. The potential off-
target reactivity as of result of TCR mutations, implicates the need for better TCR 
mutational methods and approaches.  
Herein, in collaboration with the Baker’s laboratory, we have developed and 
implemented an approach to improve specific antigen reactivity and reduce off-target 
cross-reactivity by modifying the TCR using structure-guided mutations. More 
specifically, we used the crystal structures of the TCR/pMHC to implement the 
structure-guided design as a novel component versus inducing random mutation in the 
TCR. This strategy involves the combinatorial idea of “positive and negative design”. 
“Positive and negative design” has been utilized in other fields as a method to alter 
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binding specificity [346-348]. Herein, as a way to enhance antigen specificity, the 
positive design will introduce mutations in the TCR that enhance binding to the peptide 
by introducing favorable interactions. The negative design will introduce mutations in the 
TCR that weaken or eliminate binding of TCR residues with the MHC by weakening 
existing favorable interactions [349]. Negative mutations could also be translatable to 
other TCRs if they are made at conserved MHC contacting residues in the TCR and 
thus, would be common to most presented peptides. It is imperative to recognize the 
importance of the negative mutations as a way to offset the positive mutations, as 
introducing only favorable interactions with the peptide could allow for unwanted effects 
on T cell specificity. Instances of this occurring with different TCRs has already been 
observed and examples have been described above. Even though negative TCR 
mutations would reduce the TCR affinity, the enhanced binding towards the specific 
peptide would persist [349]. The combination of these positive and negative TCR 
mutations is hypothesized to enhance antigen specificity while simultaneously reducing 
potential cross-reactivity. Although these mutations will affect the affinity of the TCR, the 
idea is to redistribute the free binding energy and not solely focus on enhancing TCR 
affinity. This redistribution of free binding energy would allow for the TCR to have an 
increased focus on the peptide and a decreased focus on the MHC [350]. This novel 
structure-guided design strategy is used in this dissertation as an approach to fine-tune 
TCR specificity and to generate a more focused DMF5 TCR, based on the solved 
crystal structure of the TCR/pMHC [351]. 
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Concluding Remarks 
 T cells play a significant role in the adaptive immune response. T cell-mediated 
immunity is dependent upon TCR recognition of pMHC. In order to maintain an inclusive 
immune system, T cells must be cross-reactive. However, negative selection in the 
thymus is critical for eliminating highly autoreactive T cells. More recently, T cells have 
been harnessed in many forms of immunotherapies for their ability to kill tumor cells. 
Namely, the use of TCR gene-modified T cells has shown success in clinical trials. To 
improve the efficacy of TCR gene-modified T cells, methods of TCR affinity 
enhancement have been utilized. These TCR modifications do not always cause harm 
to patients, but affinity enhanced TCR gene-modified T cells have resulted in lethal 
adverse events due to off-target cross-reactivity mediated by the introduced T cells. 
Consequently, the field needs more advanced and meticulous strategies in order to 
enhance the anti-tumor responses of TCR gene-modified T cells while still sustaining 
safety for treated patients. In these studies, in collaboration with the Baker lab, we 
sought to develop and utilize a novel structure-guided design approach to fine-tune the 
antigen specificity of TCRs.  
Herein, we utilized the DMF5 TCR/MART-1 model. Specifically, our objective 
was to enhance MART-1 specificity while simultaneously reducing cross-reactivity. 
Overall, when altering TCRs for therapeutic use, biology and safety should be of the 
utmost importance and herein, we emphasize the importance of rigorous preclinical 
testing of modified TCRs and the need for advancement in modeling/prediction tools for 
protein interactions. 
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
Cell Lines, Media, and Reagents 
T2 [352, 353] , HEK293GP [354-356], PG13 [357, 358], and Jurkat E6.1 cells 
[359] were obtained from the American Type Culture Collection (Manassas, VA). T2 
cells are TAP deficient and therefore cannot load their own peptide onto MHC class I. 
The MHC becomes stable on the cell surface when loaded with exogenous peptide. T2 
cells were used as stimulator cells for T cell functional assays. HEK293GPs are a 
human embryonic kidney packaging cell line that were made to express the retroviral 
gag and polymerase proteins. HEK293GP cells were used to produce high titer 
retrovirus by transient co-transfection using a retroviral vector and a plasmid containing 
the vesicular stomatitis virus (VSV) envelope. PG13 cells (based on Gibbon ape 
leukemia virus (GaLV)) are a retroviral producer cell line that when transduced with 
HEK293GP supernatant, will stably produce high titer retrovirus. Jurkat E6.1 cells are a 
CD4-CD8- human T cell lymphoblast used for TCR transduction and functional assays. 
The tumor cell lines used in T cell functional assays are listed in Table 2. All tumor lines 
were obtained from American Type Culture Collection (Manassas, VA) except MEL 624 
and 624-28 [360], UOK131 [361], and SAUJ (Rick Childs, NCBI) [362] were obtained 
from the NIH Surgery Branch (Bethesda, MD).
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Table 2. Tumor Cell Lines and Phenotypes. “+” indicates positive and “-“ indicates 
negative. 
 
All medium components were obtained from Corning Life Sciences (Corning, 
NY), unless otherwise noted. T2 and Jurkat E6.1 cells were maintained in RPMI 1640 
medium supplemented with 10% fetal bovine serum (FBS) (Invitrogen Life 
Technologies, Carlsbad, CA). HEK293GP cells were maintained in complete medium 
consisting of Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS. 
PG13 cells were maintained in complete medium consisting of Iscove’s DMEM 
supplemented with 10% FBS. All tumor cell lines, except SAUJ cells, were maintained 
in complete medium consisting of Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% FBS. SAUJ tumor cells were maintained in complete medium 
consisting of RPMI 1640 medium supplemented with 10% FBS. 
T cells 
All PBMC used in this study came from de-identified apheresis products 
purchased from Key Biologics (Memphis, TN). PBMCs were isolated from normal 
Name Tumor/ Tissue MART-1 HLA-A2 
MEL 624 Melanoma + + 
MEL 624-28 Melanoma + - 
MEL A375 Melanoma - + 
SAUJ Renal - - 
UOK131 Renal - + 
SKOV3 Ovarian - + 
CAPAN 1 Pancreas - + 
MDA 231 Breast -  + 
SW480 Colon -  + 
HEPG2 Liver - + 
SKGT5 Esophagus - + 
U251 Glioblastoma - + 
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healthy donors by Ficoll-Paque (General Electric, Fairfield, CT) density gradient 
centrifugation. Briefly, whole blood was diluted 1:2 in phosphate-buffer saline (PBS) 
(Mediatech, Inc., Manassas, VA), loaded onto Ficoll density gradients, and spun at 
2,000 RPM for 30 minutes at room temperature (RT) without brake. The density of Ficoll 
is 1.077 g/mL, which allowed red blood cells to pass through the Ficoll and inhibited the 
passage of white blood cells. Buffy coat was collected and washed three times with 
PBS. All T cells were maintained in complete T cell medium consisting of RPMI 1640 
medium supplemented with 10% FBS, 300 IU/mL recombinant human IL-2 (rhIL-2; 
Novartis Pharmaceuticals Cooperation, East Hanover, NJ), and 100 ng/mL recombinant 
human IL-15 (rhIL-15; Biologic Resources Branch, NCI, Frederick, MD) at 37°C in a 
humidified 5% CO2 incubator. 
Peptides 
All peptides were obtained from Synthetic Biomolecules (San Diego, CA) and 
were HPLC purified at 95%. Peptides were stored at 10 µg/mL in 100% DMSO at -80°C.  
Retroviral Vector 
Our lab uses a modified SAMEN retroviral construct to introduce TCR genes into T cells 
[363]. The structure of this vector is shown in Figure 3. At the 5’ end of the vector is a 
human cytomegalovirus (CMV) long terminal repeat (LTR) promoter. This promoter 
allows for enhanced constitutive levels of transcription. Following this promoter is a 
splice donor and splice acceptor site for RNA splicing. Ψ (psi) is the packing signal. The 
TCR alpha gene and TCR beta gene are linked by a P2A self-cleaving peptide. This 
allows the alpha and beta chains to be synthesized in a 1:1 ratio. 
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Figure 3. Structure of the SAMEN Retroviral Vector Used For TCR Gene Transfer. 
A modified SAMEN retroviral vector was used to transfer TCR genes to alternate 
effectors. The retroviral vector used in this study contains a CMV promoter, splice donor 
(SD) and splice acceptor (SA), psi (ψ) packaging signal, TCR alpha (α) and beta (β) 
chains, CD34t, and long terminal repeats (LTR). The TCR α and β genes and the CD34t 
molecule are linked via P2A and T2A sequences, respectively. P2A and T2A are self-
cleaving peptides cut into three separate proteins. CD34t is used as a marker for 
transduction.  
 
Following the TCR beta gene is a T2A self-cleaving peptide followed by CD34t which is 
synthesized in a 1:1 ratio with the TCR chains. CD34t is a truncated CD34 molecule 
and consequently lacks its intracellular signaling domain [364]. This is a unique marker 
of transduction and is beneficial for a number of reasons. There is nothing that limits cell 
surface expression of CD34t, therefore its expression levels are analogous to the 
amount of TCR protein being made. CD34t can also be used to sort TCR transduced 
cells which allows for an easy method of attaining a pure TCR transduced T cell 
population. Following the CD34t, is a 3’ LTR sequence for genomic insertion. The 
SAMEN vector containing each WT or modified TCR described in the dissertation was 
used to generate high titer PG13 producer cell lines. 
First Round of DMF5 TCR Mutations 
 The following seven modified TCRs were made using the WT DMF5 TCR 
sequence: αD26Y, βL98W, αD26Y/βL98W, αD26Y/αY50A/βL98W, 
αD26Y/αY50V/βL98W, αY50A, and αY50V. This was completed using a GENEART site 
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directed mutagenesis kit (Invitrogen). Mutagenesis was completed in the SAMEN vector 
with the primers listed below (IDT, Coralville, IA). Base changes are denoted by bold 
and underline.  
αD26Y forward:  
5’-CAACTGCACTTACAGTTACACTGCACTTACAGTCCT-3’ 
αD26Y reverse:  
5’-AGGACTGTAAGTGCAGTGTAACTGTAAGTGCAGTTG-3’ 
βL98W forward: 
5’-TGTACTTCTGTGCCAGCAGTTGGTCCTTCGGAACTGAAGCTTTC-3’ 
βL98W reverse: 
5’-GAAAGCTTCAGTTCCGAAGGACCAACTGCTGGCACAGGAGTACA-3’ 
αY50A forward:  
5’-CCTGAGTTGATAATGTTCATAGCCTCCAATGGTGACAAAGAAGATGG-3’ 
αY50A reverse: 
5’-CCATCTTCTTTGTCACCATTGGAGGCTATGAACATTATCAACTCAGGG -3’ 
αY50V forward: 
5’-CCTGAGTTGATAATGTTCATAGTCTCCAATGGTGACAAAGAAGATGG-3’ 
αY50V reverse: 
5’-CCATCTTCTTTGTCACCATTGGAGACTATGAACATTATCAACTCAGGG -3’ 
Methylation and PCR amplification was performed using a C1000 Thermal Cycler 
(Bio-Rad, Hercules, CA) under the following conditions: 20 minutes at 37°C (one cycle), 
2 minutes at 94°C (one cycle), 20 seconds at 94°C, 30 seconds at 57°C, and 5 minutes 
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at 68°C (18 cycles), and 5 minutes at 68°C (one cycle). Recombination reaction was 
performed at RT for 10 minutes. 
Mutated vector DNA was transformed into Escherichia coli DH5α-T1R competent 
cells (Invitrogen) onto LB ampicillin plates (25 grams LB agar (Fisher, Hampton, NH) in 
1 L de-ionized water supplemented with 100 µg/mL ampicillin (Sigma-Aldrich)) and 
colonies were expanded in superbroth (32 grams Tryptone (Fisher), 20 grams yeast 
extract (Fisher), 5 grams NaCl (Fisher), 1 liter de-ionized water) with 100 µg/mL 
ampicillin (Sigma-Aldrich)). Plasmid DNA from recombinant clones was isolated using a 
Miniprep kit (Qiagen). All mutagenesis products were sequenced (Genewiz, South 
Plainfield, NJ) to ensure no errors had occurred. 
Second Round of DMF5 TCR Mutations 
The following four DMF5 mutations were made using the αD26Y/βL98W DMF5 
TCR sequence: αD26Y/αN52A/βL98W, αD26Y/βN52A/βL98W, αD26Y/αK68A/βL98W 
and αD26Y/βT57A/βL98W. This was completed using a GENEART site directed 
mutagenesis kit (Invitrogen). Mutagenesis was completed in the SAMEN vector with the 
primers listed below (IDT, Coralville, IA). Base changes are denoted by bold and 
underline. 
αK68A forward:  
5'- CAGCACAGCTCAATGCAGCCAGCCAGTATG -3' 
αK68A reverse:  
5'- CATACTGGCTGGCTGCATTGAGCTGTGCTG -3' 
αN52A forward:  
5'-GTTCATATACTCCGCTGGTGACAAAGAAG-3' 
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αN52A reverse:  
5'-CTTCTTTGTCACCAGCGGAGTATATGAAC-3' 
βT57A forward:  
5'-TATTCAAATACTGCAGGTACCGCCGGCAAAGGAGAAGTCCC-3' 
βT57A reverse:  
5'-GGGACTTCTCCTTTGCCGGCGGTACCTGCAGTATTTGAATA-3' 
βN52A forward:  
5'-CATCCATTATTCAGCTACTGCAGGTACC-3' 
βN52A reverse:  
5'-GGTACCTGCAGTAGCTGAATAATGGATG-3' 
All mutagenesis and DNA isolation was performed with the same methods as described 
in the section above. All products were sequenced (Genewiz, South Plainfield, NJ) to 
ensure no errors had occurred. 
HCV 1406 TCR Mutations 
 The following two modified TCRs were made using the WT HCV 1406 TCR 
sequence: αY59A and αY59V. This was completed using a GENEART site directed 
mutagenesis kit (Invitrogen). Mutagenesis was completed in the SAMEN vector with the 
primers listed below (IDT, Coralville, IA). Base changes are denoted by bold and 
underline. 
αY59A forward: 5’-TATTATTTATTCTGGGCCAAGCAGCCTCCCAGC-3’ 
αY59A reverse: 5’-GCTGGGAGGCTGCTTGGCCCAGAATAAATAATA-3’ 
αY59V forward: 5’-TATTATTTATTCTGGGTCAAGCAGCCTCCCAGC-3’ 
αY59V reverse: 5’-GCTGGGAGGCTGCTTGACCCAGAATAAATAATA-3’ 
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All mutagenesis and DNA isolation was performed with the same methods as described 
in the section above. All products were sequenced (Genewiz, South Plainfield, NJ) to 
ensure no errors had occurred. 
Generating High Titer Producer Cell Lines 
Using a HEK293GP packaging cell line, retroviral supernatants were prepared 
and used to make a stable retroviral producer PG13 cell line expressing the TCRs in the 
SAMEN vector as described [280]. On day 0, 3 million HEK293GPs were plated in 10 
cm poly-D-Lysine coated plates (Corning) in 10 mL complete medium and incubated 
overnight at 37°C in 5% CO2. HEK293GP cells were transiently co-transfected with 20 
µg retroviral SAMEN vector DNA and 5 µg of a plasmid containing the VSV envelope 
gene using 50 µL Lipofectamine 2000 (Invitrogen) on day 1. Transfection medium was 
replaced 6 hours later with 10 mL fresh complete medium and incubated for 48 hours at 
37°C in 5% CO2. On day 2, PG13 cells were seeded at 2 million in a 10 cm tissue 
culture plate in 10 mL complete medium and incubated at 37°C in 5% CO2. On day 3, 
fresh HEK293GP viral supernatant was collected and filtered to sterilize using a 0.45 
µm filter (Millex, Billerica, MA). PG13 media was replaced with 9 mLs of filtered 
HEK293GP viral supernatant and 3 mL complete medium. Plates were incubated for 72 
hours at 37°C in 5% CO2. On day 6, PG13 cells were collected and stained using anti-
CD34-PE mAb (BioLegend) and analyzed for CD34 expression by flow cytometry. Four 
days later, cells were stained with an anti-CD34-PE (clone 561) mAb and CD34 positive 
cells were sorted for high and uniform expression using a BD FACSAria cell sorter (BD 
BioSciences, San Jose, CA) and the final PG13 cells were maintained in complete 
medium. 
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T cell and Jurkat E6.1 Cell Transduction 
T cells derived from normal healthy donors were activated by adding 50 ng/mL 
anti-CD3 monoclonal antibody (Miltenyi Biotec, San Diego, CA), 300 IU/mL rhIL-2 (rhIL-
2; Novartis Pharmaceuticals Cooperation, East Hanover, NJ), and 100 ng/mL rhIL-15 
(NCI-Biological Resources Branch, Frederick, MD) to RPMI supplemented with 10% 
FBS on day 0. To make high titer retroviral supernatant, PG13 cell lines were seeded 
overnight at 8x106 cells/T-175 cm2 cell culture flask at 37°C in 5% CO2 on day 1. On day 
2, 25 mLs of complete Iscove’s DMEM supplemented with 0.5 mLs (1 mM) sodium 
butyrate (Sigma-Aldrich) and 1 mL (10 mM) HEPES (Sigma-Aldrich) was added to 
flasks for 8-10 hours to stimulate virus production. Media was then replaced with fresh 
complete medium and incubated overnight at 37°C in 5% CO2. Fresh viral supernatants 
were collected on day 3 and filter sterilized to remove any cellular debris using 0.45 µm 
filters (Thermo Scientific, Waltham, MA).  
 Activated T cells were transduced by spinoculation on day 3 as described [330, 
363, 365, 366]. Briefly, 24-well-flat-bottom-non-tissue-culture-treated plates were coated 
with 0.5mL/well 30 μg/mL Retronectin (Takara, Mountain View, CA) overnight. The next 
day, plates were blocked using 2% bovine serum albumin (BSA) in PBS (Thermo 
Scientific) for 30 minutes. Next, virus was loaded by adding 2 mL of fresh retroviral 
supernatant per well and plates were spun for 2 hours at 2,000xg at 32°C. 1 mL of 
2x106 million/mL activated T cells in complete medium were added to the plates with 1 
mL of fresh viral supernatant. The plates were spun again for 2 hours at 2,000xg at 
32°C and then incubated overnight at 37°C in 5% CO2. After 24 hours, the TCR 
transduced T cells were transferred to cell culture flasks and plated at 1x106/mL in 
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complete medium. On day 7, transduction efficiency was determined by FACS analysis 
using anti-CD34-PE (clone 561) mAb. TCR transduced T cells were purified by positive 
selection using CD34 immunomagnetic beads (Miltenyi Biotec, San Diego, CA) and 
maintained in complete T cell medium at 37°C in 5% CO2.  
Rapid Expansion Protocol 
 Two days after CD34 enrichment, TCR transduced T cells were further expanded 
via a rapid expansion protocol (REP) to generate a large population of CD34+ TCR 
transduced T cells for T cell functional assays. 1x106 T cells were cultured in a T-175 
cm2 cell culture flask with 200x106 irradiated (50 Gy) allogeneic PBMCs (pooled from 
three normal donors) in 150 mL of complete T cell medium consisting of RPMI 1640 
medium supplemented with 10% FBS, 300 IU/mL recombinant IL-2 (rhIL-2; Novartis 
Pharmaceuticals Cooperation, East Hanover, NJ), and 100 ng/mL recombinant human 
IL-15 (rhIL-15; Biologic Resources Branch, NCI, Frederick, MD), and 30 ng/mL anti-CD3 
mAb (Miltenyi Biotech). T cells were incubated at 37°C in 5% CO2 for 10 days and 
harvested for use in T cell functional assays. 
Immunofluorescence Staining 
 PG13 cells were stained for CD34 surface expression by immunofluorescence 
using anti-CD34-PE (clone 581). This was done to confirm retroviral transductions were 
successful and to measure transduction efficiency. Briefly, cells were resuspended in 30 
μL of 2% PBSA (PBS with bovine serum albumin) and incubated with 1 μL of mAb and 
incubated at RT in the dark for 20 minutes. Cells were washed with 2% PBSA and 
resuspended in 300 μL of 2% PBSA. T cell surface markers were stained by 
immunofluorescence using the following mAbs: anti-CD4-PE/Cy7 (clone RPA-T4), anti-
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CD8-FITC (clone SK1), anti-CD3-APC/Cy7 (clone UCHT1), anti-CD34-AF700 (clone 
581), and anti-CD107A-AmCyan (clone H4A3) (BioLegend). Briefly, cells were 
resuspended in 30 μL of 2% PBSA and incubated with 1 μL of mAb and incubated at 
RT in the dark for 20 minutes. Intracellular cytokines were stained by 
immunofluorescence using the following mAbs: anti-IL-2-PerCP/Cy5.5 (clone MQ1-
17H12), anti-IFN-γ-PacBlue (clone 4S.B3), anti-IL-17A-Qdot 585 (clone BL168), anti-
TNF-α-Qdot 705 (clone MAb11), anti-IL-4-APC (clone 8D4-8), and anti-IL-22-PE (clone 
2G12A41). Briefly, cells were resuspended in 30 μL of 2% PBSA and incubated with 1.5 
μL of mAb and incubated at RT in the dark for 20 minutes. T2 cells were stained by 
immunofluorescence using anti-HLA-A2-APC (clone BB7.2) mAb (BioLegend). Briefly, 
cells were resuspended in 30 μL of 2% PBSA and incubated with 1 μL of mAb and 
incubated at RT in the dark for 20 minutes. Tumor cells were stained by 
immunofluorescence using anti-CD9-FITC (clone HI9a) and anti-HLA-A2-APC mAb 
(BioLegend). Briefly, cells were resuspended in 30 μL of 2% PBSA and incubated with 1 
μL of mAb and incubated at RT in the dark for 20 minutes. Cells were analyzed using an 
LSRFortessa flow cytometer (BD Biosciences, San Jose, CA) and the data was 
analyzed using FlowJo software (FlowJo Enterprise, Ashland, OR). 
Cytokine Release Assay 
Antigen reactivity of the TCR transduced T cells or Jurkat E6.1 cells was 
measured in cytokine release assays as described [94, 271, 366]. Briefly, T2 stimulators 
were loaded with 10 μg/mL of peptide two hours prior to coculture and incubated at 
37°C in 5% CO2. 1x105 washed and re-suspended responder T cells and 1x105 washed 
and re-suspended stimulator cells were cocultured in a 1:1 ratio in 96-well U-bottom 
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tissue culture plates (Corning) in 200 µL complete medium. Phorbol 12-Myristate 13-
Acetate (PMA) (Thermo Fisher) was added to cocultures using Jurkat E6.1 cells at 10 
ng/mL. Cocultures were incubated at 37°C in 5% CO2 for 18-20 hours. Plates were 
centrifuged at 1,500 RPM and supernatants were collected for analysis of cytokine 
release.  
 The amount of cytokine released was measured via sandwich ELISA using 
monoclonal antibodies to IFN-γ or IL-2 (BioLegend, San Diego, CA). Briefly, 96-well 
plates were coated overnight at 4°C with human IFN-γ capture mAb or IL-2 capture 
mAb. The next day, plates were washed with ELISA wash buffer (1X PBS, 0.01% 
Tween) then blocked with 200 μL 1X Assay Diluent (phosphate buffered saline solution 
containing bovine serum) for 1 hour at RT on a shaker. Plates were washed again with 
ELISA wash buffer and 100 μL of samples and standards were added. After 2 hours of 
shaking at RT, plates were washed and 100 μL of the enzyme-conjugated IFN-γ or IL-2 
detection mAb was added. After 1 hour of shaking at RT, 100 μL of Avidin-HRP was 
added and incubated on the shaker for 30 minutes at RT. Plates were then washed and 
100 μL of TMB Substrate Solution was added. Plates were incubated at RT in the dark 
for 20 minutes or until color developed in standard curve. 100 μL of 2N H2SO4 was used 
to stop the reaction. The absorbance of the plates was read at 450 nm using a 
spectrophotometer.  
Polyfunctional T cell Assay 
Polyfunctional antigen reactivity of TCR transduced T cells was measured by 
CD107A and intracellular cytokine expression as described [95]. 3x105 TCR transduced 
T cells were cocultured with 3x105 peptide loaded T2 cells in 96-well U-bottom tissue 
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culture plates in 200 μL of RPMI supplemented with 10% FBS at 37˚C, 5% CO2 for 5 
hours. 5.0 ng/mL brefeldin-A, 2.0 nM monensin (BioLegend), and anti-CD107A-AmCyan 
mAb were added at the beginning of coculture. After 5 hours, cells were stained for 20 
minutes for the following surface markers: anti-CD4-PE/Cy7, anti-CD8-FITC, anti-CD3-
APC/Cy7, and anti-CD34-AF700 (BioLegend). Cells were fixed, permeabilized, and 
stained for the following intracellular markers: anti-IL-2-PerCP/Cy5.5, anti-IFN-γ-
PacBlue, anti-IL-17A-Qdot 585, anti-TNF-α-Qdot 705, anti-IL-4-APC, and anti-IL-22-PE 
(BioLgend). Data were acquired using an LSRFortessa flow cytometer. Staining profiles 
were gated and analyzed using FlowJo.  
Polyfunctional Gating and Analysis 
Lymphocyte populations were determined by FSC (forward scatter) vs. SSC 
(side scatter). TCR transduced T cell populations were determined by CD34+CD3+ 
gating. TCR transduced T cells were further gated on CD4-CD8+ and CD4+CD8- 
populations and subsequent single functional markers. An example of gating on cell 
surface markers and functional markers is shown in Figures 4-6. Boolean gating was 
performed in FlowJo for CD107A, IFN-γ, TNF-α, IL-17A, IL-2, IL-4, and IL-22 to give 27 
potential functional phenotypes. After sequential gating in FlowJo, Pestle (NIH, 
Bethesda, MD) formatted the multivariate datasets and performed background 
subtraction using the irrelevant peptide (T2 + HCV) for each respective DMF5 TCR to 
account for background in immunofluorescence staining [367]. SPICE (Simplified 
Presentation of Incredibly Complex Evaluations) (NIH, Bethesda, MD) was utilized for 
its ability to compare the distributions of all the polyfunctional parameters [367].  
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Figure 4. Gating Strategy for Cell Surface T cell Markers. Samples were first gated 
on side scatter (SSC) and forward scatter (FSC) to isolate lymphocyte population. Cells 
in the lymphocyte gate were then gated on CD3 and CD34, double positive population 
indicates TCR transduced T cells. TCR transduced T cells were subsequently gated on 
CD4 and CD8. 
 
 
Figure 5. Gating Strategy for Functional T cell Markers. CD3+CD34+ and either 
CD4+CD8- or CD4-CD8+ (depicted above) cells were subsequently gated on the 
following individual functional markers: IFN-γ, CD107A, TNF-α, IL-2, IL-17A, IL-4, and 
IL-22. One representative donor and experiment is shown with T cells expressing the 
WT DMF5 TCR. (a) Gating strategy against T2 cells loaded with irrelevant, HCV 
peptide. (b) Application of gating strategy against T2 cells loaded with the MART-1 
9mer peptide. 
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Figure 6. Gating Strategy for Functional T cell Markers. Application of previous 
gating strategy on CD4-CD8+ T cells transduced to express the αD26Y DMF5 TCR. One 
representative donor and experiment is shown. (a) Application of gating strategy against 
T2 cells loaded with irrelevant, HCV peptide. (b) Application of gating strategy against 
T2 cells loaded with the MART-1 9mer peptide. 
 
Background subtraction can result in values below zero and values between 0.001% - 
0.09%. One of the advantages of SPICE is that it has a threshold approach. Therefore, 
cool plots were generated in SPICE to visualize any positive functional phenotype 
present over 0.1%. 
 
LDH (lactate dehydrogenase) Assay 
Lysis of tumor targets was measured using a Pierce LDH Cytotoxicity Assay Kit 
(Thermo Scientific). 1x105 washed and re-suspended TCR transduced T cells and 
1x105 washed and re-suspended target cells were cocultured in a 1:1 ratio in triplicate in 
96-well U-bottom tissue culture plates in 100 µL medium. Cells for the following controls 
were also plated: effector cell spontaneous LDH release, target cell spontaneous LDH 
release, target cell maximum LDH, volume correction, and culture medium background. 
Cocultures were incubated at 37°C in 5% CO2 for 18 hours. 45 minutes before 
harvesting the supernatant, 10 µL of provided Lysis Buffer was added to wells 
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containing the target cell maximum LDH control to determine the maximum lysis and to 
wells containing the volume correction control to account for volume increase caused by 
the addition of the Lysis Buffer. Plates were spun at 300 x g for 3 minutes and 50 µL of 
supernatant was collected and transferred to 96-well flat-bottom tissue culture plates 
and mixed with 50 µL of provided Reaction Mixture for 30 minutes at RT, in the dark. 
Reaction was stopped with 50 µL of provided Stopping Solution. Absorbance was read 
at 490 nm and 680 nm using a spectrophometer. Absorbance value at 680 nm 
(background signal from spectrophometer) was subtracted from the absorbance value 
at 490 nm to determine LDH activity. The percent cytotoxicity was calculated using the 
following formula: % cytotoxicity = ((experimental value – effector cell spontaneous 
control – target cell spontaneous control) / (target cell maximum control – target cell 
spontaneous control)) x 100.  
Combinatorial Peptide Library 
Functional assays using a combinatorial peptide library revealed results pertinent 
to the conclusions of these studies. These specific experiments were completed by the 
Baker Lab at the University of Notre Dame. These results were obtained as follows: A 
decameric combinatorial peptide library was obtained from Pepscan (Lelystad, 
Netherlands). The library excluded cysteine and fixed p2 and p10 to leucine and valine, 
respectively, for a total of 198 (approximately 1.7×1010) peptides. The library was 
composed of 152 sub-libraries in which each position of the peptide, except p2 and p10, 
was fixed at each amino acid, excluding cysteine. The library scan was conducted as 
previously described [368, 369]. Briefly, 1x105 T2 cells were loaded with 100 μM total 
peptide concentration of each sub-library for two hours at 37 °C. An equal number of 
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PMA simulated (50 ng/mL) Jurkat 76 CD8+ cells transduced with the WT DMF5 TCR, 
αD26Y/βL98W DMF5 TCR, or αD26Y/αY50A/βL98W DMF5 TCR were added and 
cocultured for 18-20 hours at 37°C, after which supernatant was harvested and assayed 
for IL-2 via ELISA. Combinatorial peptide library scans were repeated three times with 
freshly generated cells and the results were averaged.  
Crystallization and Structural Analysis 
 TCR/pMHC crystal structures are shown in this dissertation and are a critical 
component of the data analysis. These experiments were completed by the Baker Lab 
at the University of Notre Dame. The crystal structures were obtained as follows: 
Crystals of the αD26Y/βL98W DMF5 TCR/MART-1 decamer/HLA-A2 complexes were 
grown from 12% PEG 3350, 0.25 M MgCl2 buffered with 0.1 M HEPES (pH 8.0) at 
25°C. Crystallization was performed using sitting drop/vapor diffusion. For 
cryoprotection, crystals were transferred into 20% glycerol/80% mother liquor for 30 
seconds and immediately frozen in liquid nitrogen. Diffraction data were collected at the 
22ID (SER-CAT) beamlines at the Advanced Photon Source, Argonne National 
Laboratories, Argonne, IL. Data reduction was performed with HKL2000. The ternary 
complexes were solved by molecular replacement using PHENIX and Protein Data 
Bank (PDB) entry 3QDG as the reference model [370]. Rigid body refinement, followed 
by translation/libration/screw (TLS) refinement and multiple steps of restrained 
refinement were performed. TLS groups were automatically chosen by phenix.refine. 
Once defined, TLS parameters were included in all subsequent steps of the refinement. 
Anisotropic and bulk solvent corrections were taken into account throughout refinement. 
After TLS refinement, it was possible to unambiguously trace the position of peptides 
61 
 
and TCR CDR loops in all structures against σA-weighted 2Fo-Fc maps. Evaluation of 
models and fitting to maps were performed using COOT [371]. The template structure 
check in WHATIF [372] and MolProbity [373] was used to evaluate the structures during 
and after refinement. Atomic positioning was verified with an iterative-build OMIT map 
calculated in PHENIX [374]. Structures were visualized using PyMOL. Analysis of 
hydrogen bonds was performed with HBPlus [375], using hydrogen-acceptor maximum 
distance of 2.7 Å and a donor-acceptor maximum distance of 3.6 Å. Solvent accessible 
surface areas were measured in Discovery Studio (Accelrys Inc.) using a probe radius 
of 1.4 Å. The structure has been deposited with the Protein Data Bank (PDB ID 4L3E).  
Surface Plasmon Resonance 
 3D affinity measurements are shown in this dissertation and are a critical 
component of the data analysis. These experiments were completed by the Baker Lab 
at the University of Notre Dame. The 3D affinity measurements were obtained as 
follows: A Biacore T200 instrument was used to perform surface plasmon resonance 
experiments. Amine coupling was used to immobilize the TCR to CM-5 sensor chips at 
1500-2000 response units and pMHC complex was injected as analyte in all 
experiments. All samples were thoroughly dialyzed in HBS-EP buffer (10 mM HEPES 
(pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P-20) followed by degassing 
for at least 15 minutes before use. pMHC injections covered a concentration range of 
0.5-150 μM at a flow rate of 5 μL/minute at 25°C. Multiple steady-state data sets were 
globally fit using a 1:1 Langmuir binding model with BIAevaluation 4.1 to extend the 
range and accuracy of measurements as previously described [167, 376]. 
Measurements of TCR binding to the MMW/HLA-A2 complex were performed using a 
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kinetic titration assay at 25°C [377], with chip densities near 150 RU for the 
αD26Y/βL98W TCR and 500 RU for the αD26Y/αY50A/βL98W TCR. pMHC 
concentrations ranged from 32-500 nM for the αD26Y/βL98W TCR and 1-16 μM for the 
αD26Y/αY50A/βL98W TCR. Kinetic titrations used a flow rate of 100 μL/minute.  
Micropipette Adhesion Frequency Assay 
2D affinity measurements are shown in this dissertation and are a critical 
component of the data analysis. These experiments were completed by the Evavold 
Lab at the University of Utah. The 2D affinity measurements were obtained as follows: 
The relative 2D affinity of JurkatE6.1 cells TCR transduced to express the WT and 
mutant DMF5 TCRs was measured using the previously characterized 2D micropipette 
adhesion frequency assay [162, 378-380]. Briefly, RBCs coated with a range of Biotin-
LC-NHS (BioVision, Milpitas, CA) were then coated with 0.5 mg/mL streptavidin 
(Thermo Scientific) followed by 1 µg of biotinylated MART-1 10mer monomer. The 
adhesion frequency between TCR transduced JurkatE6.1 cells and ligand coated RBCs 
aspirated on opposing pipettes were observed using an inverted microscope. An 
electronically controlled piezoelectric actuator repeated JurkatE6.1 cell contact with the 
pMHC coated RBCs 50 times for controlled contact area (Ac) and time (t). Upon 
retraction of the T cell, adhesion (binding of TCR-pMHC) was observed by distention of 
the RBC membrane, allowing for quantification of adhesion frequency (Pa) at 
equilibrium. Surface pMHC (ml) and TCR beta (mr) densities were determined by flow 
cytometry using MHC class I anti-human HLA-A2 –PE (clone BB7.2) mAb (BioLegend) 
and anti-human α/β TCR-PE (clone IP26) mAb (BioLegend), both at saturating 
concentrations, and BD QuantiBRITE PE Beads for standardization (BD Biosciences, 
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San Jose, CA). The calculation of molecules per area were done by dividing the number 
of TCR and pMHC per cell by the respective surface areas. The relative 2D affinities 
were calculated using the following equation: AcKa = -ln [1-Pa(1)]/mrml. Normalized 
adhesion frequency was calculated using the equation (-ln(1-Pa(s))/mpMHC). Geometric 
mean of affinities and normalized adhesion bonds are reported ± SEM.  
In vivo NSG A2 Tumor Growth Models 
The in vivo studies completed in this dissertation utilized an established human 
xenograft mouse model. Using immunocompromised mice, xenografts are 
advantageous to examine therapeutic efficacy against human tumors [381-383]. 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) HLA-A2 immunodeficient mice were obtained 
from Jackson Laboratories (Bar Harbor, ME). All mice were housed in our AALAC-
approved animal facility at the Loyola University Health Science Campus. The hind 
flanks of mice were shaved at least one day prior to tumor challenge. Under inhalatory 
anesthesia, 6-8 week old NSG A2 mice were inoculated subcutaneously with 5×106 
MEL 624 tumor cells in 100 μL PBS. Tumor growth was assessed 2-3 times a week by 
caliper measurements. Tumor areas were determined by the following formula: area = 
(3.14 x length x width)/4. All TCR transduced T cells used for therapeutic injection were 
CD34 enriched using immunomagnetic beads (Miltenyi Biotec). All TCR transduced T 
cell populations completed a REP (previously described) for 10-12 days to obtain a 
large number of TCR transduced T cells for therapy. High and uniform CD34 expression 
was confirmed amongst treatment groups prior to injection. The number of injected TCR 
transduced T cells is stated in subsequent sections in each respective experimental 
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model. Mice were sacrificed when tumors reached 150 mm2 in size or 10% of body 
weight by CO2 inhalation followed by cervical dislocation. 
Human PBMC Engraftment Prior to Tumor Challenge 
 NSG mice have been previously engrafted with human hematopoietic stems cells 
to recapitulate a human immune system in the mouse [384, 385]. We developed a 
model of engraftment using human PBMC to determine if engraftment supported 
introduced human TCR transduced T cells. First, human PBMCs were thawed and 
cultured in RPMI supplemented with 10% FBS, 300 IU/mL rhIL-2, and 100 ng/mL rhIL-
15 and were incubated at 37°C in 5% CO2 for 24 hours. After 24 hours, 6-8 week old 
NSG HLA-A2 mice were injected with 10x106 human PBMCs in 100 uL PBS either via 
retro-orbital or intraperitoneal route of injection. The persistence of engrafted cells in the 
blood was monitored weekly. Briefly, a 3mm Goldenrod lancet (Fisher Scientific) was 
used to obtain one drop of blood from the facial vein. Red blood cells were lysed by 
incubation with 200 μL of ACK Lysis Buffer (Lonza, Basel, Switzerland) for 5 minutes at 
RT. Cells were washed twice with 1 mL of 2% PBSA and were immunofluorescently 
labeled using human anti-CD3-APC/Cy7 antibody (BioLegend). 7 days after PBMC 
engraftment, NSG A2 mice were inoculated subcutaneously with 5×106 MEL 624 tumor 
cells in 100 μL PBS. Tumor growth was assessed 2-3 times a week by caliper 
measurements. 17 days post tumor challenge, or when tumors reached about 4 x 4 
mm, 10x106 human TCR transduced T cells in 100 μL PBS were injected retro-orbitally. 
The persistence of TCR transduced T cells was monitored weekly in the blood of mice 
as described above. Cells were immunofluorescently labeled using human anti-CD3-
APC/Cy7 and human anti-CD34-PE antibodies (BioLegend). Mice were closely 
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observed for cachexia as a potential indicator of autoimmunity. Mice were sacrificed 
when tumors reached 150 mm2 in size or 10% of body weight by CO2 inhalation 
followed by cervical dislocation. 
Cytokine Support of Introduced Human TCR Transduced T cells 
 Cytokines were administered to NSG A2 mice to determine their effect on 
introduced human TCR transduced T cell persistence. 6-8 week old NSG A2 mice were 
inoculated subcutaneously with 5×106 MEL 624 tumor cells in 100 μL PBS. Tumor 
growth was assessed 2-3 times a week by caliper measurements.17 days later, or when 
tumors reached about 4 x 4 mm, 10x106 TCR transduced human T cells in 100 μL PBS 
were injected retro-orbitally. Beginning on day 17, groups of mice were given 2.5 μg 
rhIL-15 in 100 μL PBS every 3 days or 60,000 IU rhIL-2 in 100 μL PBS twice a day for 
four days, then once a day every 3 days via intraperitoneal injection [386, 387]. Tumors 
from one to two mice per group were processed on day 16 using a tumor dissociation kit 
(Miltenyi Biotec) to examine the persistence of TCR transduced T cells. Spleens from 
one to two mice per group were processed on day 16 to examine the persistence of 
TCR transduced T cells. Briefly, spleens were manually disrupted using the plunger of a 
3 mL syringe over a 70 μm cell strainer (Corning). Red blood cells were lysed by 
incubation with 200 μL of ACK Lysis Buffer (Lonza, Basel, Switzerland) for 5 minutes at 
RT. Tumor and spleen derived cells were washed twice with 1 mL of 2% PBSA and 
were immunofluorescently labeled using human anti-CD3-APC/Cy7 and human anti-
CD34-PE antibodies (BioLegend). Mice were sacrificed when tumors reached 150 mm2 
in size or 10% of body weight by CO2 inhalation followed by cervical dislocation. 
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Checkpoint Blockade with Human TCR Transduced T cells  
Checkpoint blockade was administered to NSG A2 mice to determine the effect 
on introduced human TCR transduced T cell persistence. 6-8 week old NSG A2 mice 
were inoculated subcutaneously with 5×106 MEL 624 tumor cells in 100 μL PBS. Tumor 
growth was assessed 2-3 times a week by caliper measurements. 17 days later, or 
when tumors reached about 4 x 4 mm, 10x106 TCR transduced human T cells in 100 μL 
PBS were injected retro-orbitally. Beginning on day 17, groups of mice were given 0.25 
mg of anti-PD-1 mAb (Bio X Cell, West Lebanon, NH) in 100 μL Buffer (Bio X Cell, West 
Lebanon, NH) every 3 days (10 mg/kg mouse) via intraperitoneal injection. Mice were 
sacrificed when tumors reached 150 mm2 in size or 10% of body weight by CO2 
inhalation followed by cervical dislocation. 
In vivo CTL Assay 
 An in vivo CTL assay was performed to determine if TCR transduced T cells 
could elicit target specific killing in vivo. 6-8 week old NSG A2 mice were injected with 
100 μL PBS or 10x106 WT DMF5 TCR transduced T cells in 100 μL PBS on day 0. On 
day 1, HLA-A2+ PBMCs were pulsed with the MART-1 9mer peptide for 2 hours, as 
previously described. HLA-A2+ PBMCs were incubated with 0.5 μM of 
carboxyfluorescein succinimidyl ester (CFSE) (Thermo Fisher) for 8 minutes at 37˚C. 
MART-1 9mer pulsed HLA-A2+ PBMCs were incubated with 5 μM of CFSE (Thermo 
Fisher) for 8 minutes at 37˚C. CFSE labeled cells were washed 3 times in 25 mLs of 
warmed RPMI supplemented with 10% FBS. CFSE high and CFSE low cells were 
mixed in a 1:1 ratio. 12x106 CFSE labeled cells in 100 μL PBS were injected into mice 
via retro-orbital route. Non-transferred CFSE labeled cells were kept in vitro at 37˚C as 
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the non-transferred control. On day 3, spleens were isolated and processed as 
described above. Cells were labeled with anti-HLA-A2-APC mAb (BioLegend) and 
analyzed via flow cytometry. Ratio = CFSE low:CFSE high. The % MART-1 specific 
lysis was determine by the following formula: % specific lysis = ((1-(non-transferred 
control ratio))/experimental ratio) x 100.  
Statistical Analysis 
 Comparisons of WT DMF5 TCR vs. mutant DMF5 TCRs were evaluated by two-
way ANOVA using Sidak’s multiple comparisons test. **** P <0.0001; *** P < 0.001; ** P 
< 0.01; * P < 0.05. Results are represented as mean ± standard error of the mean 
(SEM) unless otherwise indicated. Experiments were repeated 2-3 times in 2-4 
independent donors.  
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CHAPTER THREE 
RESULTS 
Structure-Guided Approach and DMF5 Mutations 
 Despite the success observed in clinical trials where TCR gene-modified T cells 
were used, there still remains areas in which improvement is needed. These areas 
include both the efficacy and the safety of the treatment in patients. One of the 
drawbacks of using TCRs that target self-antigens in TCR gene-modified T cells is that 
they generally harbor a low affinity, due to negative selection during T cell development. 
Negative selection is critical in order to eliminate potentially autoreactive T cells [41, 
388]. Therefore, their anti-tumor efficacy can be suboptimal for treatment. One strategy 
to enhance anti-tumor efficacy is to enhance the affinity of the TCR. Yeast or phage 
display strategies have been implemented for affinity enhancement [295, 296, 343, 344, 
389]. Albeit, affinity enhanced TCRs can result in unanticipated cross-reactivity in T 
cells and have resulted in deaths in clinical trials [5, 6]. Not all affinity enhanced TCRs 
have elicited adverse events [302]. However, when modifying a TCR, more meticulous 
strategies are needed in order to fine-tune the specificities of a TCR. 
 Here, in collaboration with the Baker’s laboratory, we have developed a novel 
structure-guided design approach to fine-tune TCR antigen specificity while 
simultaneously reducing cross-reactivity. This strategy is based on the principles of 
positive and   negative design. Positive design was proposed to introduce favorable 
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interactions between the TCR and the peptide. Conversely, negative design was 
proposed to weaken existing favorable interactions between the TCR and the MHC. 
Herein, we used the DMF5 TCR and the MART-1 peptide in the context of HLA-A2 for a 
model to test this structure-guided approach. A graphical depiction of this positive and 
negative design strategy is shown in Figure 7. Both the MART-1 nonameric (positions 
27-35) and decameric (positions 26-35) epitopes are recognized by MART-1 reactive T 
cells [314, 324-326, 390]. It was further demonstrated that the decameric epitope bound 
more tightly to the HLA-A2 molecule than the nonameric epitope [391]. Mutation of the 
decameric anchor residue, alanine, to a leucine, further enhanced immunogenicity and 
binding to the HLA-A2 molecule, more so than anchor modification with the nonameric 
epitope [391, 392]. The DMF5 TCR recognized both the MART-1 nonameric epitope 
(AAGIGILTV) and the anchor-modified decameric epitope (ELAGIGILTV) in the context 
of HLA-A2. In these studies, MART-1 9mer will refer to the AAGIGILTV peptide, and 
MART-1 10mer will refer to the anchor modified, ELAGIGILTV peptide. The crystal 
structures of the DMF5 TCR/pMHC indicated that despite differences in the MART-1 
9mer and 10mer peptide conformations in HLA-A2, the DMF5 TCR engaged both of the 
peptides with identical binding modes. The superimposed structures of the DMF5 TCR 
bound to the MART-1 9mer and 10mer peptides/HLA-A2 are shown in Figure 8 [325]. 
Specifically, the conformations of the CDR loops are the same between the two 
peptides in both the side and top view. For these reasons, the crystal structure of the 
DMF5 TCR engaged with HLA-A2 and the MART-1 10mer was utilized for structure-
based design due to the MART-1 10mer’s enhanced binding and stability in the HLA-A2 
molecule [351].  
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Figure 7. Graphical Schematic of Positive and Negative Design Approach in the 
DMF5 TCR. In collaboration with the Baker lab, we have developed a positive and 
negative structure-guided design approach to enhance antigen specificity and reduce 
cross-reactivity. This was first implemented in a model using the DMF5 TCR and 
MART-1 peptide. The MART-1 peptide in the context of the HLA-A2 MHC class I 
molecule is shown in purple and green, respectively. The DMF5 TCR is shown in blue 
and CD3 is shown in red. The left complex depicts the WT DMF5 TCR expressed on a 
T cell, engaging with the MART-1/HLA-A2 complex on a melanoma cell. The right TCR 
depicts the combinatorial strategy of positive and negative (+/-) design in the DMF5 
TCR. The TCR is expressed on a T cell and engages with the MART-1/HLA-A2 
complex on a melanoma cell. However, positive mutations, depicted by the red/orange 
bursts, were introduced in the DMF5 TCR and are proposed to enhance MART-1 
peptide specificity. Conversely, negative mutations, depicted by the white space 
between the TCR and HLA-A2, were introduced in the DMF5 TCR and are proposed to 
weaken TCR binding with the HLA-A2 MHC class I.
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Figure 8. Crystal Structure of the DMF5 TCR and MART-1 Nonamer and Decamer 
Peptide/HLA-A2 Complexes. The DMF5 TCR binding with the nonamer peptide/HLA-
A2 complex is depicted in yellow (AAGIGILTV). The DMF5 TCR binding with the 
decameric/HLA-A2 complex is depicted in purple (ELAGIGILTV). (a) Side view of the 
DMF5 TCR complex with the nonamer and decamer peptide/HLA-A2 complexes. (b) 
Top view of superimposition from panel a. Identical overlap of CDR loops of the DMF5 
TCR over the two peptide/HLA-A2 complexes is shown. These structures were provided 
by the Baker lab [370]. 
  
The structure-guided design strategy, developed in collaboration with the Baker 
lab, was first implemented in the DMF5 TCR. Two positive mutations and two negative 
mutations were designed based on the crystal structure of the DMF5 TCR/MART-1 
10mer/HLA-A2 tri-molecular complex. DMF5 TCR residues were identified for positive 
mutations by simulating different point mutations in the TCR within 5.5 Ä of the pMHC 
and were chosen based on their predicted ability to enhance the affinity of the DMF5 
TCR [351, 393, 394]. The 5.5 Ä distance threshold was set in order to avoid TCR 
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mutations enhancing binding with the MHC. The first positive mutation substituted an 
aspartic acid with a tyrosine at position 26 (αD26Y) in the CDR1 region of the TCR 
alpha chain. This mutation was designed to enhance charge complementarity with the 
N-terminal region of the MART-1 peptide. The X-ray structure of the WT DMF5 TCR 
compared to the αD26Y DMF5 TCR is shown in Figure 9 [351].  
More specifically, in the complex with the WT TCR, αD26 and the glutamic acid 
in position 1 of the MART-1 10mer peptide are in close proximity. Consequently, the 
negative charges between the aspartic acid and the glutamic acid result in an 
unfavorable repulsion of charge (Figure 10) [349]. Furthermore, the αD26 side chain 
also induces charge repulsion with the side chain of the glutamic acid at position 58 in 
the HLA-A2 α1 helix [349]. Tyrosines are large residues and thus can participate in a 
number of van der Waals forces and electrostatic interactions. The rigid, bulky, and 
amphipathic nature of tyrosine provides structural utility [395]. This explains why 
mutations that have been shown to enhance affinity frequently replaced small polar or 
charged amino acids with large hydrophobic or amphipathic amino acids [72]. The 
αD26Y TCR mutation eliminates the charge repulsion with the peptide and 
consequently enhances charge complementarity with the peptide and increases the 
TCR affinity to pMHC (MART-1/HLA-A2). The peptide is only a small exposed area 
compared to the MHC and the peptide and MHC are tightly packed together. This 
makes it quite difficult, even when utilizing a meticulous targeted design strategy, to 
identify residues and mutations in the TCR that will only affect TCR binding with peptide 
and not the MHC as well. 
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Figure 9. X-ray Structure of WT and αD26Y DMF5 TCRs in Complex with pMHC. 
The DMF5 TCR alpha chain is yellow, the HLA-A2 is green, and MART-1 peptide is 
magenta. (a) The WT residue, αD26, shown in purple. (b) The mutated, αY26, shown in 
purple. Hydrogen bonds involved in the side chain and bound water molecule are 
depicted by dashed lines. These structures were provided by the Baker lab [351].  
 
 
 
Figure 10. Structural Impact of the αD26Y DMF5 TCR Mutation on Charge 
Repulsions with the pMHC. The HLA-A2 complex is shown in blue, the MART-1 
10mer peptide is shown in yellow, and the DMF5 TCR is shown in pale brown. (a) In the 
WT DMF5 TCR, the αD26 exhibits unfavorable charge repulsion with the glutamic acid 
at position 1 of the MART-1 10mer peptide and with the glutamic acid at position 58 in 
the HLA-A2 complex. (b) In the αD26Y DMF5 TCR, the charge repulsion with the 
peptide and MHC is eliminated. These structures were provided by the Baker lab [349]. 
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A schematic of how the αD26Y TCR mutation alters unfavorable charge repulsion to 
favorable charge repulsion with the pMHC is shown in Figure 10 [349]. In conclusion, 
the αD26Y TCR mutation is a positively designed mutation proposed to enhance 
binding with the MART-1 peptide by enhancing charge complementarity with the N-
terminal region of the MART-1 peptide. 
The αD26Y TCR mutation was proposed to enhance charge complementarity 
with the N-terminal region of the MART-1 peptide. However, other epitopes that conform 
to similar structures in their N-terminal region could consequently be recognized with 
this mutation. Therefore, a different positive mutation, βL98W, was designed in the 
CDR3 region of the DMF5 TCR beta chain, to be more MART-1 specific [351]. Because 
the CDR3 loops of TCRs are most often positioned over the center of the peptide to 
make contact with the peptide, the βL98W TCR mutation was designed to target a 
specific residue in the MART-1 peptide [71]. This TCR mutation was proposed to 
improve shape complementarity with the leucine at position 7 or 8 in the 9mer or 10mer 
MART-1 peptide, respectively. The X-ray structure of the WT DMF5 TCR compared to 
the βL98W DMF5 TCR is shown in Figure 11 [351]. The βL98W TCR mutation was 
chosen based upon its ability to enhance predicted TCR affinity against the MART-
1/HLA-A2 complexes [351]. As mentioned previously about tyrosine, tryptophan is also 
a bulky and amphipathic amino acid and thus, provides structural and chemical value, 
and enhanced the DMF5 TCR affinity against the MART-1/HLA-A2 complex [72, 395]. 
Furthermore, in a previously generated peptide panel comprised of 9mer epitopes 
selected upon their sequence homology with the MART-1 peptide, the leucine in 
position 7 was absent in about 60% of the sequence homologous epitopes [327]. 
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Figure 11. X-ray Structure of WT and βL98W DMF5 TCRs in Complex with pMHC. 
The DMF5 TCR beta chain is pale pink, the HLA-A2 is green, and MART-1 peptide is 
magenta. (a) The WT residue, βL98, shown in purple. (b) The mutated, βW98, shown in 
purple. Structures were provided by the Baker lab [351].  
 
This suggested the βL98W TCR mutation might have less of an impact on the majority 
of MART-1 mimics in terms of enhancing binding and recognition. Overall, the βL98W 
DMF5 TCR mutation is the second positively designed TCR mutation, and is proposed 
to improve shape complementarity specifically with the leucine at position 7 or 8 in the 
9mer or 10mer MART-1 peptide, respectively.  
The field generally considers high affinity TCRs optimal for T cell function and 
therapeutic efficacy [180, 396]. Therefore, we wanted to determine the effect of binding 
and antigen specificity with a high affinity DMF5 TCR variant by combining the two 
previously described TCR mutations. More specifically, we wanted to determine how the 
combination of the two positive DMF5 TCR mutations (αD26Y and βL98W) in the 
αD26Y/βL98W double mutant DMF5 TCR, altered the recognition of MART-1 compared 
to either single mutant DMF5 TCRs. This combination was proposed to result in a 
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DMF5 TCR variant with substantial enhancement towards the MART-1/HLA-A2 
complex due to the additive binding enhancements. The X-ray crystal structure of the 
WT DMF5 TCR overlaid with the αD26Y/βL98W DMF5 TCR is shown in Figure 12 
[351]. Compared to the structure bearing the WT DMF5 TCR, there were no alterations 
of the interface TCR CDR loops or the peptide with the αD26Y/βL98W TCR, indicating 
this structure-based design strategy, utilized to identify specific residues for mutation, 
did not disrupt the TCR/pMHC interface or the neighboring side chains. Furthermore, 
compared to the WT TCR, the tyrosine and tryptophan mutant side chains more 
expansively make direct contact with the MART-1 peptide in the αD26Y/βL98W TCR 
[351]. In summary, the αD26Y/βL98W DMF5 TCR is proposed to enhance MART-1 
peptide binding more than either single mutant DMF5 TCRs and this is depicted in the 
crystal structures.   
This structure-guided approach is based upon the idea of positive and negative 
design. Even though the αD26Y/βL98W DMF5 TCR did not alter the CDR loops 
compared to the WT TCR in the TCR/pMHC complex, it is possible that these mutations 
could enhance off-target binding with MART-1 “like” epitopes. Therefore, introduction of 
negative mutation would offset this potentially enhanced off-target cross-reactivity. This 
is of critical importance because sole implementation of positive mutations, or sole 
introduction of only favorable interactions with the peptide could allow for unwanted 
effects on specificity. Thus, negative mutations were implemented to offset or 
compliment the DMF5 TCR mutations made to enhance peptide binding. Negative 
mutations were generated by identifying a TCR residue that if mutated, would weaken 
TCR binding with the MHC. 
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Figure 12. X-ray Structure of the WT TCR Overlaid with the αD26Y/βL98W DMF5 
TCR in Complex with pMHC. The DMF5 TCR alpha chain is yellow, the DMF5 TCR 
beta chain is pale pink, the HLA-A2 is green, and MART-1 10mer peptide is magenta. 
The α26 TCR residue is shown in purple (above N-terminal end of MART-1 peptide). 
Both the aspartic acid and tyrosine residues are depicted. The β98 TCR residue is 
shown in purple (closer to C-terminal end of MART-1 peptide). Both the leucine and 
tryptophan residues are depicted. Structure was provided by the Baker lab [351]. 
 
 
The αY50 residue in the CDR2 region of the DMF5 TCR alpha chain was 
identified and chosen for designing negative mutations for multiple reasons. First, αY50 
makes contact with an evolutionarily conserved and exposed region of HLA-A2. 
Specifically, αY50 makes contact with the glutamic acid at position 154, the glutamine at 
position 155, and the alanine at position 158 in the α2 helix of HLA-A2 [350]. Studies 
indicated that up to 16% of sequenced TCRs have a tyrosine at this residue, however, 
other amino acids at this residue still demonstrate conserved interaction with the same 
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area of HLA-A2 [37]. For example, in all known structures of Vα12-2 TCRs bound to 
pMHC, the tyrosine at position 50 interacts with the same residues in the HLA-A2 α2 
helix [397]. It has been demonstrated that this TCR residue is important for interaction 
with MHC class I in many other TCRs as well [398]. Furthermore, evidence suggest that 
tyrosines are one of the more frequently used amino acids in prominent, conserved 
interactions. The large amphipathic nature of tyrosine allows it to maintain van der 
Waals forces more due to its size, rather than geometry. Overall, this tyrosine at 
position 50 in the DMF5 TCR alpha chain could be important for TCR binding with MHC 
because it can accommodate variation in structural changes within the TCR upon 
binding different peptides in the context of MHC [337]. 
We and the Baker laboratory believed the αY50 DMF5 TCR residue was a 
suitable residue for designing negative mutations, for the reasons described above. Two 
different TCR mutations were made at this residue: αY50A and αY50V. The tyrosine to 
alanine mutation was proposed to lose all contact with the HLA-A2 at positions 154, 
155, and 158, whereas the tyrosine to valine mutation was proposed to weaken binding 
with HLA-A2 at positions 154, 155, and 158, but not lose all contact. The X-ray structure 
of the αY50A and αY50V DMF5 TCR mutations compared to the WT DMF5 TCR is 
shown in Figure 13. Overall, the crystal structures indicated no structural perturbations 
in the TCR with both of these mutations, aside from the directed removal or weakening 
of bonds with the α2 helix of HLA-A2.  
 
79 
 
 
Figure 13. X-ray Structure of αY50A and αY50V DMF5 TCR Mutations in Complex 
with pMHC. The DMF5 TCR alpha chain is yellow, the HLA-A2 is green, the WT αY50 
residue is purple, and MART-1 peptide is magenta. (a) The αA50 is shown in orange. 
(b) The αV50 is shown in red. Structures were provided by the Baker lab. 
 
The idea for utilizing this design strategy was not necessarily just to enhance 
DMF5 TCR affinity with the MART-1/HLA-A2 complex, but rather the idea was to 
redistribute the binding free energy to be more focused on the MART-1 peptide and less 
focused on the MHC. The combination approach (positive and negative design) is 
imperative in order to fine tune the antigen specificity of the DMF5 TCR. Explicitly, 
DMF5 TCR mutations that enhance binding to the MART-1 peptide (αD26Y and 
βL98W) will be offset, or counterbalanced, by the TCR mutations that weaken binding 
with the MHC (αY50A or αY50V). In summary, the proposed net effect of this strategy in 
the DMF5 TCR will result in TCRs with an enhanced affinity towards the MART-1 
peptide, but weakened affinity towards other, off-target, peptides presented in the 
context of HLA-A2.  
The following five DMF5 mutant TCRs were generated: αD26Y, βL98W, 
αD26Y/βL98W, αD26Y/αY50A/βL98W, and αD26Y/αY50V/βL98W. The 3D affinities of 
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each TCR with the MART-1 9mer and 10mer peptides in the context of HLA-A2 were 
measured via SPR (Table 3). In general, TCR affinity against pMHC has been 
measured to range within 1-300 μM [399]. T cells that recognize self-antigens generally 
harbor TCRs with affinities ranging within 10-100 μM, while T cells that recognize 
foreign antigen harbor TCRs with affinities up to 1 μM [143, 400]. While implementing 
the structure-guided design strategy, it was of interest to generate TCRs that lie within 
the low micromolar range since this is similar to TCRs that recognize foreign peptides 
and result in full T cell activation. The 3D affinity of the WT DMF5 TCR measured 
against the MART-1 9mer/HLA-A2 complex and 10mer/HLA-A2 complex was 37 μM 
and 11 μM, respectively. These measurements fall within the range of TCRs that target 
self-antigens. The αD26Y TCR mutation enhanced the affinity of the TCR within this 
range against the MART-1 9mer and 10mer with the affinity measured to be 7 μM and 
1.3 μM, respectively. The βL98W TCR mutation also enhanced the affinity compared to 
the WT TCR, with the affinity of the MART-1 9mer and 10mer measured to be 12 μM 
and 5.3 μM, respectively. When combined, the αD26Y/βL98W double mutant TCR 
further enhanced the affinity compared to the WT TCR, with MART-1 9mer and 10mer 
affinity measurements being 1.8 μM and 0.043 μM, respectively. This is notable 
because it is very rare to find natural TCRs with affinities in the nanomolar range, as the 
upper limit or threshold for optimal T cell function has been observed to fall within 1-5 
μM [142, 351]. The αD26Y/αY50A/βL98W TCR reduced affinity compared to the WT 
TCR, with MART-1 9mer and 10mer affinities measured to be 228 μM and 36.4 μM, 
respectively. 
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Table 3. WT and Mutant DMF5 TCR-pMHC 3D Binding Affinities Measured via 
SPR. The average KD values of three independent experiments + standard error of the 
mean are shown. 3D TCR affinity measurements were performed in the Baker lab. 
 
However, the affinity against the MART-1 10mer still falls within range of normal TCRs 
that recognize self-antigen, similar to the affinity of the WT TCR measured with the 
MART-1 9mer. Lastly, the αD26Y/αY50V/βL98W TCR also had reduced affinity 
compared to the WT TCR, with MART-1 9mer and 10mer affinities measured to be 140 
μM and 16.1 μM, respectively. Like the αD26Y/αY50A/βL98W TCR, the affinity of the 
αD26Y/αY50V/βL98W TCR with the MART-1 10mer falls within the upper range of 
normal TCRs that recognize self-antigen. These results implicate that as predicted, the 
DMF5 TCR mutations proposed to enhance binding to the MART-1 peptide, αD26Y and 
βL98W, enhanced TCR 3D affinity, and the combination of these two mutations, 
αD26Y/βL98W, drastically enhanced TCR 3D affinity compared to the WT DMF5 TCR. 
Furthermore, combining the αD26Y/βL98W TCR mutations with a mutation that 
weakens TCR binding with the MHC, αD26Y/αY50A/βL98W and αD26Y/αY50V/βL98W, 
reduced TCR 3D affinity lower than the WT DMF5 TCR. Lastly, these 3D TCR affinity 
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measurements exemplify the effect of optimal peptide N-terminal anchor residues on 
TCR affinity. These 3D affinity measurements will be important in later sections in terms 
of their correlation to T cell function and cross-reactivity. 
WT vs. Mutant DMF5 TCR Recognition of Individual Alterations in the MART-1 
Peptide 
 We first wanted to determine how the structure-guided mutant DMF5 TCRs 
affected recognition of the MART-1 9mer peptide when single structural alterations were 
introduced, compared to the WT DMF5 TCR. The alanine scan assay is well 
established as a method to determine residues in a peptide that are important for TCR 
recognition [393, 401, 402]. We generated a panel of alanine substituted peptides 
based on the sequence of the MART-1 9mer peptide (AAGIGILTV). If an alanine was 
already present at a residue, an isoleucine was substituted instead. Herein, we could 
determine how mutations in the DMF5 TCR altered recognition of alanine substituted 
MART-1 peptides. 
We transduced Jurkat E6.1 cells to express the WT or each mutant DMF5 TCR. 
Jurkat E6.1 cells were used here to eliminate the donor variability generally associated 
with polyclonal PBL-derived T cells. Transduction efficiencies four days after 
transduction are shown in Figure 14. The data indicates that initial Jurkat E6.1 
populations were transduced between 13% and 18% (based on our marker of 
transduction, CD34). Jurkat E6.1 cells express minimal levels of endogenous CD34, as 
shown at 5.06%. TCR transduced Jurkat E6.1 cells were subsequently enriched for high 
and uniform CD34 expression using anti-CD34 immunomagnetic beads. CD34 surface 
expression after CD34 enrichment is shown in Figure 15. The data indicate that after 
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CD34 enrichment, Jurkat E6.1 populations exhibited between 86% and 97% CD34 
surface expression. We did not stain for TCR surface expression via TCR alpha or TCR 
beta chain mAbs because this quantification would include expression of mispaired 
TCRs. Furthermore, we did not stain for TCR surface expression via tetramers or 
dextramers because is it possible that the introduced TCR mutations could affect this 
quantification. However, previous studies indicated that CD34 surface expression 
correlated with TCR surface expression in a linear fashion [94]. Figure 15 depicts an 
example of the uniform CD34+ cell populations that were obtained and used for 
functional assays after transduction and CD34 enrichment. In this dissertation, this 
method of CD34 enrichment, followed by confirmation of uniform and high CD34 
expressing populations, was completed each time a transduction generated newly TCR 
transduced cells (in both Jurkat E6.1 cells and T cells). These CD34 purified TCR 
transduced Jurkat E6.1 cells were used as effector cells and cocultured with T2 cells 
loaded with either the WT MART-1 9mer peptide or an alanine substituted peptide. The 
amount of IL-2 produced against each alanine substituted peptide was normalized to 
the amount of IL-2 produced against the MART-1 9mer peptide for each DMF5 TCR, 
respectively. This was done in order to elucidate the residues important for recognition 
relative to recognition of the MART-1 9mer peptide, and to easily observe alterations in 
the patters of recognition between each of the DMF5 TCRs (Figure 16).  
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Figure 14. CD34 Surface Expression on Jurkat E6.1 Cells Pre-CD34 Enrichment. 
Four days after retroviral transduction, untransduced and TCR transduced Jurkat E6.1 
cells were labeled with an anti-CD34 mAb to measure the transduction efficiency of 
each population.   
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Figure 15. CD34 Surface Expression on Jurkat E6.1 Cells Post-CD34 Enrichment. 
Six days after retroviral transduction, and two days after CD34 immunomagnetic bead 
enrichment, TCR transduced Jurkat E6.1 cells were labeled with an anti-CD34 mAb to 
measure the CD34 enrichment efficiency of each population. As a result, the data 
indicate high and uniform CD34 expression among the different populations.   
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Figure 16. Impact of DMF5 TCR Mutations on Recognition of Alanine Substituted 
MART-1 9mer Peptides. Jurkat E6.1 cells expressing either the WT TCR or each 
mutant DMF5 TCR were stimulated with T2 cells loaded with the WT MART-1 9mer 
peptide (AAGIGILTV) or alanine substituted peptides for 18 hours. IL-2 release was 
measured by ELISA in triplicate wells. Fold change in reactivity was normalized within 
each TCR to reactivity against the WT MART-1 9mer peptide, respectively. Average 
MART-1 9mer reactivity was 913 pg/mL. Data are the average of three independent 
experiments and error bars represent the standard error of the mean from three 
independent experiments. 
 
We first observed the pattern of recognition elicited by the WT DMF5 TCR before 
determining how the structure-guided DMF5 TCR mutants affected recognition of 
alanine substituted MART-1 9mer peptides. Alanine substitutions at positions 3 through 
6 and position 8 of the MART-1 peptide eliminated reactivity in Jurkat E6.1 cells 
expressing the WT DMF5 TCR, indicating these residues are critical for WT DMF5 
recognition of the MART-1 9mer peptide. Additionally, substitutions at positions 2 and 7 
reduced reactivity to 14% and 26% of reactivity compared to the MART-1 9mer peptide, 
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respectively, but did not completely eliminate reactivity, indicating these two peptide 
residues are important but not critical for recognition of the MART-1 9mer peptide. In 
summary, positions 3 through 6, and 8 of the MART- 1 9mer peptide are critical for 
recognition by Jurkat E6.1 cells expressing the WT DMF5 TCR. 
After determining how Jurkat E6.1 cells expressing the WT DMF5 TCR 
recognized alanine substituted MART-1 9mer peptides, we determined how mutations 
in the DMF5 TCR altered this pattern of recognition. The pattern of recognition observed 
with the WT DMF5 TCR did not hold true in Jurkat E6.1 cells expressing the αD26Y 
TCR. In cells expressing the αD26Y TCR, substitutions at positions 4 and 6 reduced 
reactivity to that of about 13% and 8% of reactivity against the MART-1 9mer peptide, 
respectively. This pattern is different compared to the WT TCR, as now substitutions at 
positions 2, 3, 5, 7, and 8 are tolerated. Despite this tyrosine mutation at position 26 of 
the TCR alpha chain targeting the N-terminal region of the MART-1 peptide, the αD26Y 
TCR allowed for enhanced reactivity relative to the MART-1 9mer peptide at positions 7 
and 8. These results indicated the tyrosine TCR mutation enhances binding with the N-
terminal region of the peptide, or the pMHC complex, substantially enough, to where the 
TCR is tolerant of alterations at the C-terminal end of the MART-1 9mer peptide. 
Overall, the αD26Y TCR modification designed to enhance binding to the N-terminal 
region of the MART-1 peptide also impacted recognition of MART-1 9mer peptides 
containing alanine substitutions at the C-terminal end.  
In the next DMF5 TCR mutant, Jurkat E6.1 cells expressing the βL98W TCR 
displayed a pattern fairly similar to that of the WT TCR. One exception is the βL98W 
TCR mutation now allows for recognition of alanine substitution at position 7, equal to 
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that of the MART-1 9mer peptide. This indicated the tryptophan mutation at position 98 
of the DMF5 TCR beta chain is not specific for the leucine at position 7 of the MART-1 
9mer peptide, as it tolerated an alanine substitution. Furthermore, the βL98W TCR was 
more tolerant of alanine substitution at position 8 of the MART-1 9mer peptide 
compared to the WT TCR. This indicated that the tryptophan TCR mutation could be 
enhancing binding with the peptide beyond position 7. In summary, the βL98W TCR is 
not as tolerant with alanine substitutions as the αD26Y TCR, but also is possibly not as 
specific for position 7 in the MART-1 peptide as initially proposed. 
After determining how the single positive DMF5 TCR mutants altered the 
recognition pattern of alanine substituted MART-1 9mer peptides, we determined how 
the combination of these DMF5 TCR mutations altered peptide recognition. The 
combination of the αD26Y and βL98W TCR mutations in the αD26Y/βL98W TCR 
allowed for the most promiscuous pattern of recognition of alanine substituted MART-1 
9mer peptides compared to all of the TCRs. The observed pattern resembled a pattern 
of recognition most similar to the αD26Y TCR. Only alanine substitution at positions 4 
and 6 resulted in reduced reactivity relative to reactivity against the MART-1 9mer 
peptide. This suggested the combination of the αD26Y and βL98W TCR mutations 
enhanced binding to the pMHC, as the TCR now allows for recognition of an alanine at 
position 4 in the MART-1 9mer. With the αD26Y/βL98W TCR, this recognition of alanine 
substitution at position 4 was 57% of the MART-1 9mer peptide, compared to about 
13% and 0% by the αD26Y and βL98W TCRs, respectively, indicating more than an 
additive effect of the two TCR mutations (57% > 13% + 0%). Overall, these results 
suggested the enhanced affinity and structural changes of the αD26Y/βL98W TCR 
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mutations allow it to be more permissive in recognition of alanine substituted MART-1 
9mer peptides compared to the αD26Y, βL98W, and WT DMF5 TCRs. 
Our results thus far indicated that single or double positive TCR mutations in the 
DMF5 TCR altered the recognition pattern of alanine substituted MART-1 9mer peptides 
compared to the WT DMF5 TCR. We next determined how these patterns were affected 
by the inclusion of a negative mutation, one that eliminated binding with three residues 
in the MHC, to the αD26Y/βL98W TCR. When a TCR mutation that eliminated binding 
to three residues in the MHC was added to the two positive TCR mutations, Jurkat E6.1 
cells expressing the αD26Y/αY50A/βL98W TCR exhibited a pattern similar to the WT 
DMF5 TCR. One minor difference is a slight enhancement in relative recognition when 
position 7 is alanine substituted, 52% compared to 26% respectively, relative to 
reactivity against the MART-1 9mer peptide. This was most likely due to the presence of 
the βL98W TCR mutation which was designed to enhance binding with the leucine at 
position 7. Additionally, alanine substitution at position 1 was very well tolerated, which 
could be attributed to the strength of the αD26Y and βL98W TCR mutations despite 
presence of the αY50A TCR mutation. In summary, these results suggested the low 3D 
affinity (228 μM against the MART-1 9mer) and structural changes of the 
αD26Y/αY50A/βL98W TCR mutations do not significantly affect the pattern of 
recognition of alanine substituted MART-1 9mer peptides compared to the WT TCR. 
Lastly, we observed how recognition patterns were affected by the inclusion of a 
different negative mutation, one that weakened binding with three residues in the MHC 
(but did not eliminate binding like αY50A), to the αD26Y/βL98W TCR. Jurkat E6.1 cells 
expressing the αD26Y/αY50V/βL98W TCR exhibited a pattern of recognition very 
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similar to the βL98W TCR. This indicated that the addition of α50V and even more so, 
α50A, to the αD26Y/βL98W TCR, counterbalanced the permissive reactivity. 
Specifically, recognition of alanine substituted position 7 was comparable to reactivity 
against the MART-1 9mer peptide, as was the case with the βL98W TCR. Albeit, 
reduced relative reactivity was observed at alanine substituted position 7 with the 
αD26Y/αY50A/βL98W TCR, indicating the αY50A mutation better offset enhanced 
promiscuity at this residue than the αY50V mutation. However, aside from position 7, 
the patterns of recognition observed with the αD26Y/αY50A/βL98W TCR and the 
αD26Y/αY50V/βL98W TCR closely resemble the pattern observed with the WT TCR, 
indicating the addition of the mutations that weaken binding with the MHC, can 
counterbalance the promiscuity observed with the αD26Y and αD26Y/βL98W TCRs. 
Overall these results suggested that each MART-1 targeting TCR mutation did not 
increase MART-1 specificity, but combination with a TCR mutation that weakens 
binding with the MHC can enhance target specificity. 
Impact of Mutant DMF5 TCRs on On-target Tumor Killing 
 The intention for designing these TCRs was to study TCR/pMHC interactions and 
furthermore, eventually to use them therapeutically to treat melanoma. Therefore, 
before moving forward with functional T cell assays, we wanted to confirm T cells 
expressing the modified DMF5 TCRs could elicit killing of HLA-A2+ melanoma cells. A 
summary of the DMF5 TCRs and their measured affinities with the MART-1 9mer 
peptide/HLA-A2 is shown in Table 4. If affinity correlates to targeted killing, based on 
the measured 3D affinities, we would expect that cells expressing the αD26Y/βL98W 
TCR would elicit the highest level of targeted tumor killing, while cells expressing the 
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αD26Y/αY50A/βL98W TCR would elicit the lowest level of targeted tumor killing. An 
LDH cytotoxicity assay was performed using human T cells transduced to express 
either the WT DMF5 TCR or each mutant DMF5 TCR and an HLA-A2-/MART-1+ 
melanoma tumor, MEL 624-28, and an HLA-A2+/MART-1+ melanoma tumor, MEL 624 
(Figure 17). The percentage of TCR transduced T cells used in these experiments 
ranged between 84% and 89% among the different DMF5 TCR expressing T cell 
populations. Among the TCR transduced T cell populations, the proportion of CD4+ T 
cells ranged between 27% and 35% and the proportion of CD8+ T cells ranged between 
65% and 73%. These minor differences in the percentages of TCR transduced T cells 
and CD4+ to CD8+ T cell ratios had no correlation with differences observed in targeted 
cytotoxicity. All killing by the WT and mutant DMF5 TCR transduced T cells was HLA-
A2 restricted, as there was no killing observed with HLA-A2- MEL 624-28 (Figure 17). T 
cells expressing each of the mutated TCRs exhibited equal or better killing of MEL 624 
than T cells expressing the WT TCR. Specifically, T cells expressing the WT DMF5 
TCR exhibited 37% cytotoxicity of MEL 624 tumor cells. T cells expressing the αD26Y 
TCR or the αD26Y/βL98W TCR exhibited statistically significantly more MEL 624 killing 
(65% and 61%, respectively) compared to T cells expressing the WT TCR. Lastly, T 
cells expressing the βL98W TCR, αD26Y/αY50A/βL98W TCR, or αD26Y/αY50V/βL98W 
TCR, exhibited MEL 624 tumor killing at similar or increased levels (48%, 39%, and 
52%, respectively) compared to T cells expressing the WT TCR. 
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Table 4. Summary of Structure-Guided DMF5 TCR Mutations. The KD values 
indicated were measured in the MART-1 nonameric peptide. DMF5 TCR mutations in 
green indicate positive, peptide targeting mutations. DMF5 TCR mutations in red 
indicate negative, MHC weakening mutations. 3D TCR affinity measurements were 
completed in the Baker lab. 
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Figure 17. Impact of DMF5 TCR Mutations on Melanoma Killing. Human 
untransduced or TCR transduced T cells (with either the WT TCR or a mutant DMF5 
TCR) were cocultured with tumor cells for 18 hours in a 1:1 effector:target ratio. MEL 
624-28 tumor cells were used as an HLA-A2-/MART-1+ melanoma control. MEL 624 
tumor cells were used as an HLA-A2+/MART-1+ melanoma line. Data represent the 
mean of two independent experiments and error bars represent the standard error of 
the mean from two independent experiments. One representative donor is shown. ***P 
< 0.001; **P < 0.01; *P < 0.05 when compared to the percent MEL 624 killing by the WT 
TCR by two-way ANOVA using Sidak’s multiple comparisons test. 
 
Based on 3D affinity, it was unexpected that T cells expressing the 
αD26Y/αY50A/βL98W or αD26Y/αY50V/βL98W TCR exhibited equal or better MEL 624 
killing compared to T cells expressing the WT TCR. However, it has been demonstrated 
that the targeted release of lytic granules only requires engagement of three 
TCR/pMHC interactions [152, 403]. This suggests TCR affinity could have less of an 
influence on lytic activity in T cells. This could further be supported by the observation 
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that despite the higher TCR affinity (roughly 3-fold higher) of the βL98W TCR, it did not 
elicit significantly more MEL 624 killing than the WT TCR. Overall, these results 
demonstrated T cells expressing each of the modified DMF5 TCRs could elicit HLA-A2 
restricted melanoma killing and 3D TCR affinity does not directly correlate with target 
cell lysis. 
Impact of Mutant DMF5 TCRs on Cross-Reactivity 
 We next sought to determine how the structure-guided DMF5 TCR mutations 
altered cross-reactivity in T cells, beyond alanine substituted peptides, compared to the 
WT DMF5 TCR. We utilized a panel of previously described peptides that were selected 
because they are homologous with the MART-1 9mer peptide [327, 328]. These 
peptides and their sequence homology with the MART-1 9mer are shown in Table 5. 
Recurring residues include glycine, alanine, valine, and leucine, as they are featured 
extensively in the MART-1 9mer epitope. Many of the selected peptides conform to the 
central [G, A, V]xGx motif at positions 3 through 6 of the MART-1 9mer epitope. The 
panel is comprised of both self- and non-self-peptides that are naturally occurring and 
physiologically relevant. Previous studies demonstrated MART-1 reactive T cells could 
lyse target cells loaded with some, but not all, of the peptides in this selected panel 
[327]. Therefore, we decided to perform preliminary screenings for cross-reactivity to 
determine which MART-1 homologs elicited a significant response from T cells 
expressing the WT TCR or each of the modified DMF5 TCRs (Figure 18). Specifically, 
TCR transduced T cells expressing either the WT TCR or each mutant DMF5 TCR were 
cocultured with T2 cells loaded with the MART-1 9mer peptide or each MART-1 
homolog. 
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Table 5. MART-1 Homolog Peptide Panel. Homology with the MART-1 9mer is 
indicated in black [327]. ● indicates self-peptide. The following abbreviations are used 
throughout the text: Human receptor expression enhancing protein 5 (HREEP 5) and G-
protein coupled receptor 3 (GPCR 3). 
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Figure 18. Example of Initial Screen for Cross-Reactivity. An example of initial 
cross-reactivity screening shown with TCR transduced T cells expressing the αD26Y 
DMF5 TCR. For screening, human T cells expressing either WT or mutant DMF5 TCR 
stimulated with T2 cells loaded with the HCV NS3 peptide (KLVALGINAV), MART-1 
9mer peptide (AAGIGILTV), or MART-1 homologs. IFN-γ release was measured by 
ELISA in triplicate wells. Antigen reactivity is defined as a T cell culture that secretes 
twice background, or twice the amount of IFN-γ production as with unpulsed T2 cells, 
and over 200 pg/mL. One representative experiment from one representative donor is 
shown.  
 
The amount of IFN-γ produced against each peptide loaded target was measured. The 
representative example shown in Figure 18 depicts antigen reactivity by T cells 
expressing the high affinity αD26Y DMF5 TCR. Here, antigen reactivity is defined as a T 
cell culture that secretes twice background, or twice the amount of IFN-γ production as 
with unpulsed T2 cells, and over 200 pg/mL. It is evident that αD26Y TCR expressing T 
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cells recognized target cells loaded with multiple MART-1 homologs. Specifically, in this 
donor and experiment, αD26Y TCR expressing T cells recognized target cells loaded 
with HSV-1 glycoprotein III, human CD9, M. tuberculosis protein I, ADP-ribose 
diphosphatase, and GPCR 3. Furthermore, there are many MART-1 homolog loaded 
targets that were not recognized. This is concurrent with previous findings in that 
despite sequence homology with the MART-1 9mer peptide, not all MART-1 homolog 
loaded target cells elicited a response from MART-1 reactive T cells [327]. This 
experiment was repeated six times with T cells expressing the WT TCR or each of the 
mutant DMF5 TCRs (two independent experiments in three different healthy donors). 
For all future functional experiments, we decided to concentrate on the MART-1 
homologs that elicited a T cell response from any of the DMF5 TCRs in any donor or 
experiment. Specifically, a T cell response was defined as any MART-1 homolog that 
elicited IFN-γ production greater than with T2 cells alone (Table 6). It was interesting to 
observe that our results obtained with the alanine scan assay did not completely 
coincide with the MART-1 homologs that were recognized. For example, results from 
the alanine scan assay (Figure 16) indicated the importance of positions 3 through 6 
and 8 in the MART-1 9mer peptide for recognition by WT TCR expressing cells, but 
many MART-1 homologs with mutations at one or more of these peptide residues were 
recognized (all of the MART-1 homologs in Table 6). Conversely, MART-1 homologs 
that maintained sequence homology at one or more of these peptide residues were not 
recognized. For example, the S. cerevisiae protein I peptide (in Table 5) differs from the 
MART-1 9mer at four residues, but the altered residues are still very hydrophobic, and 
sequence homology remains at the central peptide positions, 4 through 6.  
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Table 6. MART-1 Homolog Peptide Panel Used In Functional Assays. Homology 
with the MART-1 9mer is indicated in black [327]. ● indicates self-peptide. 
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However, T cells expressing the WT TCR or modified DMF5 TCRs did not recognize T2 
cells loaded with this peptide in any experiment. It would be plausible to hypothesize 
that cross-reactive epitopes have a better N-terminal anchor since alanine, the N-
terminal anchor in the MART-1 9mer peptide, is generally considered a weak anchor 
residue. It has been demonstrated that peptides conform differently in the MHC 
depending upon their anchor residues [404, 405]. However this was not the case with 
the S. cerevisiae protein I peptide, as it has a leucine N-terminal anchor and was not 
recognized. Furthermore, cross-reactivity was observed against MART-1 homologs with 
an N-terminal alanine anchor residue (M. tuberculosis protein II, β-endoxylanase, lmrA, 
HSV-2 glycoprotein F, HSV-1 glycoprotein III) and conversely, no cross-reactivity was 
observed against some MART-1 homologs with N-terminal leucine anchors (E. coli 
peptide, P. putida, Measles Virus, S. gordonii). Overall, altered-peptide ligands that 
have sequence homology with the MART-1 9mer peptide could be recognized despite 
mutations at residues previously implicated as imperative for MART-1 9mer peptide 
recognition in the alanine scan. These results indicated that the alanine scan assay can 
be a suitable method for making a general prediction about the importance of an 
individual residue in the MART-1 9mer peptide for recognition. However, it does not 
take into account the effects or contributions of alterations in the peptide with different 
amino acids (other than alanine) and/or the combination of multiple alterations in the 
peptide. Overall, cross-reactivity against a given peptide is probably more dependent 
upon the net effect or, the overall structure and antigenic surface of the peptide in the 
HLA-A2 complex, versus individual mutations at a given epitope. 
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We next determined how human T cells expressing each mutant DMF5 TCR 
altered MART-1 specificity and recognition of the MART-1 homologs compared to T 
cells expressing the WT DMF5 TCR in terms of polyfunctional T cell responses. WT 
TCR and mutant DMF5 TCR transduced T cells were stimulated with T2 cells loaded 
with the MART-1 peptide or the MART-1 homologs (Table 6). The typical functional 
readout in the field for T cell function is IFN-γ production. However, it is known that T 
cells are capable of more complex functional phenotypes and have been shown to be 
polyfunctional [95, 406-411]. Furthermore, analysis of intracellular IFN-γ production from 
PBL-derived T cells from stage IV melanoma patients who received therapeutic 
vaccination, revealed no correlation to survival [412]. Additionally, multiple T cell 
subtypes have been described as important in tumor and disease clearance [413-416]. 
Therefore, since polyfunctionality could be important for on-target and off-target 
recognition, we examined surface expression of CD107A as a surrogate marker for lysis 
[417, 418], and intracellular expression of IFN-γ, TNF-α, IL-17A, IL-2, IL-4, and IL-22 
following antigen stimulation on a per cell basis. This cytokine panel includes Th1, Th2, 
and Th17 cytokines.  
We first focused on antigen recognition in CD4+ T cells because true cross-
reactivity, as a result of changes in the TCR/pMHC interface, are highlighted in the 
CD4+ T cells due to the absence of assistance in signaling and stabilization from the 
CD8 co-receptor [92]. Furthermore, the DMF5 TCR mutations designed using the 
structure-guided approach did not take into account CD8. The gating strategies used for 
all experiments are shown in Figures 4-6. 
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We first observed antigen specificity and cross-reactivity of CD4+ T cells 
expressing the WT DMF5 TCR. Here, the percentage of antigen reactive T cells 
expressed any one or more functional marker (CD107A or cytokines). The percentages 
of antigen reactive T cells were determined after respective background subtraction, as 
described in Chapter Two. The average of six experiments found 19% of CD4+ T cells 
expressing the WT DMF5 TCR were reactive against MART-1 9mer loaded targets 
(Figure 19). The MART-1 10mer has a higher binding affinity for HLA-A2 [392], 
however, compared to the MART-1 9mer, the percentages of reactive T cells were 
similar (22% vs. 19%). This indicated that MART-1 peptide binding stability did not 
significantly affect the percentage of antigen reactive CD4+ T cells. Recognition of 
MART-1 homologs by CD4+ T cells expressing the WT TCR was low, between 0.15% 
and 1.8%, indicating CD4+ WT DMF5 TCR expressing T cells are barely reactive 
against the MART-1 homologs. In conclusion, CD4+ T cells expressing the WT DMF5 
TCR are MART-1 reactive, but appear to be minimally cross-reactive. 
We extended our analysis to the structure-guided mutant DMF5 TCRs after 
determining the percentages of MART-1 and MART-1 homolog reactive WT DMF5 TCR 
expressing CD4+ T cells. Since the αD26Y TCR mutation enhanced binding with the 
MART-1 peptide, we would expect an increase in the percentages of MART-1 reactive T 
cells. Although not statistically significant, as predicted, CD4+ T cells expressing the 
αD26Y TCR displayed an increase in the percentage of MART-1 9mer reactive T cells 
(27%) compared to WT TCR expressing T cells (19%). This result indicated the αD26Y 
TCR mutation enhanced binding with MART-1.  
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Figure 19. Impact of DMF5 TCR Mutations in TCR Transduced CD4+ T Cells 
against MART-1 and MART-1 Homologs. Human TCR transduced T cells were 
stimulated with peptide loaded T2 cells for 5 hours and then stained for cell surface 
CD3, CD4, CD8, CD34, CD107A, and intracellular IFN-γ, TNF-α, IL-17A, IL-2, IL-4, and 
IL-22. Subsequent percent antigen reactive T cells were calculated by subtracting the 
percentage of non-reactive TCR transduced CD4+ T cells from 100. As described in 
Chapter Two, antigen reactivity was determined after background subtraction 
(specifically, subtraction of background immunofluorescence with HCV loaded T2 cells). 
Non-reactive TCR transduced CD4+ T cells did not express CD107A or cytokines. The 
reactivity of CD3+CD34+CD4+ TCR transduced T cells is shown. Error bars represent 
the standard error of the mean from three donors, two independent repeats (6 
experiments). Self-peptides are indicated by a black triangle. **** P <0.0001; ***P < 
0.001; **P < 0.01; *P < 0.05 when the percentage of antigen reactive T cells against 
each peptide with a given TCR was compared to the percentage of antigen reactive T 
cells to the respective peptide with the WT TCR by two-way ANOVA using Sidak’s 
multiple comparisons tests. 
 
However, compared to T cells expressing the WT TCR, T cells expressing the αD26Y 
TCR demonstrated an increase in the percentages of MART-1 homolog reactive T cells 
(0.15% - 1.8% vs. 2.4% - 26%), reaching statistical significance with HSV-1 glycoprotein 
III and M. tuberculosis protein I (0.7% and 0.9% vs. 29% and 22%). Overall, the tyrosine 
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TCR mutation at position 26 in the TCR alpha chain did not increase MART-1 
specificity. 
We next observed how the introduction of a different MART-1 peptide targeting 
TCR mutation, βL98W, affected MART-1 and MART-1 homolog recognition in CD4+ T 
cells. Although not significant, as predicted, CD4+ T cells expressing the βL98W TCR 
displayed an increase in the percentage of MART-1 9mer reactive T cells (23%) 
compared to WT TCR expressing T cells (19%). Furthermore, recognition of MART-1 
homologs by T cells expressing the βL98W TCR was low, between 0.4% and 5.9%. 
This range was slightly greater than the percentage of MART-1 homolog reactive T cells 
expressing the WT TCR, but no statistically significant differences were observed. This 
indicated the tryptophan TCR mutation at position 98 of the DMF5 TCR beta chain did 
not significantly affect recognition of MART-1 or MART-1 homologs compared to the WT 
TCR. We next observed the effect of the combination of the αD26Y TCR and βL98W 
TCR mutations on antigen specificity and cross-reactivity. T cells expressing the 
αD26Y/βL98W TCR demonstrated a reduction in the percentage of MART-1 9mer 
reactive T cells compared to the WT TCR (11.6% vs. 19%). Since the 3D affinity of this 
TCR was measured to be 1.8 μM against the MART-1 9mer, this result was not 
surprising, as it has been demonstrated when a TCR’s affinity approaches 1 μM, a 
decline in TCR signaling and in T cell function is observed [142, 145, 419]. Compared to 
T cells expressing the WT TCR, an increase in the percentages of MART-1 homolog 
reactive T cells was observed with the αD26Y/βL98W TCR, reaching statistical 
significance with HSV-1 glycoprotein III and M. tuberculosis protein I loaded targets 
(0.7% and 0.9% vs. 10% and 10%). Overall, these results suggested the combination of 
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the tyrosine TCR mutation at position 26 in DMF5 TCR alpha chain and the tryptophan 
TCR mutation at position 98 in the TCR beta chain did not increase MART-1 specificity 
and attenuated MART-1 specific T cell reactivity. 
We next evaluated the effect of the introduction of a MHC weakening TCR 
mutation on antigen specificity and cross-reactivity. There was a statistically significant 
reduction in the percentage of MART-1 9mer reactive T cells expressing the 
αD26Y/αY50A/βL98W TCR compared to the WT TCR, 8% vs. 19%, but this was not 
surprising based on its reduced 3D TCR affinity. The percentages of MART-1 homolog 
reactive T cells was comparable between T cells expressing the αD26Y/αY50A/βL98W 
TCR and the WT TCR (0.6% - 2.1% vs. 0.15% - 1.8%). This indicated the addition of 
the αY50A TCR mutation to the αD26Y/βL98W TCR restored the percentage of MART-
1 homolog reactive T cells to WT TCR levels. Compared to the introduction of the 
αY50A TCR mutation, the introduction of the αY50V TCR mutation had less of an effect 
on MART-1 and MART-1 homolog recognition. Specifically, T cells expressing the 
αD26Y/αY50V/βL98W TCR exhibited a similar percentage of MART-1 9mer reactive T 
cells compared to T cells expressing the WT TCR (21% vs. 19%). Furthermore, aside 
from minor increases, (0.46% - 4.8% vs. 0.15% - 1.8%), the percentages of MART-1 
homolog reactive CD4+ T cells was comparable between T cells expressing the 
αD26Y/αY50V/βL98W TCR and the WT TCR. These results were unexpected 
considering the measured 3D TCR affinity of the αD26Y/αY50V/βL98W TCR was lower 
compared to the WT TCR. In summary, compared to the WT TCR, the percentages of 
cross-reactive CD4+ T cells was enhanced with the αD26Y TCR and the αD26Y/βL98W 
TCR, and the percentages of MART-1 9mer reactive CD4+ T cells was reduced with the 
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αD26Y/βL98W TCR and the αD26Y/αY50A/βL98W TCR. Overall, none of the DMF5 
TCR mutations enhanced MART-1 specificity in TCR transduced CD4+ T cells. 
TCR affinity has been correlated to antigen specificity and cross-reactivity and 
has been implicated to be of importance in T cell function. Thus, it was important to 
determine how the MART-1 and MART-1 homolog recognition by the modified DMF5 
TCRs correlated to their 3D affinity. It is generally well appreciated that higher affinity 
TCRs are more cross-reactive [179, 420]. Based solely on this concept, we would have 
expected to observe an increase in the percentages of MART-1, and possibly MART-1 
homolog, reactive CD4+ T cells in T cells transduced to express the TCRs whose 3D 
affinity was higher than the WT TCR (αD26Y TCR, βL98W TCR, and αD26Y/βL98W 
TCR). There was no significant increase (but trending towards) in the percentages of 
MART-1 reactive CD4+ T cells expressing the αD26Y TCR or βL98W TCR, compared to 
T cells expressing the WT TCR. However, T cells expressing the αD26Y TCR or 
αD26Y/βL98W TCR did exhibit a significant increase in the percentage of antigen 
reactive CD4+ T cells against two MART-1 homologs (HSV-1 glycoprotein III and M. 
tuberculosis protein I), coinciding with their increased 3D TCR affinity. There were no 
significant differences observed with T cells expressing the βL98W TCR compared to 
the WT TCR despite the 3-fold 3D TCR affinity enhancement of the βL98W TCR. 
However, minor increases were observed. Based solely on 3D affinity, we would have 
expected a decrease in the percentage of MART-1 and MART-1 homolog reactive CD4+ 
T cells in T cells transduced to express TCRs whose 3D affinity was lower than the WT 
TCR (αD26Y/αY50A/βL98W and αD26Y/αY50V/βL98W). A significant decrease in the 
percentage of MART-1 reactive CD4+ T cells was observed in T cells expressing the 
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αD26Y/αY50A/βL98W TCR compared to the WT TCR, coinciding with the decrease in 
3D TCR affinity. However, the percentage of MART-1 and MART-1 homolog reactive 
CD4+ T cells in T cells expressing the αD26Y/αY50V/βL98W TCR was similar to that of 
T cells expressing the WT TCR, aside from slight, non-significant increases against a 
few MART-1 homologs (ADP-ribose diphosphatase, HREEP 5, human elongation factor 
1α, and HSV-2 glycoprotein F). In summary, these results suggested the 
αD26Y/αY50V/βL98W TCR’s reduced 3D affinity does not directly correlate to the 
observed T cell specificity. However, 3D affinity generally correlated to the percentages 
of TCR transduced MART-1 reactive and cross-reactive CD4+ T cells among the WT 
TCR and modified DMF5 TCRs. 
The analysis of the WT DMF5 TCR and mutant DMF5 TCR transduced CD4+ T 
cells allowed us to examine how the structure of the TCR/pMHC influenced T cell 
function and cross-reactivity. However, it has been implicated that the CD8 co-receptor 
can affect antigen specificity and cross-reactivity through stabilization of the TCR/pMHC 
and through T cell signaling [398, 421, 422]. Therefore, we next determined how 
recognition of MART-1 and the MART-1 homologs was altered in WT TCR and mutant 
DMF5 TCR transduced CD8+ T cells. We first observed antigen specificity and cross-
reactivity of CD8+ T cells expressing the WT DMF5 TCR. The average of six 
experiments found 44% of CD8+ T cells expressing the WT DMF5 TCR were reactive 
against MART-1 9mer loaded targets (Figure 20). Contrary to CD4+ T cells, CD8+ T 
cells expressing the WT TCR recognized nine MART-1 homolog loaded targets, ranging 
from 1.4% to 18% of WT DMF5 TCR transduced T cells. Some of these recognized 
MART-1 homologs were self-peptides (HREEP 5, human elongation factor 1α, and 
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human CD9). In summary WT DMF5 TCR expressing CD8+ T cells were more reactive 
against MART-1 and MART-1 homolog loaded targets than the CD4+ T cells. These 
results implicated the role of CD8 in cross-reactivity.  
After determining how CD8+ T cells expressing the WT DMF5 TCR recognized 
MART-1 and MART-1 homologs, we determined how mutations in the DMF5 TCR 
altered reactivity in TCR transduced CD8+ T cells. Since the αD26Y TCR and βL98W 
TCR mutations enhanced binding with the MART-1 peptide, we would expect an 
increase in the percentages of MART-1 reactive T cells. However, neither of the TCR 
transduced T cell populations expressing TCRs harboring mutations that enhanced 
binding to MART-1 (αD26Y TCR and βL98W TCR) demonstrated increased 
percentages of MART-1 9mer reactive T cells compared to T cells expressing the WT 
TCR (42% and 42% vs. 43%). These results indicate CD8 can minimize the targeted 
effects of these mutations. More specifically, the contribution of the CD8 co-receptor in 
T cell function appears to overshadow the minor impact of the positive TCR mutations. 
This observation indicated the structure-guided strategy can have different effects in 
CD4+ and CD8+ T cells. As seen in the TCR transduced CD4+ T cells, the percentage of 
MART-1 homolog reactive T cells was increased in T cells expressing the αD26Y TCR 
compared to the WT TCR, with statistical significance reached with HSV-1 glycoprotein 
III (44%), M. tuberculosis protein I (34%), and GPCR 3 (23%). With the second MART-1 
targeting TCR mutation, βL98W, the pattern of antigen reactivity against the MART-1 
homologs was similar between T cells expressing the βL98W TCR and the WT TCR.   
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Figure 20. Impact of DMF5 TCR Mutations in TCR Transduced CD8+ T Cells 
against MART-1 and MART-1 Homologs. Human TCR transduced T cells were 
stimulated with peptide loaded T2 cells for 5 hours and then stained for cell surface 
CD3, CD4, CD8, CD34, CD107A, and intracellular IFN-γ, TNF-α, IL-17A, IL-2, IL-4, and 
IL-22. Subsequent percent antigen reactive T cells were calculated by subtracting the 
percentage of non-reactive TCR transduced CD8+ T cells from 100. As described in 
Chapter Two, antigen reactivity was determined after background subtraction 
(specifically, subtraction of background immunofluorescence with HCV loaded T2 cells). 
Non-reactive TCR transduced CD8+ T cells did not express CD107A or cytokines. The 
reactivity of CD3+CD34+CD8+ TCR transduced T cells is shown. Error bars represent 
the standard error of the mean from three donors, two independent repeats (6 
experiments). Self-peptides are indicated by a black triangle. **** P <0.0001; ***P < 
0.001; **P < 0.01; *P < 0.05 when the percentage of antigen reactive T cells against 
each peptide with a given TCR was compared to the percentage of antigen reactive T 
cells to the respective peptide with the WT TCR by two-way ANOVA using Sidak’s 
multiple comparisons tests. 
 
However, although not statistically significant, an increase in the percentage of human 
CD9 reactive T cells was observed in T cells expressing the βL98W TCR, compared to 
the WT TCR (9.4% vs. 3%). With the βL98W TCR mutation, we would expect enhanced 
reactivity against the four MART-1 homologs that contain a leucine at position 7 (GPCR 
3, β-endoxylanase, ADP-ribose diphosphatase, and HSV-1 glycoprotein III). This was 
not observed, indicating the tryptophan is unable to differentiate a leucine from other 
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hydrophobic residues at position 7 of the 9mer peptides. We next observed the effect of 
the combination of the αD26Y TCR and βL98W TCR mutations on antigen specificity 
and cross-reactivity in TCR transduced CD8+ T cells. T cells expressing the 
αD26Y/βL98W TCR exhibited a significant decrease in MART-1 reactive T cells 
compared to the WT TCR (16% vs. 44%). This again, coincides with this TCR’s 
supraphysiological high affinity. Compared to T cells expressing the WT TCR, 
expression with the αD26Y/βL98W TCR enhanced the percentages of MART-1 
homolog reactive T cells in seven homologs, but none reached statistical significance. 
However, it is difficult to discern the extent of how the supraphysiological TCR affinity 
affects the percentage of MART-1 and MART-1 homolog reactive T cells. Lastly, we 
observed the effect of the introduction of a MHC weakening TCR mutation on antigen 
specificity and cross-reactivity in TCR transduced CD8+ T cells. T cells expressing the 
αD26Y/αY50A/βL98W TCR demonstrated an overall trend in the reduction of the 
percentages of MART-1 homolog reactive CD8+ T cells compared to T cells expressing 
the WT TCR (0.25% - 4% vs. 1.4% - 18%), with statistical significance reached with 
HSV-1 glycoprotein III (2.3%) and M. tuberculosis protein I (2.3%). Albeit, these T cells 
also exhibited a statistically significant reduction in the percentage of MART-1 9mer 
reactive T cells compared to the WT TCR (29% vs. 44%). This indicated the addition of 
the αY50A mutation to the αD26Y/βL98W TCR was enough to reduce percentages of 
cross-reactive T cells, even below WT levels, but at the expense of T cell potency 
against MART-1 loaded targets. As observed with the CD4+ T cells, the introduction of 
the αY50V TCR mutation yielded different results than the introduction of the αY50A 
TCR mutation. Although not statistically significant, there was a trend towards a 
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reduction in the percentage of MART-1 9mer reactive T cells in T cells expressing the 
αD26Y/αY50V/βL98W TCR compared to T cells expressing the WT TCR. Furthermore, 
the pattern of reactivity against MART-1 homologs exhibited by T cells expressing the 
αD26Y/αY50V/βL98W TCR was similar to that of T cells expressing the WT TCR. In 
summary, these results indicated that the percentage of MART-1 homolog reactive T 
cells was enhanced in CD8+ T cells expressing the αD26Y TCR or αD26Y/βL98W TCR, 
indicating, cross-reactivity is augmented by CD8. Lastly, our structure-guided design 
strategy worked, as CD8+ T cells expressing the αD26Y/αY50A/βL98W TCR exhibited 
reduced cross-reactivity compared to T cells expressing the WT TCR. However, this 
was at the expense of reduced MART-1 specific T cell reactivity. 
We previously described how the 3D TCR affinity correlated to the antigen 
specificity and cross-reactivity of CD4+ T cells transduced to express the WT TCR or 
each mutant DMF5 TCR. The 3D TCR affinity measurements did not take into account 
the CD8 co-receptor, however, it was of interest to determine if the presence of the CD8 
co-receptor affected any of the previous correlations. The observed percentages of 
MART-1 and MART-1 homolog reactive TCR transduced T cells generally correlated to 
3D affinity in the CD8+ T cells, with a few exceptions. Specifically, there was an overall 
increase in the percentage of MART-1 homolog reactive T cells expressing the αD26Y 
TCR compared to the WT TCR, coinciding with the increased in TCR affinity. However, 
despite the 3-fold TCR affinity enhancement in the βL98W TCR, the percentages of 
MART-1 and MART-1 homolog reactive T cells were generally similar to T cells 
expressing the WT TCR. The statistically significant reduction in the percentage of 
MART-1 reactive T cells in T cells expressing the αD26Y/βL98W TCR was most likely 
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again, attributed to its high affinity. Although not significant, trends in increased 
percentages of MART-1 homolog reactive αD26Y/βL98W TCR expressing T cells were 
observed compared to T cells expressing the WT TCR, coinciding with 3D TCR affinity. 
As predicted based on its lower 3D TCR affinity, T cells expressing the 
αD26Y/αY50A/βL98W TCR exhibited a significant reduction in the percentage of MART-
1 reactive T cells compared to T cells expressing the WT TCR, and an overall reduction 
in MART-1 homolog reactive T cells, reaching statistical significance in two (HSV-1 
glycoprotein I and M. tuberculosis protein I). Lastly, although not statistically significant, 
T cells expressing the αD26Y/αY50V/βL98W TCR displayed a trend toward a reduction 
in the percentage of MART-1 reactive T cells compared to T cells expressing the WT 
TCR, coinciding with 3D TCR affinity. However, the percentages of MART-1 homolog 
αD26Y/αY50V/βL98W TCR expressing reactive T cells were similar to T cells 
expressing the WT TCR. Overall, there were examples where 3D TCR affinity 
correlated to MART-1 reactivity and cross-reactivity in TCR transduced CD8+ T cells, 
but this was not the case with every DMF5 TCR. Specifically, TCR transduced CD8+ T 
cells harboring DMF5 TCRs with the highest or lowest 3D affinities compared to the WT 
TCR (αD26Y, αD26Y/βL98W, and αD26Y/αY50A/βL98W) generally correlated with 
MART-1 homolog reactivity and/or MART-1 reactivity. 
Thus far we have observed how mutations in the DMF5 TCR affected recognition 
of the MART-1 homologs by comparing the average percentages of antigen reactive T 
cells amongst six experiments. These results demonstrated trends in how mutations in 
the DMF5 TCR affected recognition of individual MART-1 homologs. However, it was 
difficult to observe the effect of mutations in the DMF5 TCR on the overall, or total, level 
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of cross-reactivity compared the WT TCR. Therefore, we wanted to quantitatively 
examine how mutations in the DMF5 TCR affected the overall level of cross-reactivity 
compared to the WT TCR. For this analysis we focused only on CD8+ T cells for a few 
reasons. First, compared to CD4+ T cells expressing the WT TCR, only statistically 
significant differences in MART-1 homolog reactivity were observed in CD4+ T cells 
expressing the αD26Y TCR or αD26Y/βL98W TCR (Figure 19). Secondly, only two out 
of the eleven MART-1 homologs elicited more than 1% WT TCR expressing reactive 
CD4+ T cells (Figure 19). Furthermore, these two MART-1 homologs elicited lower than 
2% WT TCR expressing reactive CD4+ T cells (Figure 19). The purpose of this analysis 
was to determine how each modified DMF5 TCR altered total cross-reactivity compared 
to the WT TCR. Since CD8+ T cells were much more cross-reactive, we focused solely 
on CD8+ T cells for this analysis of cross-reactivity. 
We compared the percentages of MART-1 homolog reactive CD8+ T cells 
between each of the modified DMF5 TCRs and the WT DMF5 TCR on a per experiment 
basis (Figure 21). Each data point (X, Y value) represents the percentages of reactive 
CD8+ T cells in response to a MART-1 homolog by both the WT DMF5 TCR (X-axis) 
and a modified DMF5 TCR (Y-axis) in the same experiment. Numbers in the upper left 
square of each graph (51, 31, 32, 20, and 28) indicate the total number of occurrences 
there was an increased frequency of reactive T cells against a MART-1 homolog by a 
modified DMF5 TCR, relative to the WT TCR in the six experiments. Conversely, the 
numbers in the bottom right square of each graph (5, 20, 22, 34, and 23) indicate the 
total number of occurrences there was an increased frequency of MART-1 homolog 
reactivity by the WT TCR, relative to a modified DMF5 TCR in the six experiments. 
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There are a total of 66 data points from the six experiments, however, values of 0, 0 
were not counted. Therefore, the numbers in the top left and the bottom right corners of 
each graph serve as an index of the frequency of cross-reactivity. In the first graph, the 
percentages of MART-1 homolog reactive WT TCR expressing T cells were plotted 
against the percentages of MART-1 homolog reactive WT TCR expressing T cells. 
Thus, a linear regression is observed with a slope of 1 and a Y-intercept of 0. Overall, 
there are three pieces of information to analyze from these data. The first piece of 
information is the number of occurrences in which a modified TCR elicited a higher 
percentage of MART-1 homolog specific T cells compared to the WT TCR. This is a 
quantitative, yes/no measurement that does not take into account differences in 
magnitudes. The second piece of information is the slope of the linear regression line. 
This measurement takes into account the differences in magnitudes amongst a modified 
TCR and the WT TCR and overall indicates how the modified DMF5 TCR affected 
recognition of the MART-1 homologs in relation to the WT DMF5 TCR. Thirdly, the Y-
intercept represents the average percentage of cross-reactive T cells expressing a 
modified TCR, when the percentage of cross-reactive WT TCR expressing T cells is 0. 
Specifically, the higher the Y-intercept, the more cross-reactive the modified TCR is. In 
the second graph, the percentages of MART-1 homolog reactive CD8+ T cells 
expressing the WT TCR is plotted against the percentages of MART-1 homolog reactive 
CD8+ T cells expressing the αD26Y TCR. CD8+ T cells expressing the αD26Y TCR 
dramatically enhanced overall cross-reactivity compared to T cells expressing the WT 
TCR, specifically, in 51/56 responses against the MART-1 homologs.   
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Figure 21. Impact of DMF5 TCR Mutations in TCR Transduced CD8+ T Cells 
against MART-1 Homologs. The individual percentages of MART-1 homolog reactive 
CD8+ T cells (from Figure 20) were plotted for each TCR with the percentage of reactive 
T cells expressing each modified TCR on the Y-axis and the percentage of reactive T 
cells expressing the WT TCR on the X-axis. Data from all 6 experiments (two 
independent repeats in three donors) are plotted to total 66 data points, each point 
being plotted from the same experiment. Numbers in the upper left square indicate the 
total number of occurrences there was an increased frequency of reactive T cells 
against a MART-1 homolog by a modified TCR relative to the WT TCR and conversely, 
the numbers in the bottom right square indicate the total number of occurrences there 
was an increased frequency of reactive T cells against a MART-1 homolog by the WT 
TCR relative to a modified TCR. Values of 0, 0 were not counted. Linear regression line 
and the equation are shown on each graph. 
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For simplicity, the frequency in which each modified DMF5 TCR resulted in an increase 
in the percentages of MART-1 homolog reactive CD8+ T cells relative to the WT TCR is 
shown in Table 7. Percentages over 50% indicated the modified DMF5 TCR, overall, 
exhibited an increase in the percentages of MART-1 homolog reactive CD8+ T cells 
compared to the WT TCR. Specifically, T cells expressing the αD26Y TCR 
demonstrated an increased percentage of MART-1 homolog reactive T cells in 91% 
(51/56) of responses compared to the WT TCR. Here, the denominator is 56, not 66, 
because values of 0, 0 were not counted. This conclusion was further supported by 
observing a slope above 1 (1.3633) in the calculated linear regression. The Y-intercept 
of 9.1601 indicates that on average, 9.2% of αD26Y TCR expressing T cells were cross-
reactive when 0% of WT TCR expressing T cells were cross-reactive. Overall, these 
data quantitatively demonstrated the αD26Y TCR mutation elicited an increase in the 
level of cross-reactivity compared to the WT TCR. In the third graph, T cells expressing 
the βL98W TCR demonstrated an increased percentage of MART-1 homolog reactive 
CD8+ T cells in 60.8% (31/51) of responses compared to the WT TCR (Table 7). 
Interestingly, the slope of the linear regression line was less than 1 (0.6358), indicating 
there was an increase in the percentages of MART-1 homolog reactive WT TCR 
expressing T cells. This illustrates the difference in conclusions that can be made about 
cross-reactivity based upon the frequency calculation or the slope calculation. 
Specifically, the frequency is based upon a yes/no calculation, whereas the slope 
accounts for changes in magnitudes between the modified DMF5 TCRs and the WT 
DMF5 TCR in all 6 experiments. 
  
116 
 
 
Table 7. Frequencies of Occurrences of Mutated DMF5 TCRs with Enhanced 
MART-1 Homolog Recognition Compared To the WT TCR. 
 
Therefore, cross-reactivity is enhanced, or it is not enhanced, with CD8+ T cells 
expressing the βL98W TCR compared to the WT TCR, depending upon how the data is 
analyzed. The Y-intercept of 1.3796 indicates that on average, 1.4% of βL98W TCR 
expressing T cells were cross-reactive when 0% of WT TCR expressing T cells were 
cross-reactive. Overall, these data indicated in terms of the number of occurrences and 
the Y-intercept, the βL98W TCR mutation enhanced cross-reactivity compared to the 
WT TCR. However, in terms of the magnitudes of overall cross-reactivity, the βL98W 
TCR mutation decreased cross-reactivity compared to the WT TCR. In the fourth graph, 
CD8+ T cells expressing the αD26Y/βL98W TCR demonstrated an increased 
percentage of MART-1 homolog reactive T cells in 59.2% (32/54) of responses 
compared to the WT TCR (Table 7). Conversely, the slope of the linear regression line 
was less than 1 (0.534), indicating there was an increase in the percentages of MART-1 
homolog reactive WT TCR expressing T cells. The Y-intercept of 3.5174 indicates that 
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on average, 3.5% of αD26Y/βL98W TCR expressing T cells were cross-reactive when 
0% of WT TCR expressing T cells were cross-reactive. Overall, these data indicated in 
terms of the number of occurrences and the Y-intercept, the αD26Y/βL98W TCR 
mutation enhanced cross-reactivity compared to the WT TCR. However, in terms of the 
magnitudes of overall cross-reactivity, the αD26Y/βL98W TCR mutations decreased 
cross-reactivity compared to the WT TCR. In the fifth graph, CD8+ T cells expressing 
the αD26Y/αY50A/βL98W TCR demonstrated an increased percentage of MART-1 
homolog reactive T cells in 37% (20/54) of responses compared to the WT TCR (Table 
7). However, a majority of the cross-reactive values that were enhanced with the 
αD26Y/αY50A/βL98W TCR were very similar to the WT TCR values and were under 
4%. The close proximity of some these values is therefore, unseen with this frequency 
quantification, but rather is more apparent in the stark decrease in the slope. 
Specifically, this result is further supported by the observation of the slope far below 1 
(0.1356) in the calculated linear regression. The Y-intercept of 0.6643 indicates that on 
average, 0.67% of αD26Y/αY50A/βL98W TCR expressing T cells were cross-reactive 
when 0% of WT TCR expressing T cells were cross-reactive. Overall, these data 
quantitatively demonstrate the αD26Y/αY50A/βL98W TCR mutations elicited a 
decrease in the level of cross-reactivity compared to the WT TCR. Lastly, CD8+ T cells 
expressing αD26Y/αY50V/βL98W TCR demonstrated an increased percentage of 
MART-1 homolog reactive T cells in 54.9% (28/51) of responses compared to the WT 
TCR (Table 7). However, the slope of the linear regression line (0.7047) implicated 
when taking magnitudes into account, cross-reactivity was reduced with the 
αD26Y/αY50V/βL98W TCR compared to the WT TCR. The Y-intercept of 0.9032 that 
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on average, 0.9% of αD26Y/αY50V/βL98W TCR expressing T cells were cross-reactive 
when 0% of WT TCR expressing T cells were cross-reactive. Overall, these data 
indicated in terms of the number of occurrences, the αD26Y/αY50V/βL98W TCR 
mutations enhanced cross-reactivity compared to the WT TCR. However, in terms of 
the magnitudes of overall cross-reactivity, the αD26Y/αY50V/βL98W TCR mutation 
decreased cross-reactivity compared to the WT TCR.  
In totality, these results exemplify the different conclusions that can be inferred 
about cross-reactivity based upon the occurrences of cross-reactivity or the magnitudes 
of cross-reactivity. It is plausible that both of these conclusions have biological 
implications for cross-reactivity in a human. Conclusively, these results quantitatively 
imply that overall cross-reactivity against MART-1 homologs was enhanced in CD8+ T 
cells expressing the αD26Y TCR and was decreased in CD8+ T cells expressing the 
αD26Y/αY50A/βL98W TCR compared to CD8+ T cells expressing the WT DMF5 TCR.  
Thus far we have determined how mutations in the DMF5 TCR altered cross-
reactivity in CD4+ and CD8+ T cells by observing recognition of sequence homologous 
MART-1 peptides. We have also observed how mutations in the DMF5 TCR affect 
cross-reactivity in totality, compared to the WT TCR. It would be beneficial to elucidate if 
there were any correlations between the structural aspects of the introduced DMF5 TCR 
mutations and changes observed in MART-1 homolog reactivity compared to the WT 
DMF5 TCR. To do this we individually compared each of the average percentages of 
MART-1 and MART-1 homolog reactive CD4+ and CD8+ T cells between each modified 
DMF5 TCR with the WT DMF5 TCR. Specifically, we listed the peptides in descending 
order based on the percent antigen reactive T cells to compare differences in the order 
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of recognition between the WT DMF5 TCR and a modified DMF5 TCR. For this 
analysis, recognition of a peptide by less than 2% of TCR transduced T cells and 
differences of less than 2% amongst two different TCRs, were not considered for 
comparative analysis. Since the percentages of antigen reactive T cells are the 
averages of six experiments, these thresholds allowed us to better compare overall 
trends in the altered recognition of the MART-1 homologs. Table 8 represents the 
percentages of reactive T cells expressing either the WT TCR or αD26Y TCR in CD4+ 
and CD8+ T cells. As previously described, the percent antigen reactive T cells 
expressed any one or more functional markers (CD107A or cytokines). In CD4+ T cells, 
T cells expressing the αD26Y TCR exhibited enhanced reactivity against every MART-1 
homolog compared to T cells expressing the WT TCR. Consequently, it is difficult to 
make specific comparisons as T cells expressing the WT TCR hardly recognized the 
MART-1 homologs. Specifically, only two out of the eleven MART-1 homologs elicited 
reactivity in more than 1% of WT TCR expressing CD4+ T cells and these two MART-1 
homologs elicited reactivity in less than 2% of WT TCR expressing CD4+ T cells. 
However, there are a few points to make in regards to the order of MART-1 homologs 
recognized by αD26Y TCR expressing CD4+ T cells. The most highly recognized 
MART-1 homolog maintained homology in the peptide core, HSV-1 glycoprotein III 
(GIGI). This hydrophobic “GIGI” at positions 3 through 6 has been shown to be 
important for DMF5 TCR recognition [404, 423]. Secondly, CD4+ T cells expressing the 
αD26Y TCR recognized the ADP-ribose diphosphatase peptide. This was most likely 
due to the removal of unfavorable charge repulsed with the WT DMF5 TCR and the 
aspartic acid at position two of the peptide.  
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Table 8. Summary of Percentage of MART-1 Homolog Reactive T Cells Expressing 
the WT or αD26Y TCR. The differences in sequence homology with the MART-1 9mer 
is in bold and underlined. The percent reactive T cells are the average of six 
independent experiments. The percent reactive T cells was determined following 
background subtraction, as described in Chapter Two. Antigen reactive T cells 
expressed any one or more functional marker.   
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Lastly, this tyrosine TCR mutation at position 26 in the TCR alpha chain was proposed 
to have an effect on the N-terminal region of the peptide. However, there appears to be 
no apparent preference for N-terminal peptide residues. Specifically, the top four 
recognized MART-1 homologs each contain a different amino acid at position one. This 
indicated the tyrosine mutation non-specifically enhanced recognition of the MART-1 
homologs. Overall, αD26Y TCR mutation in the DMF5 TCR non-specifically enhanced 
the percentages of CD4+ reactive T cells against all of the MART-1 homologs compared 
to T cells expressing the WT TCR.  
We next examined how the presence of the CD8 co-receptor affected any 
structural correlations between the αD26Y TCR mutation and recognition of MART-1 
homologs. In the CD8+ T cells, T cells expressing the αD26Y TCR again demonstrated 
an increase in all the percentages of MART-1 homolog reactive T cells compared to T 
cells expressing the WT TCR. One notable difference in recognition was with the GPCR 
3 peptide, as it was not recognized by CD8+ T cells expressing the WT TCR. The stark 
increase in the percent αD26Y TCR expressing reactive CD8+ T cells could be due to 
enhanced binding with the N-terminal end of the peptide or an overall favorable 
antigenic surface due to the four mutations (positions 2, 4, 6, and 8) in the GPCR 3 
peptide. Like in the CD4+ T cells, there appears to be no apparent preference for N-
terminal peptide residues by CD8+ T cells expressing the αD26Y TCR. Overall, the 
αD26Y mutation non-specifically enhanced the percentages of MART-1 homolog 
reactive T cells compared to T cells expressing the WT TCR in both CD4+ and CD8+ T 
cells. Moreover, CD8 augmented the magnitudes of cross-reactivity. 
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We subsequently elucidated any structural correlations between MART-1 
homolog recognition and the tryptophan mutation at position 98 in the TCR beta chain. 
Table 9 represents the percentage of antigen reactive T cells expressing either the WT 
TCR or βL98W TCR in TCR transduced CD4+ and CD8+ T cells. Contributions of the 
tryptophan substitution in the βL98W TCR are hard to elucidate in CD4+ T cells because 
as like CD4+ T cells expressing the WT TCR, they were not very reactive against the 
MART-1 homologs. Specifically, seven MART-1 homologs were recognized by less than 
2% of βL98W TCR expressing CD4+ T cells. However, the percentage of βL98W TCR 
expressing ADP-ribose diphosphatase reactive CD4+ T cells was enhanced compared 
to CD4+ T cells expressing the WT TCR (5.9% vs. 1.67%). This could be attributed to 
the leucine at position 7 because the βL98W mutation enhanced shape 
complementarity with position 7 in the MART-1 9mer peptide. Albeit, this is not 
reproducible in other MART-1 homologs with that contain a leucine at position 7 (HSV-1 
glycoprotein III, GPCR 3, β-endoxylanase). Overall, the tryptophan mutation at position 
98 in the TCR beta chain did not preferentially enhance recognition of MART-1 
homologs with a leucine at position 7.  
We next examined how the presence of the CD8 co-receptor affected any 
structural correlations between the βL98W mutation and recognition of MART-1 
homologs. The percentages and order of MART-1 homolog reactive CD8+ T cells is 
fairly similar between CD8+ T cells expressing the WT TCR or βL98W TCR. One 
notable difference was the increase in the percentage of human CD9 reactive T cells in 
T cells expressing the βL98W TCR compared to the WT TCR (9.43% vs. 3.02%).  
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Table 9. Summary of Percentage of MART-1 Homolog Reactive T Cells Expressing 
the WT or βL98W TCR. The differences in sequence homology with the MART-1 9mer 
is in bold and underlined. The percent reactive T cells are the average of six 
independent experiments. The percent reactive T cells was determined following 
background subtraction, as described in Chapter Two. Antigen reactive T cells 
expressed any one or more functional marker.   
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Human CD9 contains an alanine at position 7, and thus, it is possible that the 
tryptophan in the βL98W TCR enhanced binding with the small nonpolar alanine. 
Overall, the tryptophan in the βL98W TCR did not significantly affect the pattern of 
recognition against the MART-1 homologs compared to T cells expressing the WT TCR. 
Furthermore, the tryptophan mutation at position 98 in the TCR beta chain did not 
preferentially enhance recognition of MART-1 homologs with a leucine at position 7 in 
CD4+ or CD8+ T cells. 
We next elucidated any structural correlations between MART-1 homolog 
recognition and the combination of the αD26Y TCR and βL98W TCR mutations. Table 
10 represents the percentage of antigen reactive T cells expressing either the WT TCR 
or αD26Y/βL98W TCR in CD4+ and CD8+ T cells. In CD4+ T cells, the αD26Y/βL98W 
TCR generally enhanced the percentage of MART-1 homolog reactive T cells compared 
to T cells expressing the WT TCR. In αD26Y/βL98W TCR expressing CD4+ T cells, the 
MART-1 homologs that elicited the highest percentages of reactive T cells were similar 
to T cells expressing the αD26Y TCR (M. tuberculosis protein I, HSV-1 glycoprotein III, 
ADP-ribose diphosphatase, human CD9, HREEP 5). These results implicated the 
structural effect of the αD26Y TCR mutation. Surprisingly, 6.8% of αD26Y TCR 
expressing CD4+ T cells recognized the lmrA MART-1 homolog, while only 1.23% of 
αD26Y/βL98W TCR expressing CD4+ T cells recognized lmrA. However, as discussed 
previously, it is possible that the affinity of the αD26Y/βL98W TCR is too high and thus, 
T cell function has reached its maximum threshold, or has been arrested. Moreover, 3D 
αD26Y/βL98W TCR affinity measurements with the MART-1 10mer indicated a 
nanomolar value.  
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Table 10. Summary of Percentage of MART-1 Homolog Reactive T Cells 
Expressing the WT or αD26Y/βL98W TCR. The differences in sequence homology 
with the MART-1 9mer is in bold and underlined. The percent reactive T cells are the 
average of six independent experiments. The percent reactive T cells was determined 
following background subtraction, as described in Chapter Two. Antigen reactive T cells 
expressed any one or more functional marker.  
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This indicated anchor residues could very much affect 3D TCR affinity. Therefore, it is 
difficult to correlate αD26Y/βL98W TCR structure with T cell responses against the 
MART-1 homologs if the T cell functional output has been subsequently affected due to 
the supraphysiological high affinity. Patterns of the percentages of MART-1 homolog 
reactive αD26Y/βL98W TCR expressing CD8+ T cells generally coincided with the 
hypothesis associated with TCR affinity being too high and subsequently arresting T cell 
function. For example, 7.73% of αD26Y TCR expressing CD8+ T cells recognized the 
HREEP 5 peptide, while only 1.2% αD26Y/βL98W TCR expressing CD8+ T cells 
recognized the HREEP 5 peptide. However, we would expect a higher percentage of 
reactive T cells with higher affinity TCR. Furthermore, CD4+ and CD8+ αD26Y/βL98W 
TCR expressing T cells recognized ADP-ribose diphosphatase with the same 
percentage of T cells (5.2% vs. 5.25%). A similar trend was observed in CD4+ T cells vs 
CD8+ T cells with HSV-1 glycoprotein III (10.18% vs. 13.33%) and M. tuberculosis 
protein I (10.57% vs 10.68%) peptides. These results indicated the addition of CD8 had 
no effect on the percentage of reactive T cells. Overall, these results suggested specific 
patterns of MART-1 homolog recognition observed in αD26Y/βL98W TCR expressing 
CD4+ and CD8+ T cells and how they structurally correlate with the TCR mutations are 
difficult to elucidate because the supraphysiological affinity is most likely affecting T cell 
function. 
We next elucidated any structural correlations between MART-1 homolog 
recognition and the introduction of a MHC weakening TCR mutation, αY50A, with the 
αD26Y and βL98W TCR mutations. Table 11 represents the percentage of antigen 
reactive T cells expressing either the WT TCR or αD26Y/αY50A/βL98W TCR in CD4+ 
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and CD8+ T cells. Structural contributions of the αD26Y/αY50A/βL98W TCR mutations 
are hard to make in CD4+ T cells, because as observed with T cells expressing the WT 
TCR, they are minimally reactive against the MART-1 homologs. Specifically, only one 
MART-1 homolog (HREEP 5) was recognized by over 2% of αD26Y/αY50A/βL98W 
TCR expressing CD4+ T cells, at 2.13%. Overall, the introduction of the 
αD26Y/αY50A/βL98W TCR mutations did not affect MART-1 homolog recognition in 
CD4+ T cells compared to the WT TCR.  
In αD26Y/αY50A/βL98W TCR expressing CD8+ T cells, only a small percentage 
of MART-1 homolog reactive T cells were observed. The three peptides recognized by 
over 2% of αD26Y/αY50A/βL98W TCR expressing CD8+ T cells were the same top 
three recognized by CD8+ T cells expressing the WT TCR (ADP-ribose diphosphatase, 
M. tuberculosis protein I, HSV-1 glycoprotein III). These peptides reveal sequence 
homology with the MART-1 9mer at positions 3 through 6. In summary, T cells 
expressing the αD26Y/αY50A/βL98W TCR exhibited a reduction in the percentages of 
MART-1 homolog reactive T cells, indicating the αY50A TCR mutation counterbalanced 
the αD26Y and βL98W TCR mutations. Moreover, the structure of the 
αD26Y/αY50A/βL98W TCR had no impact on the patterns of MART-1 homolog 
recognition compared to the WT TCR. 
We next elucidated any structural correlations between MART-1 homolog 
recognition and the introduction of a different MHC weakening TCR mutation, αY50V, 
with the αD26Y TCR and βL98W TCR mutations. Table 12 represents the percentage 
of antigen reactive T cells expressing either the WT TCR or αD26Y/αY50V/βL98W TCR 
in CD4+ and CD8+ T cells. 
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Table 11. Summary of Percentage of MART-1 Homolog Reactive T Cells 
Expressing the WT or αD26Y/αY50A/βL98W TCR. The differences in sequence 
homology with the MART-1 9mer is in bold and underlined. The percent reactive T cells 
are the average of six independent experiments. The percent reactive T cells was 
determined following background subtraction, as described in Chapter Two. Antigen 
reactive T cells expressed any one or more functional marker.  
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Table 12. Summary of Percentage of MART-1 Homolog Reactive T Cells 
Expressing the WT or αD26Y/αY50V/βL98W TCR. The differences in sequence 
homology with the MART-1 9mer is in bold and underlined. The percent reactive T cells 
are the average of six independent experiments. The percent reactive T cells was 
determined following background subtraction, as described in Chapter Two. Antigen 
reactive T cells expressed any one or more functional marker.   
130 
 
Contributions of the αD26Y/αY50V/βL98W TCR mutations are hard to make in CD4+ T 
cells, as with T cells expressing the WT TCR, they are minimally reactive against the 
MART-1 homologs. However, HREEP 5 and ADP-ribose diphosphatase elicited the 
highest percentages of αD26Y/αY50V/βL98W CD4+ reactive T cells (4.88% and 4.07%). 
The percentage of HREEP 5 reactive CD4+ T cells was similar between 
αD26Y/αY50V/βL98W TCR and αD26Y/βL98W TCR expressing CD4+ T cells (4.88% 
vs. 4.07%), but less than αD26Y TCR expressing T cells (9.07%). This again suggested 
the αD26Y/βL98W TCR affinity was too high, thus attenuating T cell potency, but the 
addition of the αY50V mutation could offset the effect of the other MART-1 targeting 
mutations. It was interesting that the MART-1 homolog, HREEP 5, elicited the highest 
percentages of reactive CD4+ T cells with the αD26Y/αY50A/βL98W TCR and 
αD26Y/αY50V/βL98W TCR, but none of the other TCRs. HREEP 5 only shares 
sequence homolog with the MART-1 9mer at positions 4 and 5. These results implicate 
that the addition of a TCR mutation that eliminates or weakens binding with three 
residues in the MHC to the αD26Y/ βL98W TCR, could have less of an effect on 
recognition of HREEP 5 compared to the other MART-1 homologs. This could be due to 
the structural, antigenic surface of HREEP 5 in the MHC. In summary, the introduction 
of the αD26Y/αY50V/βL98W TCR mutations had minimal overall effects on the patterns 
in recognition of the MART-1 homologs compared to the WT TCR in CD4+ T cells.  
We next examined how the presence of the CD8 co-receptor affected any 
structural correlations between the αD26Y/αY50V/βL98W TCR mutations and 
recognition of MART-1 homologs. In the αD26Y/αY50V/βL98W TCR expressing CD8+ T 
cells, the order of MART-1 homolog recognition was the same, for MART-1 homologs 
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that elicited reactivity, compared to T cells expressing the WT TCR. In summary, these 
results indicated that these three TCR mutations did not significantly affect structural 
recognition of the MART-1 homologs compared to T cells expressing the WT TCR.  
These results of this analysis highlight a few key points in regards to TCR 
structure and antigen recognition. First, CD8 generally augments antigen recognition. 
Secondly, recognition of MART-1 homologs did not always align with predictions based 
upon the structural impact of the introduced DMF5 TCR mutations. Specifically, the 
αD26Y TCR mutation non-specifically enhanced all MART-1 homolog recognition and 
the βL98W TCR mutation did not specifically enhance recognition of MART-1 homologs 
with a leucine at position 7. Conclusively, this analysis indicated the net antigenic 
surface of the whole pMHC complex is more important than individual or specific 
alterations in peptide residues. 
Impact of Mutant DMF5 TCRs on Polyfunctional T cell Phenotypes 
 Our conclusions about cross-reactivity thus far have been based solely on 
reactive T cells determined by expression of any one or more functional markers 
(CD107A, IFN-γ, TNF-α, IL-17A, IL-2, IL-4, or IL-22). However, it has been shown that 
polyfunctional phenotypes are important in different effector T cell functions. Therefore, 
we sought to determine how mutations in the DMF5 TCRs altered polyfunctional 
phenotypes of TCR transduced T cells. Since seven functional markers were evaluated 
(CD107A, IFN-γ, TNF-α, IL-17A, IL-2, IL-4, and IL-22), there was a potential for each T 
cell to exhibit 1 of 128 (27) possible functional phenotypes. “Cool plots” were generated 
to display how mutations in the DMF5 TCR altered functional phenotypes compared to 
the WT DMF5 TCR in different donors. We first focused on the CD4+ T cells to 
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determine how the structure of the TCR/pMHC interaction affected polyfunctional T cell 
responses. A representative example of the CD4+ reactivity against T2 cells loaded with 
the MART-1 9mer is shown in Figure 22. The percentage of reactive CD4+ T cells 
expressing a specific functional phenotype ranged from 0% to about 6.5%. As described 
in Chapter Two, reactivity is defined after background subtraction (subtraction of the 
background immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, 
peptide). Specifically, any phenotype expressed by over 0.1% of TCR transduced T 
cells were defined as reactive. Previous studies performing this analysis focused on 
phenotypes elicited by over 0.25% of TCR transduced T cells [95]. Thus, we decided to 
be more conservative by examining phenotypes elicited by over 0.1% of any DMF5 
TCR transduced T cell population. Here, among six TCR transduced CD4+ T cell 
populations, 25 out of the potential 128 polyfunctional phenotypes were detected in at 
least one DMF5 TCR transduced T cell population, by over 0.1% of TCR transduced 
CD4+ T cells. It is evident that individual TCR transduced CD4+ T cells are very 
polyfunctional and are capable of producing Th1 (IFN-γ, TNF-α, IL-2), Th2 (IL-4), and 
Th17 (IL-17A and IL-22) cytokines [424, 425]. Th1, Th2, and Th17 cytokine producing TCR 
transduced CD4+ T cells are also capable of lysis, as measured by CD107A. 
Furthermore, the production of Th1, Th2, and Th17 cytokines are not mutually exclusive, 
meaning TCR transduced T cells produced combinations of cytokines from the different 
T cell subsets. Overall, these results indicated TCR transduced CD4+ T cells were 
capable of exhibiting functional phenotypes comprised of lysis and Th1, Th2, and Th17 
cytokines.  
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We subsequently observed how the distribution of functional phenotypes was 
altered amongst T cells expressing each of the different DMF5 TCRs when stimulated 
with the MART-1 9mer. It is evident that there is variability in the CD107A and cytokine 
responses amongst the different DMF5 TCRs even when presented with the same 
ligand in the same donor and the same experiment (Figure 22). For example, the first 
listed polyfunctional phenotype consisted of CD107A+, IFN-γ+, TNF-α+, IL-4+ TCR 
transduced CD4+ T cells. This phenotype consisted of both type 1 and type 2 cytokines 
and lysis. This phenotype was exhibited in less than 0.5% of αD26Y TCR, βL98W TCR, 
and αD26Y/αY50V/βL98W TCR expressing T cells but absent in T cells expressing the 
other DMF5 TCRs. In a second example, the second functional phenotype consisted of 
CD107A+, IFN-γ+, TNF-α+ TCR transduced CD4+ T cells. This phenotype was present in 
about 2% to 3% of T cells expressing the WT TCR, βL98W TCR, and 
αD26Y/αY50V/βL98W TCR, less than 0.5% of T cells expressing the αD26Y TCR, and 
was not exhibited in T cells expressing the αD26Y/βL98W TCR or 
αD26Y/αY50A/βL98W TCR. Another example of this variability between the different 
DMF5 TCRs was observed in the TNF-α+ only phenotype. This phenotype was present 
in around 1% to 2% of T cells expressing the WT TCR, αD26Y TCR, and 
αD26Y/αY50V/βL98W TCR, less than 0.5% of T cells expressing the 
αD26Y/αY50A/βL98W TCR, and was not present in T cells expressing the 
αD26Y/βL98W TCR or βL98W TCR. Overall, these are a few of many examples of how 
the polyfunctional phenotypes expressed are TCR dependent in the same donor and 
experiment when presented with the same ligand.  
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Figure 22. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on 
Polyfunctional Responses against MART-1 (Donor One). The data indicate reactivity 
against T2 cells loaded with the MART-1 9mer peptide in donor one, experiment one. 
“Cool plots” were generated to include any functional phenotype present over 0.1%. In 
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates 
negative for the marker. As described in Chapter Two, reactivity is defined after 
background subtraction and specifically, any phenotype expressed by over 0.1% of 
TCR transduced T cells (subtraction of the background immunofluorescence observed 
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool 
plot” correlates to the scale on the right. An “X” indicates no T cells were positive 
(<0.1% after background subtraction) for given functional phenotype. The color white for 
a given functional phenotype indicates a percentage less than 0.5%.  
 
Despite the variability in the magnitudes of responses and in the polyfunctional 
phenotypes amongst T cells expressing each of the different DMF5 TCRs, there are two 
functional phenotypes reproducibly exhibited with T cells expressing each of the DMF5 
TCRs when stimulated with the MART-1 9mer (Figure 22). These two phenotypes are 
IFN-γ+, TNF-α+ and TNF-α+, IL-4+. TNF-α is type 1 cytokine while IL-4 is type 2 cytokine, 
thus exemplifying the ability for the T cells to commonly express cytokines that have 
been previously categorized into different T cell subsets. Overall, this experiment 
demonstrated the polyfunctionality of TCR transduced CD4+ T cells and the variability in 
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the functional phenotypes demonstrated in T cells expressing different DMF5 TCRs 
despite presentation of the same ligand. Despite variability in the patterns of 
polyfunctional phenotypes, two phenotypes were reproducibly exhibited by T cells 
expressing each of the DMF5 TCRs in response to the MART-1 9mer. 
It is well appreciated that polyclonal PBL-derived T cells will not function in the 
exact same manner when stimulated on different days after previous activations. 
Specifically, the duration of in vitro cell culture after T cell activation can affect the 
expansion of different T cell populations [426]. Furthermore, one study indicated four 
day anti-CD3 T cell activation only induced proliferation of 60% of T cells, depending 
upon T cell populations [427]. It has also been shown that T cells will become less 
functional, the longer they are cultured in vitro [428]. Consequently, proportions of T cell 
populations and overall T cell function could vary depending upon the duration of in vitro 
cell culture. Therefore, we determined if the patterns described above were reproducible 
in a second repeat in donor one, with the same TCR transduced T cell culture, four days 
later (Figure 46, in the appendix). In the repeat of donor one among six TCR transduced 
CD4+ T cell populations, 31 out of the potential 128 polyfunctional phenotypes were 
detected in at least one DMF5 TCR transduced T cell population, by over 0.1% of TCR 
transduced CD4+ T cells. Six more phenotypes were represented in the second 
experiment, but the percentage of reactive CD4+ T cells expressing a specific functional 
phenotype decreased from a maximum of 6.5% to a maximum of 2.5%. These findings 
indicated the polyfunctional patterns are not completely reproducible in this donor. For 
example, the IFN-γ+, TNF-α+ and TNF-α+, IL-4+ phenotypes were exhibited by T cells 
expressing each DMF5 TCR in the first experiment. In the second experiment, the IFN-
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γ+, TNF-α+ phenotype was exhibited by T cells expressing each DMF5 TCR. However, 
the second phenotype exhibited by T cells expressing each DMF5 TCR was CD107A+, 
IL-4+, rather than the TNF-α+, IL-4+ phenotype. In summary, these two repeats indicated 
that functional phenotypes are not completely reproducible in the same donor when 
observed in two independent experiments. However, one functional phenotype was 
reproducibly exhibited by CD4+ T cells expressing each of the DMF5 TCRs in both 
experiments in response to the MART-1 9mer. 
Donor variability occurs in human polyclonal PBL-derived T cells. This 
phenomenon has been observed both in vitro and in vivo. Therefore, we performed this 
analysis in another donor to determine how mutations in the DMF5 TCR altered 
polyfunctional phenotypes in polyclonal PBL-derived T cells from a different donor when 
stimulated with the MART-1 9mer. A representative cool plot for the second donor is 
shown in Figure 23. In this experiment, the percentage of reactive CD4+ T cells 
expressing a specific functional phenotype ranged from 0% to around 9%. Among six 
TCR transduced CD4+ T cell populations, 71 out of the potential 128 polyfunctional 
phenotypes were detected in at least one DMF5 TCR transduced population, by over 
0.1% of TCR transduced CD4+ T cells. It is evident that the TCR transduced T cells are 
again, very polyfunctional. Furthermore, phenotypes consisting of lysis and 
combinations of Th1, Th2 and Th17 cytokines were exhibited. Overall, these results 
indicated that this donor and experiment exhibited more functional phenotypes than 
donor one, and included functional phenotypes consisting of combinations of lysis and 
Th1, Th2 and Th17 cytokines.  
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Next, we examined how the distribution of functional phenotypes changed 
amongst T cells expressing each of the different DMF5 TCRs when stimulated with the 
MART-1 9mer. As observed with donor one, different polyfunctional phenotypes were 
exhibited by T cells expressing the different DMF5 TCRs despite presentation of the 
same ligand (Figure 23). For example, the first functional phenotype listed consisted of 
CD107A+, IFN-γ+, TNF-α+, IL-22+, IL-17A+, IL-2+ TCR transduced CD4+ T cells. This 
phenotype is exhibited in less than 0.5% of αD26Y TCR expressing T cells but absent in 
T cells expressing each of the other DMF5 TCRs. In another example, the last 
phenotype in the first row consisted of CD107A+ TCR transduced CD4+ T cells. This 
phenotype is exhibited in 2% of WT TCR and αD26Y/βL98W TCR expressing T cells, 
but absent in T cells expressing each of the other DMF5 TCRs. Overall, these are a few 
of the many examples of how the polyfunctional phenotypes expressed are TCR 
dependent in the same donor and experiment despite presentation of the same ligand. 
Despite the variability in polyfunctional phenotypes exhibited amongst T cells 
expressing each of the different DMF5 TCRs, there are 14 functional phenotypes that 
are reproducibly exhibited by T cells expressing each DMF5 TCR when stimulated with 
the MART-1 9mer (Figure 23). This observation indicated this donor, in this experiment, 
exhibited functional phenotypes consisting of lysis and cytokines from combinations of 
different T cell subsets. Overall, this experiment demonstrated the polyfunctionality of 
TCR transduced CD4+ T cells and the variability in the functional phenotypes 
demonstrated in T cells expressing each of the different DMF5 TCRs despite 
presentation of the same ligand. Nonetheless, 14 phenotypes were reproducibly 
exhibited by T cells expressing each of the DMF5 TCRs in this experiment. 
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Figure 23. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on 
Polyfunctional Responses against MART-1 (Donor Two). The data indicate reactivity 
against T2 cells loaded with the MART-1 9mer peptide in donor two, experiment one. 
“Cool plots” were generated to include any functional phenotype present over 0.1%. In 
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates 
negative for the marker. As described in Chapter Two, reactivity is defined after 
background subtraction and specifically, any phenotype expressed by over 0.1% of 
TCR transduced T cells (subtraction of the background immunofluorescence observed 
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool 
plot” correlates to the scale on the right. An “X” indicates no T cells were positive 
(<0.1% after background subtraction) for given functional phenotype. The color white for 
a given functional phenotype indicates a percentage less than 0.5%.  
 
We observed variability and similarity within the patterns of polyfunctionality 
when we compared two independent repeats in the first donor. Therefore, we 
determined if the patterns described above were reproducible in a second repeat in 
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donor two, with the same TCR transduced T cell culture, four days later (Figure 47, in 
the appendix). In the repeat of donor two among six TCR transduced CD4+ T cell 
populations, 67 out of the potential 128 polyfunctional phenotypes were detected in at 
least one DMF5 TCR transduced T cell population, by over 0.1% of TCR transduced 
CD4+ T cells. Four fewer phenotypes were represented in the second experiment and 
the percentage of reactive CD4+ T cells expressing a specific functional phenotype 
decreased from a maximum of 9% to a maximum of 7%. This indicated the patterns 
were not completely reproducible in this donor. For example, the IL-4+ only phenotype is 
exhibited by T cells expressing each DMF5 TCR in the second experiment, but only by 
T cells expressing the αD26Y TCR in the first experiment. However, nine functional 
phenotypes were reproducibly exhibited by T cells expressing each of DMF5 TCRs in 
the two experiments. These functional phenotypes included 1.) CD107A+, IFN-γ+, TNF-
α+, 2.) CD107A+, IL-17A+, 3.) IFN-γ+, TNF-α+, IL-17+, 4.) IFN-γ+, TNF-α+, 5.) IFN-γ+, 6.) 
TNF-α+, IL-22+, IL-17A+, 7.) TNF-α+, IL-17A+, 8.) TNF-α+, and 9.) IL-17A+. These results 
indicated that in this donor, T cells expressing each of the DMF5 TCRs exhibited 
phenotypes consisting of combinations of lysis and Th1 and Th17 cytokines. In summary, 
these two repeats indicated that functional phenotypes are not completely reproducible 
in the same donor when observed in two independent repeats. However, nine functional 
phenotypes were reproducibly exhibited by T cells expressing each of the DMF5 TCRs 
in response to the MART-1 9mer in both experiments. 
It would be important to observe the differences and similarities in patterns of 
polyfunctional phenotypes amongst the first two donors. However, to first determine if 
variability was reproducibly observed in more than two donors, we performed this 
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analysis in a third donor. A representative cool plot for the third donor is shown in Figure 
24. In this donor, the percentage of antigen reactive CD4+ T cells expressing a specific 
functional phenotype ranged from 0% to about 12%. Among six TCR transduced CD4+ 
T cell populations, 44 out of the potential 128 polyfunctional phenotypes were detected 
in at least one DMF5 TCR transduced T cell population, by over 0.1% of TCR 
transduced CD4+ T cells. It is evident that the TCR transduced T cells are again, very 
polyfunctional. Overall, these results indicated in this donor and experiment, TCR 
transduced T cells exhibited functional phenotypes comprised of lysis and Th1, Th2, and 
Th17 cytokines. 
We next examined how the distribution of functional phenotypes changed 
amongst T cells expressing each of the different DMF5 TCRs when stimulated with the 
MART-1 9mer. As with donors one and two, different polyfunctional phenotypes were 
exhibited by T cells expressing the different DMF5 TCRs despite presentation of the 
same ligand (Figure 24). For example, the first functional phenotype listed consisted of 
CD107A+, IFN-γ+, TNF-α+, IL-17A+, IL-2+ TCR transduced CD4+ T cells. This phenotype 
was exhibited by less than 0.5% of αD26Y/βL98W TCR expressing T cells but absent in 
T cells expressing each of the other DMF5 TCRs. In another example, the second 
functional phenotype listed consisted of CD107A+, IFN-γ+, TNF-α+, IL-2+ TCR 
transduced CD4+ T cells. This phenotype was expressed by less than 0.5% of 
αD26Y/αY50V/βL98W TCR expressing T cells, but absent in T cells expressing each of 
the other DMF5 TCRs. If we move further down the cool plot to the CD107A+, IL-4+ 
phenotype, this phenotype is expressed by less than 0.5% of αD26Y/αY50V/βL98W 
TCR expressing T cells, 6% of αD26Y TCR expressing T cells, about 2.5% of βL98W 
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TCR and αD26Y/βL98W TCR expressing T cells, and absent in WT TCR and 
αD26Y/αY50A/βL98W TCR expressing T cells. Overall, these results demonstrated that 
the exhibited polyfunctional phenotypes are TCR dependent within the same donor and 
the same experiment despite presentation of the same ligand.  
Despite the variability in polyfunctional phenotypes amongst T cells expressing each of 
the different DMF5 TCRs, there were seven functional phenotypes that were 
reproducibly exhibited by T cells expressing each of the DMF5 TCRs (Figure 24). These 
functional phenotypes included 1.) CD107A+, IFN-γ+, TNF-α+, 2.) CD107A+, IFN-γ+, 3.) 
IFN-γ+, TNF-α+, IL-2+, 4.) IFN-γ+, TNF-α+, IL-4+, 5.) IFN-γ+, TNF-α+, 6.) IFN-γ+, and 7.) 
TNF-α+, IL-2+. These results implicated that Th1 and Th2 cytokines were commonly 
expressed amongst in T cells expressing each different DMF5 TCR. Furthermore, 
combinations of lysis, Th1, or Th2 cytokines were sometimes expressed in the same 
phenotype. Overall, this experiment demonstrated the polyfunctionality of TCR 
transduced CD4+ T cells and the variability of the functional phenotypes demonstrated 
in T cells expressing different DMF5 TCRs despite presentation of the same ligand. 
Nonetheless, seven phenotypes were reproducibly exhibited by T cells expressing each 
of the DMF5 TCRs in response to the MART-1 9mer in this experiment.  
We observed variability and similarity within the patterns of polyfunctionality 
when comparing two independent repeats in the first two donors. Therefore, we 
determined if the patterns described above were reproducible in a second repeat in the 
third donor, with the same TCR transduced T cell culture, four days later (Figure 48, in 
the appendix). 
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Figure 24. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on 
Polyfunctional Responses against MART-1 (Donor Three). The data indicate 
reactivity against T2 cells loaded with the MART-1 9mer peptide in donor three, 
experiment one. “Cool plots” were generated to include any functional phenotype 
present over 0.1%. In the functional phenotypes listed, “+” indicates positive for the 
marker and “-“ indicates negative for the marker. As described in Chapter Two, 
reactivity is defined after background subtraction, specifically, any phenotype expressed 
by over 0.1% of TCR transduced T cells (subtraction of the background 
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide). 
The color depicted in the “cool plot” correlates to the scale on the right. An “X” indicates 
no T cells were positive (<0.1% after background subtraction) for given functional 
phenotype. The color white for a given functional phenotype indicates a percentage less 
than 0.5%.   
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In the repeat of donor three among six TCR transduced T cell populations, 27 out of the 
potential 128 polyfunctional phenotypes were detected in over 0.1% of TCR transduced 
CD4+ T cells in this donor and this experiment. Seventeen fewer phenotypes were 
exhibited in the second experiment compared to the first experiment, indicating the 
patterns were not completely reproducible in this donor. For example, the TNF-α+ only 
phenotype was exhibited by T cells expressing the αD26Y TCR in the second 
experiment, but not in the first experiment. However, four functional phenotypes were 
reproducibly exhibited by T cells expressing each of DMF5 TCRs in the two 
experiments. These exhibited phenotypes included 1.) CD107A+, IFN-γ+, 2.) IFN-γ+, 
TNF-α+, 3.) IFN-γ+, and 4.) TNF-α+, IL-2+. These results indicated that in this donor, T 
cells expressing each of the DMF5 TCRs exhibited phenotypes consisting of lysis 
and/or Th1 and Th2 cytokines in response to the MART-1 9mer. In summary, these two 
repeats indicated that functional phenotypes are not completely reproducible in the 
same donor when observed in two independent repeats. However, four functional 
phenotypes were reproducibly exhibited by T cells expressing each of the DMF5 TCRs 
in both experiments. 
Thus far, we have demonstrated that TCR transduced CD4+ T cells were lytic 
and polyfunctional. Furthermore, in CD4+ T cells there is no CD8 co-receptor and thus, 
interactions are dependent upon the TCR/pMHC. There are a few overarching 
conclusions that can be made based upon the polyfunctional responses of T cells 
expressing each of the DMF5 TCRs against the MART-1 9mer in different experiments 
and donors. The first set of conclusions encompassed variability and similarity amongst 
polyfunctional patterns between donors and experiments. Table 13 depicts a numerical 
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summary of the number of functional phenotypes observed and their reproducibility 
amongst each experiment and donor. First, the number of polyfunctional patterns 
exhibited was donor and experiment dependent. For example, donor two was more 
polyfunctional than donors one and three. Furthermore, no two experimental repeats 
exhibited the same number of functional phenotypes. Secondly, the number of 
reproducible patterns of polyfunctional phenotypes amongst T cells expressing each of 
the DMF5 T cells was experiment dependent. For example, in donor one, experiment 
one, one reproducible functional phenotype was exhibited with T cells expressing each 
of the DMF5 TCRs, whereas in experiment two, two reproducible functional phenotypes 
were exhibited. Thirdly, the number of reproducible patterns of functional phenotypes 
exhibited in T cells expressing each of the DMF5 TCRs was donor dependent. For 
example, the number of unique reproducible functional phenotypes in T cells expressing 
each of the DMF5 TCRs was different in every donor (donor 1 – one, donor 2 – nine, 
donor 3 – four). Fourthly, one functional phenotype was exhibited by CD4+ T cells 
expressing each of the DMF5 TCRs in every donor and in every experiment. This was a 
Th1 cytokine pattern, IFN-γ+, TNF-α+. This makes sense as expression of these two 
cytokines can be mediated by the same transcription factors (STAT1 and NF-κB) [424, 
429-432]. Furthermore, IFN-γ is considered an early response cytokine and shown to be 
important to modulate the adaptive immune response [433-435]. In summary, these 
data indicated polyfunctional responses of CD4+ T cells are dependent upon the TCR, 
experiment, and donor. However, we demonstrated that in response to the MART-1 
9mer, T cells expressing each of the DMF5 TCRs always exhibited the IFN-γ+, TNF-α+ 
phenotype.  
145 
 
 
Table 13. Summary of Polyfunctional Phenotypes in TCR Transduced CD4+ T cells 
amongst Six Experiments. *Reproducible phenotypes with every DMF5 TCR indicate 
that within a specific experiment, all six TCR transduced CD4+ T cell populations (WT 
DMF5 TCR and each mutant DMF5 TCR) exhibited the functional phenotype. 
**Reproducible phenotypes with every DMF5 TCR within donor indicate that within a 
specific donor, all six TCR transduced CD4+ T cell populations (WT DMF5 TCR and 
each mutant DMF5 TCR) exhibited the functional phenotype in both experimental 
repeats.  
 
The second set of conclusions encompassed variability and similarity amongst 
polyfunctional patterns between donors and experiments in regards to each of the 
DMF5 TCRs. Table 14 depicts a numerical summary of the number of functional 
phenotypes observed amongst T cells expressing each of the DMF5 TCRs in each 
experiment and donor. First, the number of polyfunctional phenotypes exhibited is 
DMF5 TCR dependent. For example, in donor one and experiment one, T cells 
expressing each of the DMF5 TCRs exhibited a different number of polyfunctional 
phenotypes. Secondly, the number of polyfunctional phenotypes exhibited amongst T 
cells expressing any given DMF5 TCR is experiment and donor dependent. For 
example, T cells expressing the WT DMF5 TCR exhibited a different number of 
polyfunctional phenotypes in five out of the six experiments. Thirdly, the total number 
and the average number of functional phenotypes amongst the six experiments, 
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generally trends towards a correlation between number of polyfunctional phenotypes 
and the overall percentages of antigen reactive TCR transduced CD4+ T cells. For 
example, in Figure 19, CD4+ T cells expressing the αD26Y TCR and the βL98W TCR 
exhibited a trend towards an increase in the percentage of MART-1 9mer reactive T 
cells, compared to T cells expressing the WT TCR, in the six experiments. Herein, CD4+ 
T cells expressing the αD26Y TCR and the βL98W TCR exhibited a trend towards an 
increase in the average and total number of functional phenotypes exhibited in the six 
experiments, compared to T cells expressing the WT TCR. Conversely, in Figure 19, 
CD4+ T cells expressing the αD26Y/βL98W TCR and the αD26Y/αY50A/βL98W TCR 
exhibited a trend towards (statistically significant in T cells expressing the 
αD26Y/αY50A/βL98W TCR) a reduction in the percentage of MART-1 9mer reactive T 
cells, compared to T cells expressing the WT TCR, in the six experiments. Herein, CD4+ 
T cells expressing the αD26Y/βL98W TCR and the αD26Y/αY50A/βL98W TCR 
exhibited a trend towards a reduction in the average and total number of functional 
phenotypes exhibited in the six experiments, compared to T cells expressing the WT 
TCR. The one exception to this correlation is T cells expressing the 
αD26Y/αY50V/βL98W TCR exhibited a comparable percentage of MART-1 9mer 
reactive T cells but exhibited an increase in the average and total number of functional 
phenotypes, compared to T cells expressing the WT TCR. Conclusively, these results 
indicated polyfunctional phenotypes exhibited amongst T cells expressing each of the 
DMF5 TCRs is TCR, experiment, and donor dependent. However, CD4+ T cells 
expressing each of the DMF5 TCRs always exhibited the IFN-γ+, TNF-α+ functional 
phenotype in response to the MART-1 9mer.  
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Table 14. Summary of Polyfunctional Phenotypes in TCR Transduced CD4+ T cells 
amongst Six Experiments per each of the DMF5 TCRs. 
 
Lastly, the number of different functional phenotypes exhibited generally correlated to 
the overall pattern in the percentages of MART-1 9mer reactive TCR transduced CD4+ 
T cells. Specifically, the greater the percentage of antigen reactive TCR transduced T 
cells, the more functional phenotypes exhibited. 
The analysis of TCR transduced CD4+ T cells allowed us to examine how the 
structure of the TCR/pMHC altered polyfunctional T cell responses. However, as 
mentioned previously, CD8 has been shown to affect antigen recognition and T cell 
function. Therefore, we next examined how mutations in the DMF5 TCR altered the 
polyfunctional responses of CD8+ T cells. A representative example of the CD8+ 
reactivity against T2 cells loaded with the MART-1 9mer is shown in Figure 25. In the 
first donor, the percentage of reactive CD8+ T cells expressing a specific functional 
phenotype ranged from 0% to around 20%.  
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Figure 25. Impact of DMF5 Mutations in Transduced CD8+ T cells on 
Polyfunctional Responses against MART-1 (Donor One). The data indicate reactivity 
against T2 cells loaded with the MART-1 9mer peptide in donor one, experiment one. 
“Cool plots” were generated to include any functional phenotype present over 0.1%. In 
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates 
negative for the marker. As described in Chapter Two, reactivity is defined after 
background subtraction, specifically, any phenotype expressed by over 0.1% of TCR 
transduced T cells (subtraction of the background immunofluorescence observed with 
T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool plot” 
correlates to the scale on the right. An “X” indicates no T cells were positive (<0.1% 
after background subtraction) for given functional phenotype. The color white for a given 
functional phenotype indicates a percentage less than 0.5%. Five prominent 
phenotypes are highlighted with red boxes.  
 
Among six TCR transduced CD8+ T cell populations, 17 out of the potential 128 
polyfunctional phenotypes were detected in at least one DMF5 TCR transduced T cell 
population, by over 0.1% of TCR transduced CD8+ T cells. Combinations of lysis and 
Th1, Th2, and Th17 cytokines are all exhibited, except for phenotypes including IL-22. As 
observed with the CD4+ T cells, differences in the patterns of polyfunctional phenotypes 
are evident among T cells expressing the different DMF5 TCRs despite seeing the 
same ligand. For example, the first functional phenotype listed consisted of CD107A+, 
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IFN-γ+, TNF-α+, IL-17A+ TCR transduced CD8+ T cells. This phenotype was exhibited by 
less than 0.5% of WT TCR, αD26Y TCR, βL98W TCR and αD26Y/αY50A/βL98W TCR 
expressing T cells, but absent in T cells expressing the αD26Y/βL98W TCR and 
αD26Y/αY50V/βL98W TCR expressing T cells. Despite the differences observed in 
polyfunctional patterns amongst the DMF5 TCRs, there were nine functional 
phenotypes that were reproducibly exhibited by T cells expressing each of the DMF5 
TCRs. However, it was notable that a majority of the functional T cells exhibited five 
prominent functional phenotypes. These five prominent phenotypes (highlighted in red 
boxes) were comprised of combinations of CD107A, IFN-γ, and TNF-α. Overall, these 
results indicated in this donor and experiment, TCR transduced T cells exhibited 
functional phenotypes comprised of lysis and Th1, Th2, and Th17 cytokines. 
Furthermore, five distinct functional phenotypes were reproducibly exhibited by T cells 
expressing each of the DMF5 TCRs in response to the MART-1 9mer. 
We observed variability and similarity within patterns of polyfunctionality when we 
compared two independent repeats within the same donor in the TCR transduced CD4+ 
T cells when stimulated with the MART-1 9mer.Therefore, we determined if the patterns 
described above were reproducible or inconsistent in a second repeat in donor one, with 
the same TCR transduced CD8+ T cell culture, four days later (Figure 49, in the 
appendix). In the repeat of donor one among six TCR transduced CD8+ T cell 
populations, 21 out of the potential 128 polyfunctional phenotypes were detected in at 
least one DMF5 TCR transduced T cell population, by over 0.1% of transduced CD8+ T 
cells. Four more phenotypes were exhibited in the second experiment and the 
percentage of reactive CD8+ T cells was reduced from a maximum of 20% to a 
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maximum of 11%. This indicated the patterns are not completely reproducible in this 
donor. For example, the IL-4+ only phenotype is exhibited in experiment two and not in 
experiment one. Furthermore, IL-22 is exhibited in two functional phenotypes, whereas 
it was absent in experiment one. Despite differences, the five predominant functional 
phenotypes that were exhibited previously, are reproducibly exhibited in this experiment 
in T cells expressing each of the DMF5 TCRs. In summary, these two experiments 
indicated that functional phenotypes are not completely reproducible in the same donor 
when observed in two independent repeats. Moreover, the five predominant functional 
phenotypes that were exhibited previously, are reproducibly exhibited by T cells 
expressing each of the DMF5 TCRs in both experiments.  
To determine if donor variability reproducibly occurred in polyclonal PBL-derived 
CD8+ T cells, we performed this analysis in multiple donors. A representative cool plot 
for the second donor is shown in Figure 26. In this experiment, the percentage of 
reactive CD8+ T cells expressing a specific functional phenotype ranged from 0% to 
around 12%. Among six TCR transduced CD8+ T cell populations, 26 out of the 
potential 128 polyfunctional phenotypes were detected in at least one DMF5 TCR 
transduced T cell population, by over 0.1% of TCR transduced CD8+ T cells. 
Combinations of lysis and Th1, Th2, and Th17 cytokines are all represented, except for 
phenotypes including IL-22. As observed in the transduced CD4+ T cells, the patterns of 
polyfunctional phenotypes exhibited was TCR dependent. For example, the first 
functional phenotype listed consisted of CD107A+, IFN-γ+, TNF-α+, IL-17A+, IL-2+ 
transduced CD8+ T cells.  
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Figure 26. Impact of DMF5 Mutations in Transduced CD8+ T cells on 
Polyfunctional Responses against MART-1 (Donor Two). The data indicate reactivity 
against T2 cells loaded with the MART-1 9mer peptide in donor two, experiment one. 
“Cool plots” were generated to include any functional phenotype present over 0.1%. In 
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates 
negative for the marker. As described in Chapter Two, reactivity is defined after 
background subtraction, specifically, any phenotype expressed by over 0.1% of TCR 
transduced T cells (subtraction of the background immunofluorescence observed with 
T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool plot” 
correlates to the scale on the right. An “X” indicates no T cells were positive (<0.1% 
after background subtraction) for given functional phenotype. The color white for a given 
functional phenotype indicates a percentage less than 0.5%. Five prominent 
phenotypes are highlighted with red boxes.  
 
This phenotype was exhibited by less than 0.5% of αD26Y/αY50A/βL98W TCR and 
αD26Y/αY50V/βL98W TCR expressing T cells, and not exhibited by T cells expressing 
each of the other DMF5 TCRs. The five prominent phenotypes (highlighted in red 
boxes) comprised of combinations of CD107A, IFN-γ, and TNF-α were also observed in 
this donor and experiment. Overall, these results indicated transduced T cells were 
capable of exhibiting functional phenotypes comprised of lysis and Th1, Th2, and Th17 
cytokines. Moreover, five functional phenotypes were reproducibly exhibited by T cells 
expressing each of the DMF5 TCRs in response to the MART-1 9mer. 
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When previously comparing two independent repeats in the same donors, we 
observed variability and similarity within patterns of polyfunctionality elicited by TCR 
transduced CD4+ T cells when stimulated with the MART-1 9mer. Therefore, we 
determined if the patterns described above were reproducible in a second repeat in 
donor two, with the same TCR transduced CD8+ T cell culture, four days later (Figure 
50, in the appendix). In the repeat of donor two among six TCR transduced CD8+ T cell 
populations, 48 out of the potential 128 polyfunctional phenotypes were detected in at 
least one DMF5 TCR transduced T cell population, by over 0.1% of transduced CD8+ T 
cells. 21 more phenotypes were represented in the second experiment. This indicated 
the patterns are not completely reproducible in this donor. Here, the five predominant 
functional phenotypes that were exhibited in the first experiment are reproducibly 
exhibited. However, in addition to these five, there are additional polyfunctional 
phenotypes exhibited by the transduced T cells expressing each of the DMF5 TCRs. 
Furthermore, IL-22 is exhibited in functional phenotypes, whereas it was not in 
experiment one. In summary, these two repeats indicated that functional phenotypes 
are not completely reproducible in the same donor when observed in two independent 
repeats. However, the five predominant functional phenotypes that were exhibited in the 
first experiment are reproducibly exhibited by T cells expressing each of the DMF5 
TCRs. 
To determine if donor variability was again observed with another donor in TCR 
transduced CD8+ T cells when stimulated with the MART-1 9mer, we performed this 
analysis in a third donor. A representative cool plot for the third donor is shown in Figure 
27.  
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Figure 27. Impact of DMF5 Mutations in Transduced CD8+ T cells on 
Polyfunctional Responses against MART-1 (Donor Three). The data indicate 
reactivity against T2 cells loaded with the MART-1 9mer peptide in donor three, 
experiment one. “Cool plots” were generated to include any functional phenotype 
present over 0.1%. In the functional phenotypes listed, “+” indicates positive for the 
marker and “-“ indicates negative for the marker. As described in Chapter Two, 
reactivity is defined after background subtraction, specifically, any phenotype expressed 
by over 0.1% of TCR transduced T cells (subtraction of the background 
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide). 
The color depicted in the “cool plot” correlates to the scale on the right. An “X” indicates 
no T cells were positive (<0.1% after background subtraction, as described in Chapter 
Two) for given functional phenotype. The color white for a given functional phenotype 
indicates a percentage less than 0.5%. Five prominent phenotypes are highlighted with 
red boxes.  
 
In donor three, the percentage of reactive CD8+ T cells expressing a specific functional 
phenotype ranged from 0% to around 13%. Among six TCR transduced CD8+ T cell 
populations, 30 out of the potential 128 polyfunctional phenotypes were detected in at 
least one DMF5 TCR transduced T cell population, by over 0.1% of TCR transduced 
CD8+ T cells. Differences in polyfunctional phenotypes are evident among T cells 
expressing the different DMF5 TCRs despite seeing the same ligand. For example, the 
first phenotype consisted of CD107A+, IFN-γ+, TNF-α+, IL-22+ CD8+ transduced T cells. 
This phenotype was exhibited by less than 0.5% of βL98W TCR expressing T cells, but 
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absent in T cells expressing each of the other DMF5 TCRs. Despite the differences 
among T cells expressing each of the DMF5 TCRs, the five prominent phenotypes 
(highlighted in red boxes) comprised of combinations of CD107A, IFN-γ, and TNF-α 
were also observed in this donor and experiment (except in T cells expressing the 
αD26Y/βL98W TCR). Overall, this experiment demonstrated the polyfunctionality of 
transduced CD8+ T cells and the variability of the functional phenotypes demonstrated 
in T cells expressing different DMF5 TCRs despite presentation of the same ligand. 
Furthermore, the five predominant functional phenotypes that were exhibited in the first 
donor are reproducibly exhibited. 
We observed variability and similarity within patterns of polyfunctionality elicited 
by TCR transduced T cells when stimulated with the MART-1 9mer when we compared 
two independent repeats in the first two donors. Therefore, we determined if the 
patterns described above were reproducible in a second repeat in the third donor, with 
the same TCR transduced T cell culture, four days later (Figure 51, in the appendix). In 
the repeat of donor three among six TCR transduced T cell populations, 42 out of the 
potential 128 polyfunctional phenotypes were detected in over 0.1% of TCR transduced 
CD8+ T cells in this donor and this experiment. 21 more phenotypes were represented 
in the second experiment and the maximum percentage of reactive CD8+ T cells was 
increased from a maximum of 13% to about 16%. This indicated the patterns are not 
completely reproducible in this donor. For example, the IFN-γ+, TNF-α+, IL-2+ phenotype 
is exhibited by T cells expressing each DMF5 TCR in the second experiment, but is only 
exhibited by T cells expressing the WT TCR, βL98W TCR, and αD26Y/αY50V/βL98W 
TCR in experiment one. Despite differences in the patterns amongst the different DMF5 
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TCRs, the five predominant functional phenotypes that were exhibited previously are 
reproducibly exhibited in this second experiment. In summary, these two repeats 
indicated that functional phenotypes are not completely reproducible in the same donor 
when observed in two independent repeats. Moreover, the five predominant functional 
phenotypes that were exhibited previously, are reproducibly exhibited in T cells 
expressing each of the DMF5 TCRs. 
Thus far, we demonstrated that transduced CD8+ T cells were polyfunctional 
against the MART-1 9mer. There are a few overarching conclusions that were made 
based upon the polyfunctional responses of T cells expressing each of the DMF5 TCRs 
against the MART-1 9mer in different experiments and donors. The first set of 
conclusions encompassed variability and similarity amongst polyfunctional patterns 
between donors and experiments. Table 15 depicts a numerical summary of the number 
of functional phenotypes observed and their reproducibility amongst each experiment 
and donor. First, as with the CD4+ T cells, the number of polyfunctional phenotypes 
exhibited was donor and experiment dependent. Secondly, as with the CD4+ T cells, the 
number of reproducible polyfunctional phenotypes amongst T cells expressing each of 
the DMF5 T cells were experiment dependent. Thirdly, the number of reproducible 
functional phenotypes exhibited in T cells expressing each of the DMF5 TCRs was 
donor dependent. For example, the number of unique reproducible functional 
phenotypes in T cells expressing each of the DMF5 TCRs was different in every donor 
(donor 1 – five, donor 2 – eight, donor 3 – five). Fourthly, five functional phenotypes 
were exhibited by CD8+ T cells expressing each of the DMF5 TCRs in every donor and 
in every experiment (except with one TCR in donor three, experiment one).   
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Table 15. Summary of Polyfunctional Phenotypes in TCR Transduced CD8+ T cells 
amongst Six Experiments. *Reproducible phenotypes with every DMF5 TCR indicate 
that within a specific experiment, all six TCR transduced CD8+ T cell populations (WT 
DMF5 TCR and each mutant DMF5 TCR) exhibited the functional phenotype.  
**Reproducible phenotypes with every DMF5 TCR within donor indicate that within a 
specific donor, all six TCR transduced CD8+ T cell populations (WT DMF5 TCR and 
each mutant DMF5 TCR) exhibited the functional phenotype in both experimental 
repeats.  
 
The five phenotypes identified are: 1.) CD107A+, IFN-γ+, TNF-α+, 2.) IFN-γ+, TNF-α+, 3.) 
CD107A+, IFN-γ+, 4.) IFN-γ+ only, and 5.) CD107A+ only. This indicated that in CD8+ T 
cells expressing each of the DMF5 TCRs will be lytic, produce type 1 cytokines, or do 
both in response to the MART-1 9mer. In summary, these data indicated polyfunctional 
responses of CD8+ T cells are dependent upon the TCR, experiment, and donor. 
However, we demonstrated that in response to the MART-1 9mer, T cells expressing 
each of the DMF5 TCRs almost always exhibited a lytic and/or IFN-γ+ and TNF-α+ 
phenotype. 
The second set of conclusions encompassed variability and similarity amongst 
polyfunctional patterns between donors and experiments in regards to each of the 
DMF5 TCRs. Table 16 depicts a numerical summary of the number of functional 
phenotypes observed amongst T cells expressing each of the DMF5 TCRs in each 
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experiment and donor. First, the number of polyfunctional phenotypes exhibited is 
DMF5 TCR dependent. Secondly, the number of polyfunctional phenotypes exhibited 
amongst T cells expressing any given DMF5 TCR is experiment and donor dependent. 
For example, T cells expressing the WT DMF5 TCR exhibited a different number of 
polyfunctional phenotypes in each of the six experiments. Thirdly, like the CD4+ T cells, 
the total number and the average number of functional phenotypes amongst the six 
experiments, generally trends towards a correlation between number of polyfunctional 
phenotypes and the overall percentages of reactive TCR transduced CD8+ T cells. For 
example, in Figure 20, CD8+ T cells expressing each of the DMF5 TCRs exhibited a 
trend towards a reduction (statistically significant in T cells expressing the 
αD26Y/βL98W TCR or αD26Y/αY50A/βL98W TCR) in the percentage of MART-1 9mer 
reactive T cells compared to T cells expressing the WT TCR. With the one exception of 
T cells expressing the αD26Y/αY50V/βL98W TCR, the total number and the average 
number of polyfunctional phenotypes exhibited by T cells expressing each of the DMF5 
TCRs trends towards a reduction compared to T cells expressing the WT TCR amongst 
the six experiments. Conclusively, these results indicated polyfunctional phenotypes 
exhibited amongst T cells expressing each of the DMF5 TCRs is TCR, experiment, and 
donor dependent. However, CD8+ T cells expressing each of the DMF5 TCRs nearly 
always exhibited the same five functional phenotypes in response to the MART-1 9mer. 
Lastly, the number of different functional phenotypes exhibited generally correlated to 
the overall patterns observed with the percentages of MART-1 9mer reactive TCR 
transduced CD8+ T cells.  
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Table 16. Summary of Polyfunctional Phenotypes in TCR Transduced CD8+ T cells 
amongst Six Experiments per each of the DMF5 TCRs. 
 
 
We have independently concluded that the polyfunctional responses of CD4+ and 
CD8+ T cells expressing either the WT DMF5 or each of the mutant DMF5 TCRs 
against the MART-1 9mer. Many of the conclusions remained consistent between CD4+ 
and CD8+ T cells. However, there are also some notable differences. For example, the 
magnitudes of the percentages of T cells expressing a given phenotype in CD8+ T cells 
was increased compared to the CD4+ T cells. This was expected due to the contribution 
of CD8 in stabilization and in signaling. Secondly, with the one exception of T cells 
expressing the αD26Y/αY50A/βL98W TCR, on average, TCR transduced CD4+ T cells 
exhibited more polyfunctional phenotypes than TCR transduced CD8+ T cells. This 
indicated that the response of CD8+ T cells are less heterogeneous than CD4+ T cells. 
Additionally, different polyfunctional phenotypes were reproducibly exhibited in T cells 
expressing each of the DMF5 TCRs between the CD4+ and CD8+ T cells. Notably, 
CD107A+ only phenotypes were more prevalent in the CD8+ T cells than the CD4+ T 
cells. This is consistent with the knowledge in the field that CD8+ T cells are generally 
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more lytic than CD4+ T cells [436]. Overall, CD4+ and CD8+ T cells were polyfunctional 
and the polyfunctional phenotypes displayed were dependent upon the donor, 
experiment, and DMF5 TCR. Lastly, the number of polyfunctional phenotypes exhibited 
against the MART-1 9mer with a given DMF5 TCR, generally correlated to the pattern 
associated with the percentages of MART-1 9mer reactive T cells. 
Thus far we have focused on polyfunctional responses against the MART-1 9mer 
peptide. Furthermore, we observed five prominent and reproducible functional patterns 
in CD8+ T cells expressing each of the DMF5 TCRs. However, altered-peptide ligands 
have been shown to elicit different polyfunctional phenotypes in CD8+ T cells [95]. 
Therefore, we wanted to determine if these five prominent functional patterns were 
observed amongst T cells expressing each of the different DMF5 TCRs. Polyfunctional 
responses would be important in CD4+ T cells, however, since only T cells expressing 
the αD26Y TCR and αD26Y/βL98W TCR elicited significant reactivity against the 
MART-1 homologs in CD4+ T cells (based on Figure 19), we focused our attention on 
the CD8+ T cells. Therefore, we sought to determine how the DMF5 TCRs altered 
polyfunctional phenotypes against the MART-1 homologs in DMF5 TCR transduced 
CD8+ T cells. These five functional phenotypes were also apparent in polyfunctional 
responses against the MART-1 homologs amongst T cells expressing the different 
DMF5 TCRs in different donors and experiments. For proof of concept, representative 
cool plots from the three donors depicting polyfunctional responses against M. 
tuberculosis I protein, HSV-1 glycoprotein III, and ADP-ribose diphosphatase are shown 
in Figures 28-30. These three peptides were chosen as examples for proof of concept 
160 
 
because they were the top three most recognized MART-1 homologs (based on Figure 
20). 
Reproducible conclusions are evident when observing the polyfunctional 
responses against the M. tuberculosis protein I (Figure 28). Specifically, the TCR 
transduced CD8+ T cells are polyfunctional, and polyfunctional responses are DMF5 
TCR and donor dependent. However, the five prominent phenotypes previously 
described in CD8+ T cell responses against the MART-1 9mer, are evident here, with 
the different ligand. These results indicated a reproducible pattern of polyfunctional 
responses with different ligands. Furthermore, CD8+ T cells expressing the WT TCR 
exhibited 11, 11, and 12 functional phenotypes against the M. tuberculosis protein I, per 
each donor, respectively. CD8+ T cells expressing the αD26Y TCR exhibited more 
functional phenotypes compared to T cells expressing the WT TCR at 13, 19, and 18 
functional phenotypes per each donor, respectively. CD8+ T cells expressing the 
αD26Y/αY50A/βL98W TCR exhibited fewer functional phenotypes than T cells 
expressing the WT TCR at 3, 7, and 2 functional phenotypes per each donor, 
respectively. These results coincided with the results in Figure 20 depicting a 
statistically significant increase and decrease in the percentages of M. tuberculosis 
protein I reactive CD8+ T cells in T cells expressing the αD26Y TCR and 
αD26Y/αY50A/βL98W TCR, respectively, compared to T cells expressing the WT TCR. 
Specifically, these results indicated that a greater percentage of TCR transduced M. 
tuberculosis protein I reactive CD8+ T cells correlates to a greater number of functional 
phenotypes exhibited.  
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Figure 28. Impact of DMF5 Mutations in TCR Transduced CD8+ T cells on 
Polyfunctional Responses against M. tuberculosis protein I. “Cool plots” were 
generated to include any functional phenotype present over 0.1%. In the functional 
phenotypes listed, “+” indicates positive for the marker and “-“ indicates negative for the 
marker. As described in Chapter Two, reactivity is defined after background subtraction, 
specifically, any phenotype expressed by over 0.1% of TCR transduced T cells 
(subtraction of the background immunofluorescence observed with T2 cells loaded with 
an irrelevant, HCV, peptide). The color depicted in the “cool plot” correlates to the scale 
on the right. An “X” indicates no T cells were positive (<0.1% after background 
subtraction) for given functional phenotype. The color white for a given functional 
phenotype indicates a percentage less than 0.2% (a) or 0.5% (b and c). Five prominent 
phenotypes are highlighted with red boxes. (a) donor one (b) donor two (c) donor three.  
 
Overall, T cell polyfunctionality and the five predominant polyfunctional phenotypes 
were observed with CD8+ T cells expressing each of the different DMF5 TCRs against a 
different ligand. 
We next observed the polyfunctional patterns demonstrated in response to the 
HSV-1 glycoprotein III. Polyfunctional responses against the HSV-1 glycoprotein III 
indicated reproducible observations that have been previously described (Figure 29). 
Moreover, the TCR transduced CD8+T cells are polyfunctional, and polyfunctional 
responses are DMF5 TCR and donor dependent. Nonetheless, the five prominent 
phenotypes previously described in CD8+ T cell responses against the MART-1 9mer, 
are evident here, with the different ligand. Furthermore, CD8+ T cells expressing the WT 
TCR exhibited 7, 10, and 13 functional phenotypes against the HSV-1 glycoprotein III, 
per each donor, respectively. CD8+ T cells expressing the αD26Y TCR exhibited more 
functional phenotypes compared to T cells expressing the WT TCR at 10, 20, and 36 
functional phenotypes per each donor, respectively. 
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Figure 29. Impact of DMF5 Mutations in TCR Transduced CD8+ T cells on 
Polyfunctional Responses against HSV-1 glycoprotein III. “Cool plots” were 
generated to include any functional phenotype present over 0.1%. In the functional 
phenotypes listed, “+” indicates positive for the marker and “-“ indicates negative for the 
marker. As described in Chapter Two, reactivity is defined after background subtraction, 
specifically, any phenotype expressed by over 0.1% of TCR transduced T cells 
(subtraction of the background immunofluorescence observed with T2 cells loaded with 
an irrelevant, HCV, peptide). The color depicted in the “cool plot” correlates to the scale 
on the right. An “X” indicates no T cells were positive (<0.1% after background 
subtraction) for given functional phenotype. The color white for a given functional 
phenotype indicates a percentage less than (a) 0.2% or (b and c) 0.5%. Five prominent 
phenotypes are highlighted with red boxes. (a) donor one (b) donor two (c) donor three.  
 
CD8+ T cells expressing the αD26Y/αY50A/βL98W TCR exhibited fewer functional 
phenotypes than T cells expressing the WT TCR at 2, 4, and 6 functional phenotypes 
per each donor, respectively. These results coincided with the results in Figure 20 
depicting a statistically significant increase and decrease in the percentages of HSV-1 
glycoprotein III reactive CD8+ T cells in T cells expressing the αD26Y TCR and 
αD26Y/αY50A/βL98W TCR, respectively, compared to T cells expressing the WT TCR. 
Specifically, these results indicated that a greater percentage of TCR transduced HSV-
glycoprotein III reactive CD8+ T cells correlates to a greater number of functional 
phenotypes exhibited. Overall, T cell polyfunctionality and the five predominant 
polyfunctional phenotypes were observed with CD8+ T cells expressing each of the 
different TCRs against a different ligand.  
Lastly, we demonstrated that polyfunctional responses against the ADP-ribose 
diphosphatase are dependent upon the DMF5 TCR and the donor (Figure 30). 
However, the five prominent phenotypes previously described in CD8+ T cell responses 
are evident here, with the different MART-1 homolog. 
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Figure 30. Impact of DMF5 Mutations in TCR Transduced CD8+ T cells on 
Polyfunctional Responses against ADP-ribose diphosphatase. “Cool plots” were 
generated to include any functional phenotype present over 0.1%. In the functional 
phenotypes listed, “+” indicates positive for the marker and “-“ indicates negative for the 
marker. As described in Chapter Two, reactivity is defined after background subtraction, 
specifically, any phenotype expressed by over 0.1% of TCR transduced T cells 
(subtraction of the background immunofluorescence observed with T2 cells loaded with 
an irrelevant, HCV, peptide). The color depicted in the “cool plot” correlates to the scale 
on the right. An “X” indicates no T cells were positive (<0.1% after background 
subtraction) for given functional phenotype. The color white for a given functional 
phenotype indicates a percentage less than 0.2%. Five prominent phenotypes are 
highlighted with red boxes. (a) donor one (b) donor two (c) donor three. 
 
Furthermore, CD8+ T cells expressing the WT TCR exhibited 7, 14, and 11 functional 
phenotypes against the ADP-ribose diphosphatase, per each donor, respectively. CD8+ 
T cells expressing the αD26Y TCR exhibited an equal number or more functional 
phenotypes compared to T cells expressing the WT TCR at 7, 16, and 27 functional 
phenotypes per each donor, respectively. CD8+ T cells expressing the 
αD26Y/αY50A/βL98W TCR exhibited fewer functional phenotypes than T cells 
expressing the WT TCR at 4, 11, and 4 functional phenotypes per each donor, 
respectively. These results coincided with the results in Figure 20 depicting a trend 
towards an increase and decrease in the percentages of ADP-ribose diphosphatase 
reactive CD8+ T cells in T cells expressing the αD26Y TCR and αD26Y/αY50A/βL98W 
TCR, respectively, compared to T cells expressing the WT TCR. As observed with the 
MART-1 9mer, M. tuberculosis protein I, and HSV-1 glycoprotein III, these results 
indicated that a greater percentage of TCR transduced ADP-ribose diphosphatase 
reactive CD8+ T cells correlates to a greater number of functional phenotypes exhibited. 
Overall, T cell polyfunctionality and the five predominant polyfunctional phenotypes 
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were observed with CD8+ T cells expressing each of the different TCRs against a 
different ligand.  
In light of all the polyfunctional results against different ligands from CD8+ T cells 
expressing each of the DMF5 TCRs in different experiments and donors, there are 
reproducible and overarching conclusions that can be made. First, it is evident that 
polyfunctional responses are DMF5 TCR, experiment, donor, and ligand dependent. 
However, amongst the variability, five reproducible functional phenotypes are frequently 
exhibited by T cells expressing each of DMF5 TCRs against different ligands, in 
different donors and experiments. Secondly, the number of polyfunctional phenotypes 
exhibited against a given ligand, generally correlated to the patterns observed in the 
percentages of ligand reactive T cells. This indicated the more antigen reactive T cells 
there are, the more polyfunctional phenotypes they will exhibit. Overall, these data 
suggested that patterns in polyfunctionality are evident, but specific functional 
phenotypes are ultimately dependent upon the TCR, ligand, experiment, and donor. 
Impact of Mutant DMF5 TCRs on Cross-Reactivity within Major Polyfunctional 
Phenotypes 
Thus far, we have described patterns of polyfunctionality in CD8+ T cells against 
four targets in the form of cool plots. Analysis via cool plots is advantageous to visually 
examine all the polyfunctional phenotypes exhibited and to visually examine how 
mutations in the DMF5 TCR altered polyfunctional phenotypes against a specific ligand. 
However, cool plots did not feasibly allow us to quantitatively determine how mutations 
in the DMF5 TCR altered cross-reactivity patterns against all the MART-1 homologs 
within specific functional phenotypes. Nonetheless, this analysis is of importance, since 
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our previous conclusions on cross-reactivity were centered on antigen reactivity based 
upon expression of any one or more functional marker. Through the analysis of cool 
plots, we have identified five functional phenotypes that were predominantly expressed 
among CD8+ T cells expressing each of the DMF5 TCRs, against different ligands, and 
in different experiments and donors. The five phenotypes identified were: 1.) CD107A+, 
IFN-γ+, TNF-α+, 2.) IFN-γ+, TNF-α+, 3.) CD107A+, IFN-γ+, 4.) IFN-γ+ only, and 5.) 
CD107A+ only. Seven potential combinations of functional phenotypes were possible 
with these three functional markers. CD107A+, TNF-α+ and TNF-α+ only are the two 
phenotypes missing from these combinations. However, these two phenotypes were not 
reproducibly exhibited in our analysis. This indicated that generally, if TNF-α was 
produced, IFN-γ was also produced. Based upon these reproducible findings, we next 
determined if the cross-reactive patterns observed against the MART-1 homologs in 
Figure 20 were reproducible when focusing on each of these five predominant 
functional phenotypes. We first examined TCR transduced CD8+ T cells expressing 
CD107A, IFN-γ, and TNF-α (Figure 31). The average of six experiments found 9.2% of 
T cells expressing the WT TCR exhibited the CD107A+, IFN-γ+, TNF-α+ polyfunctional 
phenotype in response to targets loaded with the MART-1 9mer. Furthermore, T cells 
expressing the WT TCR recognized four of the MART-1 homologs, ranging between 1% 
and 2.6% reactive T cells. We observed similar patterns in reactivity against MART-1 
and the MART-1 homologs with T cells expressing the mutant DMF5 TCRs that were 
previously observed when examining reactivity based on any one or more functional 
marker. 
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Figure 31. Impact of DMF5 Mutations on Cross-Reactivity in TCR Transduced 
CD8+ T cells Expressing the CD107A+, IFN-γ+, TNF-α+ Phenotype. Percent reactive 
CD8+ T cells expressing the CD107A+, IFN-γ+, TNF-α+ functional phenotype were 
determined using data generated from the six cool plots. Self-peptides are indicated by 
a black triangle. Data represent the average of 6 experiments (three donors, two 
independent repeats) and error bars represent the standard error of the mean. As 
described in Chapter Two, reactivity is defined after background subtraction, 
specifically, any phenotype expressed by over 0.1% of TCR transduced T cells 
(subtraction of the background immunofluorescence observed with T2 cells loaded with 
an irrelevant, HCV, peptide) . **** P <0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 when 
the percentage of antigen reactive T cells against each peptide with a given TCR was 
compared to the percentage of antigen reactive T cells to the respective peptide with 
the WT TCR by two-way ANOVA using Sidak’s multiple comparisons tests. 
 
Specifically, the percentage of MART-1 9mer reactive T cells was comparable between 
T cells expressing the αD26Y TCR and T cells expressing the WT TCR (9.6% vs. 
9.2%). Furthermore, the percentages of αD26Y TCR expressing MART-1 homolog 
reactive T cells was increased compared to T cells expressing the WT TCR. Statistical 
significance was reached in HSV-1 glycoprotein III (10%), M. tuberculosis protein I 
(8.3%), human CD9 (3.4%) and GPCR 3 (4.5%). In T cells expressing the βL98W TCR, 
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the percentage of MART-1 9mer (9.1% vs. 9.2%) and MART-1 homolog (0.1% - 2.6% 
vs. 1% - 2.6%) reactive T cells was comparable to T cells expressing the WT TCR. 
However, there was one apparent exception, although not significant, the percentage of 
antigen reactive βL98W TCR expressing T cells was increased against human CD9, 
compared to T cells expressing the WT TCR (1.4% vs. 0%). This coincided with our 
previous conclusions made in Figure 20. T cells expressing the αD26Y/βL98W TCR 
demonstrated a statistically significant reduction in the percentage of MART-1 9mer 
reactive T cells compared to T cells expressing the WT TCR (2% vs. 9.2%), consistent 
with previous findings. There were no statistically significant changes in the percentage 
of MART-1 homolog reactive T cells, consistent with previous findings. Although not 
statistically significant compared to T cells expressing the WT TCR, T cells expressing 
the αD26Y/αY50A/βL98W TCR exhibited a trend towards a reduction in the percentage 
of MART-1 9mer reactive T cells (9.2% vs. 6.5%). and MART-1 homolog reactive T cells 
(1% to 2.6% vs. 0.28% to 1.1%). Lastly, there were no statistically significant differences 
between the WT TCR and the αD26Y/αY50V/βL98W TCR in terms of the percentages 
of MART-1 9mer (9.2% vs. 7.7%) and MART-1 homolog reactive (1% to 2.6% vs. 0.1% 
to 2.5%) TCR transduced CD8+ T cells, consistent with previous findings in Figure 20. 
Overall, when examining the percentages of MART-1 and MART-1 homolog reactive T 
cells exhibiting the CD107A+, IFN-γ+, TNF-α+ polyfunctional phenotype, we generated 
conclusions that were similar to the conclusions we generated from Figure 20. Mainly, 
the percentages of MART-1 homolog reactive TCR transduced CD8+ T cells were 
generally enhanced with the αD26Y TCR and reduced with the αD26Y/αY50A/βL98W 
TCR, compared to the WT DMF5 TCR. Furthermore, T cells expressing the 
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αD26Y/αY50A/βL98W TCR exhibited a trend towards a reduction in the percentage of 
MART-1 9mer and MART-1 homolog reactive T cells compared to T cells expressing 
the WT TCR. These results indicated that patterns in MART-1 9mer and MART-1 
homolog reactivity were comparable when observing the overall percentages of antigen 
reactive TCR transduced CD8+ T cells (Figure 20), or the percentages of antigen 
reactive TCR transduced CD8+ T cells expressing a specific polyfunctional phenotype 
(Figure 31). We next determined if the patterns observed in MART-1 9mer and MART-1 
homolog reactivity were reproducible in the other four functional phenotypes: IFN-γ+, 
TNF-α+ (Figure 32), CD107A+, IFN-γ+ (Figure 33), IFN-γ+ only (Figure 34), and 
CD107A+ only (Figure 35).  
Our observations from these data indicated that patterns in antigen recognition 
among different DMF5 TCR transduced CD8+ T cell populations are frequently 
reproducible when examining antigen reactivity in terms of the total percentage of 
antigen reactive T cells (Figure 20), or when examining antigen reactivity in terms of 
expressing individual functional phenotypes (Figures 31-35). Moreover, CD8+ T cells 
expressing the WT TCR are cross-reactive, as they recognized between four and nine 
MART-1 homologs within each functional phenotype (Figures 31-35). Overall, CD8+ T 
cells expressing each of the mutant DMF5 TCRs generally exhibited similar patterns in 
the percentages of MART-1 9mer and MART-1 homolog reactive T cells among the five 
specific functional phenotypes, compared to T cells expressing the WT TCR.  
  
172 
 
 
Figure 32. Impact of DMF5 Mutations on Cross-Reactivity in TCR Transduced 
CD8+ T cells Expressing the IFN-γ+, TNF-α+ Phenotype. Percent reactive CD8+ T 
cells expressing the IFN-γ+, TNF-α+ functional phenotype were determined using data 
generated from the six cool plots. Self-peptides are indicated by a black triangle. Data 
represent the average of 6 experiments (three donors, two independent repeats) and 
error bars represent the standard error of the mean. As described in Chapter Two, 
reactivity is defined after background subtraction, specifically, any phenotype expressed 
by over 0.1% of TCR transduced T cells (subtraction of the background 
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide). 
**** P <0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 when the percentage of antigen 
reactive T cells against each peptide with a given TCR was compared to the percentage 
of antigen reactive T cells to the respective peptide with the WT TCR by two-way 
ANOVA using Sidak’s multiple comparisons tests. 
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Figure 33. Impact of DMF5 Mutations on Cross-Reactivity in TCR Transduced 
CD8+ T cells Expressing the CD107A+, IFN-γ+ Phenotype. Percent reactive CD8+ T 
cells expressing the CD107A+, IFN-γ+ functional phenotype were determined using data 
generated from the six cool plots. Self-peptides are indicated by a black triangle. Data 
represent the average of 6 experiments (three donors, two independent repeats) and 
error bars represent the standard error of the mean. As described in Chapter Two, 
reactivity is defined after background subtraction, specifically, any phenotype expressed 
by over 0.1% of TCR transduced T cells (subtraction of the background 
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide). 
**** P <0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 when the percentage of antigen 
reactive T cells against each peptide with a given TCR was compared to the percentage 
of antigen reactive T cells to the respective peptide with the WT TCR by two-way 
ANOVA using Sidak’s multiple comparisons tests. 
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Figure 34. Impact of DMF5 Mutations on Cross-Reactivity in TCR Transduced 
CD8+ T cells Expressing the IFN-γ+ only Phenotype. Percent reactive CD8+ T cells 
expressing the IFN-γ+ only functional phenotype were determined using data generated 
from the six cool plots. Self-peptides are indicated by a black triangle. Data represent 
the average of 6 experiments (three donors, two independent repeats) and error bars 
represent the standard error of the mean. As described in Chapter Two, reactivity is 
defined after background subtraction, specifically, any phenotype expressed by over 
0.1% of TCR transduced T cells (subtraction of the background immunofluorescence 
observed with T2 cells loaded with an irrelevant, HCV, peptide). **** P <0.0001; ***P < 
0.001; **P < 0.01; *P < 0.05 when the percentage of antigen reactive T cells against 
each peptide with a given TCR was compared to the percentage of antigen reactive T 
cells to the respective peptide with the WT TCR by two-way ANOVA using Sidak’s 
multiple comparisons tests. 
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Figure 35. Impact of DMF5 Mutations on Cross-Reactivity in TCR Transduced 
CD8+ T cells Expressing the CD107A+ only Phenotype. Percent reactive CD8+ T 
cells expressing the CD107A+ only functional phenotype were determined using data 
generated from the six cool plots. Self-peptides are indicated by a black triangle. Data 
represent the average of 6 experiments (three donors, two independent repeats) and 
error bars represent the standard error of the mean. As described in Chapter Two, 
reactivity is defined after background subtraction, specifically, any phenotype expressed 
by over 0.1% of TCR transduced T cells (subtraction of the background 
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide). 
**** P <0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 when the percentage of antigen 
reactive T cells against each peptide with a given TCR was compared to the percentage 
of antigen reactive T cells to the respective peptide with the WT TCR by two-way 
ANOVA using Sidak’s multiple comparisons tests. 
 
Specifically, T cells expressing the αD26Y TCR exhibited more MART-1 homolog 
reactive T cells compared to T cells expressing the WT TCR, with statistical significance 
reached with some MART-1 homologs in four of the five functional phenotypes (Figures 
31 and 33-35). It was notable that T cells expressing the αD26Y TCR exhibited 
significantly more MART-1 9mer reactive T cells in the CD107A+ only (Figure 35) and 
CD107A+, IFN-γ+ (Figure 33) phenotype. This was not observed in Figure 20 when 
examining the total percentage of MART-1 9mer reactive CD8+ T cells. This indicated 
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that these patterns of MART-1 9mer reactivity are not 100% reproducible within 
individual phenotypes. Overall, these results indicated that the tyrosine mutation at 
position 26 in the TCR alpha chain did not enhance MART-1 9mer antigen specificity in 
TCR transduced CD8+ T cells expressing specific functional phenotypes. However, 
compared to the WT TCR, a statistically significant increase in the percentages of 
MART-1 9mer reactive CD8+ T cells was observed in αD26Y TCR transduced CD8+ T 
cells expressing the CD107A+ only and CD107A+, IFN-γ+ phenotypes. 
We next examined reproducible patterns in MART-1 9mer and MART-1 homolog 
reactivity with CD8+ T cells expressing the βL98W TCR. Specifically, the percentages of 
MART-1 9mer reactive T cells were comparable between βL98W TCR and WT TCR 
expressing CD8+ T cells amongst the five functional phenotypes (Figures 31-35). 
Additionally, the percentages of MART-1 homolog reactive T cells were comparable 
between βL98W TCR and WT TCR expressing CD8+ T cells amongst the five functional 
phenotypes (Figures 31-35). Although not significant, one notable difference was a 
trend towards an increase in human CD9 reactive T cells expressing the βL98W TCR 
compared to T cells expressing the WT TCR amongst the five functional phenotypes 
(Figures 31-35). This was also previously demonstrated in Figure 20. Overall, these 
results indicated that the tryptophan mutation at position 98 in the TCR beta chain did 
not enhance MART-1 9mer antigen specificity in TCR transduced CD8+ T cells 
expressing specific functional phenotypes. 
We next elucidated reproducible patterns in MART-1 9mer and MART-1 homolog 
reactivity with T cells expressing the αD26Y/βL98W TCR. Specifically, the percentages 
of MART-1 9mer reactive T cells were statistically significantly reduced in T cells 
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expressing the αD26Y/βL98W TCR compared to T cells expressing the WT TCR in four 
of the five functional phenotypes (Figures 31-34). Furthermore, the percentages of 
MART-1 homolog reactive T cells were comparable, with no statistically significant 
differences (Figures 31-35). Overall, the combination of the αD26Y and βL98W TCR 
mutations did not enhance MART-1 9mer antigen specificity and attenuated MART-1 
reactivity in TCR transduced CD8+ T cells expressing specific functional phenotypes. 
We next examined comparable patterns in MART-1 9mer and MART-1 homolog 
reactivity with T cells expressing the αD26Y/αY50A/βL98W TCR. Specifically, T cells 
expressing the αD26Y/αY50A/βL98W TCR significantly reduced the percentages of 
MART-1 reactive CD8+ T cells in two of the five functional phenotypes, compared to the 
WT TCR (Figures 33-34). Furthermore, T cells expressing the αD26Y/αY50A/βL98W 
TCR exhibited a trend towards a reduction in the percentages of MART-1 homolog 
reactive T cells compared to T cells expressing the WT TCR (Figures 31-32, and 35), 
reaching statistical significance with some of the MART-1 homologs in two of the five 
functional phenotypes (Figures 33-34). In summary, the addition of the alanine TCR 
mutation at position 50 in the TCR alpha chain to the αD26Y/βL98W TCR resulted in an 
overall trend in reduced MART-1 9mer and MART-1 homolog reactivity in TCR 
transduced CD8+ T cells expressing specific functional phenotypes. 
 Lastly, there were no significant differences in the percentages of MART-1 9mer 
and MART-1 homolog reactive αD26Y/αY50V/βL98W TCR or WT TCR expressing T 
cells amongst the five functional phenotypes (Figures 31-35). Overall, the valine TCR 
mutation at position 50 in the TCR alpha did not have as much as an impact on MART-1 
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9mer and MART-1 homolog reactivity as the alanine TCR mutation in TCR transduced 
CD8+ T cells expressing specific functional phenotypes. 
Based on all the data observing antigen specificity and cross-reactivity in DMF5 
TCR transduced CD8+ T cells expressing specific functional phenotypes, a few 
comprehensive conclusions were generated. First, trends in MART-1 9mer and MART-1 
homolog recognition amongst T cells expressing each of the DMF5 TCRs were 
commonly reproducible whether examining the total percentages of antigen reactive 
CD8+ T cells (Figure 20), or the percentages of antigen reactive CD8+ T cells 
expressing a specific functional phenotype (Figures 31-35). However, these trends were 
not 100% reproducible with each DMF5 TCR in each individual phenotype. This 
suggested that observing antigen reactivity in regards to exhibiting any functional 
phenotype (Figure 20) gives a baseline for the total percentage of antigen reactive T 
cells. Subsequently, it is plausible to observe minor variation around that baseline within 
individual functional phenotypes (Figures 31-35). In summary, these results indicated 
the patterns of MART-1 and MART-1 homolog reactivity elicited with T cells expressing 
each of the different DMF5 TCRs are generally or broadly reproducible when comparing 
the total percentage of antigen reactive T cells or the percentage of antigen reactive T 
cells within an individual phenotype. 
It was of interest to determine if the patterns of the CD107A+ only phenotype 
(Figure 35) in response to the MART-1 9mer correlated to patterns in lysis of MEL 624 
in Figure 17. Our results indicated that the percentages of CD107A+ only CD8+ T cells in 
response to the MART-1 9mer generally correlated with cytotoxicity. For example, 
compared to T cells expressing the WT TCR, αD26Y TCR expressing T cells exhibited 
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a statistically significant increase in MEL 624 killing (Figure 17) and exhibited a 
statistically significant increase in the percentage of CD107A+ only CD8+ T cells in 
response to the MART-1 9mer (Figure 35). Furthermore, compared to T cells 
expressing WT TCR, T cells expressing the βL98W TCR, αD26Y/αY50A/βL98W TCR, 
or αD26Y/αY50V/βL98W TCR exhibited comparable, or a trend towards an increase in 
MEL 624 killing (Figure 17) and exhibited similar percentages of CD107A+ only CD8+ T 
cells in response to the MART-1 9mer (Figure 35). However, there was one exception to 
this correlation. αD26Y/βL98W TCR expressing T cells exhibited a statistically 
significant increase in MEL 624 killing (Figure 17), but exhibited a trend towards a 
decrease in the percentages of CD107A+ only CD8+ T cells compared to CD8+ T cells 
expressing the WT TCR (Figure 35). One caveat is that the percentage of CD107A+ 
only CD8+ T cells was much lower than the percentages of functional phenotypes 
exhibiting both CD107A and cytokines. This indicated CD107A+ T cells, or T cells that 
have potentially killed, generally also expressed cytokines. Therefore, we examined the 
total percentages of CD107A+ T cells against the MART-1 9mer to determine if there 
was a correlation with MEL 624 lysis (Figure 36). In CD8+ T cells, T cells expressing the 
αD26Y/βL98W TCR exhibited a statistically significantly lower percentage of MART-1 
9mer reactive CD107A+ T cells compared to T cells expressing the WT TCR (Figure 
36A). This did not correlate with lysis of MEL 624 in Figure 17. Although not statistically 
significant compared to CD8+ T cells expressing the WT TCR, T cells expressing the 
αD26Y exhibited a trend towards an increase in the percentage of CD107A+ MART-1 
9mer reactive T cells (Figure 36A), corresponding to the statistically significant increase 
in MEL 624 lysis (Figure 17).  
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Figure 36. Percentage of Total CD107A+ CD8+ and CD4+ MART-1 9mer Reactive T 
cells. The percentages of MART-1 9mer reactive (a) CD8+ and (b) CD4+ T cells 
expressing CD107A is displayed. Data represent the average of 6 experiments (three 
donors, two independent repeats) and error bars represent the standard error of the 
mean. As described in Chapter Two, reactivity is defined after background subtraction, 
specifically, any CD107A+ T cells expressed by over 0.1% of TCR transduced T cells 
(subtraction of the background immunofluorescence observed with T2 cells loaded with 
an irrelevant, HCV, peptide). **P < 0.01; *P < 0.05 when the percentage of antigen 
reactive T cells given with a given modified DMF5 TCR was compared to the 
percentage of antigen reactive T cells expressing the WT TCR by one-way ANOVA.  
181 
 
Although not statistically significant compared to CD8+ T cells expressing the WT TCR, 
T cells expressing the αD26Y/αY50A/βL98W TCR exhibited a trend towards a decrease 
in the percentage of CD107A+ MART-1 9mer reactive T cells (Figure 36A) despite 
exhibiting comparable levels of MEL 624 lysis (Figure 17). Lastly, although not 
statistically significant compared to CD8+ T cells expressing the WT TCR, T cells 
expressing the αD26Y/αY50V/βL98W TCR or βL98W TCR exhibited comparable 
percentages of CD107A+ MART-1 9mer reactive T cells (Figure 36A) despite exhibiting 
a trend towards an increase in MEL 624 killing (Figure 17). Overall, the percentages of 
CD107A+ MART-1 9mer reactive CD8+ T cells roughly followed to the patterns observed 
in MEL 624 lysis. The one drastic exception was observed with T cells expressing the 
αD26Y/βL98W TCR. 
TCR transduced T cells expressing either the WT DMF5 TCR or each of the 
mutant DMF5 TCRs used in the MEL 624 lysis assay were comprised of both CD4+ and 
CD8+ T cells. Therefore, we determined if the percentages of MART-1 9mer reactive 
CD4+ T cells expressing CD107A correlated to MEL 624 lysis (Figure 36B). Although 
not significant compared to CD4+ T cell expressing the WT TCR, CD4+ T cells 
expressing the αD26Y TCR or βL98W TCR exhibited a trend towards an increase in the 
percentages of CD107A+ MART-9mer reactive T cells (Figure 36B), coinciding with their 
significant or trend towards an increase in MEL 624 lysis (Figure 17), respectively. 
Compared to CD4+ T cell expressing the WT TCR, CD4+ T cells expressing the 
αD26Y/βL98W TCR exhibited a comparable percentage of CD107A+ MART-9mer 
reactive T cells (Figure 36B), despite their significant increase in MEL 624 lysis (Figure 
17). Lastly, CD4+ T cells expressing the αD26Y/αY50A/βL98W TCR or 
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αD26Y/αY50V/βL98W TCR exhibited comparable or a trend towards an increase in the 
percentages of CD107A+ MART-9mer reactive T cells (Figure 36B), coinciding with their 
comparable or a trend towards an increase in MEL 624 lysis (Figure 17), respectively. In 
summary, the percentages of CD107A+ MART-1 9mer reactive CD4+ T cells 
corresponded to patterns in MEL 624 lysis. One exception was observed in CD4+ T 
cells expressing the αD26Y/βL98W TCR.  
A few conclusions can be made based on the correlations between CD107A+ 
9mer reactive CD4+ and CD8+ T cells and MEL 624 lysis. First, the lysis assays were 
done using CD4+ and CD8+ pooled T cells. As previously stated, the proportion of CD4+ 
T cells ranged between 27% and 35% and the proportion of CD8+ T cells ranged 
between 65% and 73% amongst the TCR transduced T cells populations. Therefore, we 
can draw overarching conclusions from the data (as we did previously), but we cannot 
directly compare lysis without performing the lysis assay with only CD4+ T cells or only 
CD8+ T cells. However, if we observe overall trends in the patterns, it is evident that the 
percentages of CD107A+ T cells generally correlated to the patterns observed in MEL 
624 lysis. The one exception was observed with T cells expressing the αD26Y/βL98W 
TCR. There a few possible explanations for this result. Notably, the αD26Y/βL98W TCR 
harbors the supraphysiological 3D TCR affinity. It is possible that with this level of 
affinity, CD107A expression is not reflective of lysis. Additionally, at this level of affinity, 
it is possible that CD107A expression is antigen density dependent. In summary, 
patterns observed in CD107A expression in response to the MART-1 9mer were 
generally correlative with patterns observed in MEL 624 lysis, except with T cells 
expressing a TCR harboring a supraphysiological 3D TCR affinity. Based on all the data 
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observing antigen specificity and cross-reactivity in DMF5 TCR transduced CD8+ T cells 
expressing specific functional phenotypes, a few comprehensive conclusions were 
generated. First, trends in MART-1 9mer and MART-1 homolog recognition amongst T 
cells expressing each of the DMF5 TCRs were commonly reproducible whether 
examining the total percentages of antigen reactive CD8+ T cells (Figure 20), or the 
percentages of antigen reactive CD8+ T cells expressing a specific functional phenotype 
(Figures 31-35). However, these trends were not 100% reproducible with each DMF5 
TCR in each individual phenotype. This suggested that observing antigen reactivity in 
regards to exhibiting any functional phenotype (Figure 20) gives a baseline for the total 
percentage of antigen reactive T cells. Subsequently, it is plausible to observe minor 
variation around that baseline within individual functional phenotypes (Figures 31-35). In 
summary, these results indicated the patterns of MART-1 and MART-1 homolog 
reactivity elicited with T cells expressing each of the different DMF5 TCRs are generally 
or broadly reproducible when comparing the total percentage of antigen reactive T cells 
or the percentage of antigen reactive T cells within an individual phenotype. 
Impact of Single MHC Targeted Mutations on Cross-Reactivity in DMF5 TCR 
 Our findings indicated that in combination with the αD26Y and βL98W TCR 
mutations that target the MART-1 peptide, the addition of the αY50V mutation could 
reduce the cross-reactivity to levels similar to the WT TCR. Furthermore, the addition of 
the αY50A mutation reduced cross-reactivity lower than that of the WT TCR. We 
therefore determined if these mutations that weaken TCR binding to the MHC could 
reduce cross-reactivity while maintaining reactivity against MART-1 expressing targets.  
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Figure 37. Impact of Single, MHC Weakening, TCR Alpha Chain Mutations in the 
DMF5 TCR. Human T cells expressing either WT or mutated DMF5 TCRs were 
stimulated with T2 cells loaded with the control HCV NS3 peptide (KLVALGINAV), 
MART-1 9mer peptide (AAGIGILTV), or MART-1 homologs. Cells were incubated with 
CD3/CD28 Dynabeads in a 1:1 bead to cell ratio for positive control. IFN-γ release was 
measured by ELISA in triplicate wells. Error bars represent the standard error of the 
mean from three independent repeats of one representative donor. Antigen reactivity is 
defined as a T cell culture that secretes twice background, or twice the amount of IFN-γ 
produced against T2 cells loaded with the HCV peptide, and greater than 200 pg/mL.  
 
Mutant DMF5 TCRs were constructed with only the αY50A TCR mutation or the αY50V 
TCR mutation. Human T cells were transduced to express either the WT, αY50A, or 
αY50V DMF5 TCRs. T cells expressing the single mutant DMF5 TCRs eliminated all 
recognition of MART-1 and MART-1 homologs (Figure 37). Furthermore, activation with 
CD3/CD28 beads indicated that these T cells were capable of secreting IFN-γ. These 
results indicated that in the DMF5 TCR, αY50 binding to HLA-A2 is essential for antigen 
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recognition. However, when αY50 TCR mutations are counterbalanced with TCR 
mutations that enhance binding to the MART-1 peptide, the reduced αY50 TCR and 
HLA-A2 binding is permissible. Overall, these results exemplify the importance of this 
TCR/pMHC contact site for antigen recognition.  
Impact of Single MHC Targeted Mutations on Cross-Reactivity in HCV 1406 TCR 
 In our structure-guided design strategy, positive TCR mutations that target the 
peptide would be TCR and ligand specific. However, it is plausible that the negative 
mutations that weaken binding with the MHC could be translatable to other TCRs if they 
were introduced at evolutionarily conversed residues or binding sites. The αY50 residue 
makes contact with an evolutionarily conserved region of HLA-A2 [37]. Therefore, we 
determined how the single MHC weakening mutations affected antigen recognition in 
another TCR. Herein, we utilized our previously described HLA-A2 restricted hepatitis C 
(HCV) NS3:1406-1415-reactive TCR because this TCR recognized a number of NS3 
mutant epitopes [437, 438]. Mutations were made in the alpha chain to that same 
tyrosine that contacts the same conserved region of HLA-A2, αY59A or αY59V. A panel 
of naturally occurring mutant epitopes of the HCV NS3 protein were used to measure 
cross-reactivity [438]. Human T cells were transduced to express either the WT, αY59A, 
or αY59V HCV 1406 TCRs. We first determined how T cells expressing the WT HCV 
1406 TCR recognized the mutant NS3 epitopes. T cells expressing the WT HCV TCR 
are cross-reactive against all of the mutant epitopes except 8S/9G/12L (Figure 38). 
After determining which mutant NS3 epitopes were recognized by T cells expressing the 
WT HCV 1406 TCR, we determined how the mutant HCV 1406 TCRs affected 
recognition of the WT and mutant NS3 epitopes. 
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Figure 38. Impact of Single, MHC Weakening, TCR Alpha Chain Mutations in the 
HCV 1406 TCR. Human T cells expressing either WT or mutated HCV 1406 TCRs were 
stimulated with T2 cells loaded with the control MART-1 9mer peptide (AAGIGILTV), 
HCV NS3 peptide (KLVALGINAV), or mutant NS3 peptides. Cells were incubated with 
CD3/CD28 Dynabeads in a 1:1 bead to cell ratio for positive control. IFN-γ release was 
measured by ELISA in triplicate wells. Error bars represent the standard error of the 
mean from three independent repeats of one representative donor. Black triangles 
indicate CD8 dependent epitopes. Antigen reactivity is defined as a T cell culture that 
secretes twice background, or twice the amount of IFN-γ produced against T2 cells 
loaded with the MART-1 peptide, and greater than 200 pg/mL. 
 
The αY59A TCR mutation in the HCV 1406 TCR eliminated detectable all detectable 
recognition of the WT NS3 HCV peptide and all HCV NS3 peptide mutants. Activation 
with CD3/CD28 beads indicated that these T cells were capable of secreting IFN-γ. 
Dissimilar to the single mutations in the DMF5 TCR, the αY59V TCR mutation in the 
HCV 1406 TCR reduced reactivity against the WT NS3 peptide compared to the T cells 
expressing the WT HCV 1406 TCR. The αY59V TCR mutation in the HCV 1406 TCR 
reduced cross-reactivity against three mutant epitopes (V1408L, I1412L, I1412V) even 
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eliminating detectable cross-reactivity against four (A1409T, I1412N, V1408T, 
8S/9G/12L/14S), compared to T cells expressing the WT HCV 1406 TCR. More 
specifically, recognition of epitopes previously determined to be CD8 dependent 
(A1409T, I1412N, and 8S/9G/12L/14S) were no longer recognized [438, 439]. While the 
3D affinity of the DMF5 TCR is around 37 μM, the HCV 1406 TCR has a higher 3D 
affinity, around 16.8 μM [439]. It is possible that this increase in TCR affinity contributes 
to the ability of the αY59V HCV TCR to recognize the WT NS3 peptide and some of the 
mutant NS3 epitopes. In summary, these results indicated this conserved MHC contact 
residue in the TCR could be a potential site for mutation in order to reduce potential 
cross-reactivity of high affinity TCRs. 
Impact of Mutant DMF5 TCRs on Recognition of Processed Antigens 
Thus far, we have observed how T cells expressing each of the mutant DMF5 
TCRs alter antigen recognition and cross-reactivity by recognition of T2 cells loaded 
with a peptide panel comprised of MART-1 homologs. However, many peptide reactive 
T cells do not recognize the processed antigen. Therefore, we sought to determine if the 
four human MART-1 homologs (human CD9, human elongation factor 1α, G-protein 
coupled receptor 3, and human receptor expression enhancing protein 5) were 
processed and presented by HLA-A2, and recognized by TCR transduced T cells 
expressing the WT or modified DMF5 TCRs. To answer this, we planned to transfect 
COS-A2 cells with cDNAs encoding the full length MART-1, human CD9, human 
elongation factor 1α, G-protein coupled receptor 3, and human receptor expression 
enhancing protein 5. However, preliminary experiments comparing COS cells, COS-A2 
cells, and COS-A2 cells loaded with the MART-1 9mer revealed an unexpected result.   
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Figure 39. Impact of DMF5 TCRs on COS-A2 Cell Recognition. Human T cells 
expressing either WT or a mutant DMF5 TCR were stimulated with COS cells, COS-A2 
cells, or COS-A2 cells loaded with the MART-1 9mer peptide (AAGIGILTV) for 18 hours. 
Antigen reactivity is as defined as a T cell culture that secretes twice background (COS 
cells) and greater than 200 pg/mL IFN-γ. IFN-γ release was measured by ELISA in 
triplicate wells. One representative experiment from is shown.  
 
First, T cells expressing the WT DMF5 TCR did not recognize COS cells or COS-A2 
cells, but did recognize MART-1 loaded COS-A2 cells (Figure 39). Surprisingly, T cells 
expressing the αD26Y, αD26Y/βL98W, and αD26Y/αY50V/βL98W TCRs recognized 
COS-A2 cells and MART-1 loaded COS-A2 cells, but not COS cells. The recognition of 
COS-A2 cells by T cells expressing the modified DMF5 TCRs suggested HLA-A2 
restricted recognition of other antigens. This observation led us to determine if COS-A2 
MART-1- recognition was unique, or if COS-A2 MART-1- recognition was due to broad 
cross-reactivity. Therefore, we composed a panel of tumors derived from a variety of 
tissues to examine potential cross-reactivity with naturally processed self-antigens 
(Table 2, Chapter Two - Methods). 
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Human T cells transduced to express the WT DMF5 TCR or each modified DMF5 TCR 
were used as effector T cells and stimulated with the tumor panel in cytokine release 
assays. Of note, included in this panel was A375, an HLA-A2+ MART-1- melanoma cell 
line. One representative donor and experiment is shown in Figure 40. First, two patterns 
of cross-reactivity were observed. The first pattern was mutant DMF5 TCRs that were 
highly cross-reactive compared to the WT TCR (generally, three times as reactive as 
the WT TCR) (Figure 40A). The second pattern was mutant DMF5 TCRs that were 
modestly cross-reactive compared to the WT TCR (generally, less than two times as 
reactive as the WT TCR) (Figure 40B). T cells expressing WT TCR were cross-reactive 
against the HLA-A2+ off-target tumors (Figure 40A). Somewhat surprisingly, T cells 
expressing either the αD26Y TCR or αD26Y/βL98W TCR were reactive against all the 
HLA-A2+ off-target tumors, more than T cells expressing the WT TCR (Figure 40A). 
Furthermore, T cells expressing the αD26Y/αY50V/βL98W TCR were reactive against 
all the HLA-A2+ off-target tumors, although not as reactive as T cells expressing the 
αD26Y or αD26Y/βL98W TCRs, but more reactive than T cells expressing the WT TCR 
(except with A375) (Figure 40A). Lastly, T cells expressing the βL98W TCR or 
αD26Y/αY50A/βL98W TCR exhibited enhanced cross-reactivity against some, but not 
all of the HLA-A2+ off-target tumors, compared to T cells expressing the WT TCR 
(Figure 40B). It was interesting to note that off-target tumor recognition was tumor 
specific within each mutant DMF5 TCR. Variability in recognition and potential off-target 
tumor antigens being recognized will be discussed in further detail in a subsequent 
section. 
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Figure 40. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue 
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were 
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release 
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all 
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed. 
(a) Highly cross-reactive TCRs compared to the WT TCR (generally, three times as 
reactive as the WT TCR). (b) Modestly cross-reactive TCRs compared to the WT TCR 
(generally, less than two times as reactive as the WT TCR). One representative 
experiment and donor is shown. Reactivity is defined as a T cell culture that secretes 
twice background, or twice the amount of IFN-γ produced as against MEL 624-28, and 
greater than 200 pg/mL. 
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Additionally, it was surprising when T cells expressing the βL98W TCR or 
αD26Y/αY50A/βL98W TCR were cross-reactive, T cells expressing the 
αD26Y/αY50A/βL98W TCR generally exhibited higher magnitudes of reactivity. These 
results would not have been predicted based upon 3D affinity or our conclusions from 
MART-1 homolog peptide loaded targets, where T cells expressing the 
αD26Y/αY50A/βL98W TCR reduced cross-reactivity. In summary, T cells expressing 
each of the mutant DMF5 TCRs were generally more cross-reactive against the off-
target, HLA-A2+ tumors than T cells expressing the WT TCR. Furthermore, the DMF5 
WT TCR is cross-reactive. 
Our previous results have indicated that donor variability occurs in polyclonal 
PBL-derived T cells. Therefore, it was of importance to analyze this off-target cross-
reactivity in multiple donors. All individual experiments and donors are shown in Figures 
52-58, in the appendix. In all the individual experiments, we observed variability in the 
patterns of recognition, magnitudes of responses, and magnitudes in background 
amongst T cells expressing each of the DMF5 TCRs. Thus, instead of averaging 
together experiments, we developed a scoring index to examine how mutations in the 
DMF5 TCR altered recognition of the off-target tumors compared to the WT DMF5 TCR 
among different donors and experiments. We based this index off of our standard of 
defining antigen reactivity as twice over background and greater than 200 pg/mL. 
Therefore, we examined each experiment and allocated a score to each mutant DMF5 
TCR in response to each off-target tumor. A score of 1 indicated IFN-γ production 
against an off-target tumor was twice over the IFN-γ production against MEL 624-28 
within the respective mutant DMF5 TCR, AND twice over the IFN-γ production exhibited 
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by the WT DMF5 TCR, AND over 200 pg/mL. A score of 0 was given if ANY of the three 
criteria were NOT met. This scoring was completed in each experiment in each donor. 
We used MEL 624-28 as the negative control because this is a relevant MART-1+ 
melanoma, but it is HLA-A2-. We used the WT DMF5 TCR in the scoring index so that 
we could compare off-target tumor recognition by each modified DMF5 TCR compared 
to the WT DMF5 TCR. Overall, with this scoring index we could examine both 
differences in recognition over background (MEL 624-28) within a respective mutant 
DMF5 TCR and differences in recognition compared to the WT DMF5 TCR. Table 17 
specifies the scores given to each modified DMF5 TCR, in each experiment, against 
each off-target tumor. These scores were based on the raw data shown in Figures 52-
58 in the appendix. We subsequently averaged the scores together and obtained an 
index that demonstrated the frequency at which T cells expressing each mutant DMF5 
TCR exhibited twice the level of recognition against an off-target tumor as T cells 
expressing the WT TCR (Figure 41). The criteria for comparing to the WT DMF5 TCR is 
just classified as twice over recognition by the WT DMF5 TCR, and thus, we understand 
this index does not take into account the magnitude in which a response is greater than 
twice of the WT TCR. However, this index gives us an objective way to compare 
experiments given the donor and experimental variability. These results indicated T 
cells expressing the αD26Y TCR recognized the off-target A375, UOK131, SW480, 
SKGT5, and U251 tumors more than T cells expressing the WT TCR in every 
experiment. Furthermore, T cells expressing the αD26Y TCR recognized the off-target 
SKOV3, CAPAN 1, MDA 231, and HEPG2 tumors more than T cells expressing the WT 
TCR with a frequency between 0.83 and 0.86.  
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Table 17. Scoring Index for DMF5 TCRs against Off-Target Tumors. Experiment 1 in 
donor 1 was not included in analysis because a minimal off-target tumor panel was used. 
A blank space indicates off-target tumor was not used in that experiment. A score of 1 
indicated IFN-γ production against an off-target tumor was twice over IFN-γ production 
against MEL 624-28 within the respective mutant DMF5 TCR, AND twice over IFN-γ 
production exhibited by the WT DMF5 TCR, AND over 200 pg/mL. A score of 0 was given 
if ANY of the three criteria were NOT met. Shown are scores from four donors, including 
1-2 experiments, were averaged for each off-target tumor with each DMF5 TCR.  
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Figure 41. Frequency Mutant DMF5 TCRs Exhibited Enhanced Recognition of Off-
Target Tumors Compared WT DMF5 TCR. Given experimental variability, a reactivity 
score was developed to enable a direct comparison of experiments. Recognition of 
each off-target tumor by each mutant DMF5 TCR was given a score of 1 or 0 in every 
experiment. A score of 1 indicated IFN-γ production was twice over IFN-γ production 
against MEL 624-28 (HLA-A2-) within respective mutant DMF5 TCR, AND twice over 
IFN-γ production exhibited by the WT DMF5 TCR, AND over 200 pg/mL. A score of 0 
was given if ANY of the three criteria were NOT met. Scores from each experiment 
were averaged for each mutant DMF5 TCR and off-target tumor. Data indicate the 
averages of seven experiments and error bars indicate the standard error of the mean.   
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T cells expressing the βL98W TCR recognized the off-target tumors more than T cells 
expressing the WT TCR with a frequency between 0.14 and 0.33. T cells expressing the 
αD26Y/βL98W TCR recognized the off-target SKOV3, MDA 231, SW480, HEPG2, 
SKGT5, and U251 tumors more than T cells expressing the WT TCR in every 
experiment. Furthermore, T cells expressing the αD26Y/βL98W TCR recognized the off-
target A375, UOK131, and CAPAN 1 tumors with frequencies between 0.83 and 0.85. T 
cells expressing the αD26Y/αY50A/βL98W TCR did not recognize the off-target 
UOK131 or HEPG2 tumor more than T cells expressing the WT TCR in any experiment. 
Moreover, T cells expressing the αD26Y/αY50A/βL98W TCR recognized the other off-
target tumors more than T cells expressing the WT TCR with frequencies between 0.14 
and 0.71, with U251 yielding the highest frequency. Lastly, T cells expressing the 
αD26Y/αY50V/βL98W TCR recognized the off-target tumors more than T cells 
expressing the WT TCR with frequencies between 0.33 and 0.71. Overall, these results 
coincided with the two patterns of off-target recognition we previously described in 
Figure 40. Specifically, T cells expressing the αD26Y TCR and αD26Y/βL98W TCR 
exhibited greater off-target tumor recognition in nearly all the experiments compared to 
T cells expressing the WT TCR. T cells expressing the αD26Y/αY50V/βL98W TCR 
frequently exhibited greater off-target tumor recognition compared to T cells expressing 
the WT TCR. Lastly, T cells expressing the βL98W TCR and αD26Y/αY50A/βL98W 
TCR sometimes exhibited greater off-target tumor recognition compared to T cells 
expressing the WT TCR, but demonstrated the lowest frequencies amongst the mutant 
DMF5 TCRs. 
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Creating the previous index allowed us to examine the frequency at which T cells 
expressing a given mutant DMF5 TCR exhibited greater recognition of an off-target 
tumor than T cells expressing the WT TCR in a yes/no manner. While this provided 
valuable conclusions based upon all the experiments and donors, it is important to also 
note conclusions that were revealed based upon the magnitudes and patterns of off-
target tumor recognition. First, off-target recognition was not completely reproducible 
among experiments. For example, in donor three, T cells expressing the αD26Y TCR 
exhibited comparable recognition of SKOV3 (3, 128 pg/mL) and UOK131 (3,671 pg/mL) 
in experiment one (Figure 55, in the appendix), but were 4.5 times more reactive 
against UOK131 (17,469 pg/mL) than SKOV3 (3,854 pg/mL) in experiment two (Figure 
56, in the appendix). Secondly, off-target recognition was donor dependent. For 
example, T cells expressing the αD26Y/αY50V/βL98W exhibited similar levels of 
recognition of the off-target U251 tumor compared to T cells expressing the WT TCR in 
donor two (Figures 53-54, in the appendix) but increased recognition in donor four 
(Figures 57-58, in the appendix). Thirdly, T cells expressing the WT DMF5 TCR 
recognized at least one off-target tumor in every experiment. This occurred against 
MDA 231 and CAPAN 1 (Figure 52, in the appendix), CAPAN 1 (Figure 53, in the 
appendix), CAPAN 1 and SW480 (Figure 54, in the appendix), CAPAN 1 (Figure 55, in 
the appendix), A375, SCOV 3, UOK131, CAPAN 1, MDA 231, and SW480 (Figure 56, 
in the appendix), A375, SKOV3, CAPAN 1, and MDA 231 (Figure 57, in the appendix), 
and A375, SKOV3, UOK131, CAPAN 1, MDA 231, SW480, HEPG2, SKGT5, and U251 
(Figure 58, in the appendix). Specifically, T cells expressing the WT TCR recognized 
the CAPAN 1 tumor in every experiment. Conclusively, all of these results suggested 
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off-target tumor recognition was generally experiment and donor dependent. Despite 
donor and experimental variability, a few overarching conclusions in regards to off-
target tumor recognition can be made. First, the observed cross-reactivity was HLA-A2 
restricted. Secondly, T cells expressing the WT DMF5 TCR are cross-reactive. Thirdly, 
T cells expressing the αD26Y TCR or αD26Y/βL98W TCR are highly cross-reactive 
against all the tumors. T cells expressing the αD26Y/αY50V/βL98W TCR are frequently 
cross-reactive against all the tumors. T cells expressing the βL98W TCR are mildly 
cross-reactive against the tumors and sometimes this recognition is above the level of 
recognition by T cells expressing the WT TCR. Lastly, T cells expressing the 
αD26Y/αY50A/βL98W TCR are mildly cross-reactive against the tumors and sometimes 
this recognition is above the level of recognition by T cells expressing the WT TCR or 
βL98W TCR.  
Impact of Mutant DMF5 TCRs on 2D Affinity 
It was very interesting that the patterns of cross-reactivity against the HLA-A2+ 
tumors did not coincide with the DMF5 TCRs measured 3D affinity. More recently, it has 
been demonstrated that 2D affinity measurements can better predict T cell functional 
outcomes compared to 3D affinity measurements [162, 170, 172]. This is most likely 
due to the fact that 2D affinity measurements account for aspects unique to membrane-
bound proteins, where 3D affinity measurements are strictly dependent upon the 
TCR/pMHC. We measured the 2D affinity of the WT DMF5 TCR and each of the mutant 
DMF5 TCRs to determine if these measurements correlated to the observed patterns in 
off-target tumor reactivity. To eliminate the variability associated with polyclonal PBL-
derived T cells, we utilized Jurkat E6.1 cells transduced with the WT DMF5 TCR or 
each of the mutant DMF5 TCRs for this experiment. The 2D affinity measurements of 
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the DMF5 TCRs with the MART-1 10mer peptide/HLA-A2 complex are shown in Figure 
42. The observed patterns of cross-reactivity against the off-target tumor panel better 
correlated with 2D affinity measurements. Specifically, T cells expressing the αD26Y 
TCR or the αD26Y/βL98W TCR exhibited the highest 2D affinity, corresponding to their 
high levels of cross-reactivity against the off-target tumors. Most notably, the 
αD26Y/αY50A/βL98W TCR and αD26Y/αY50V/βL98W TCR revealed higher affinities 
compared to the βL98W or WT TCR, which coincided with their enhanced cross-
reactivity against the off-target tumor lines. One explanation for the disconnect between 
3D and 2D affinity measurements could be due to differences in TCR affinity when 
using purified proteins or membrane-bound interactions. In conclusion, 2D affinity 
measurements correlated better to the cross-reactivity observed against the off-target 
tumor panel than the 3D affinity measurements. 
Potential DMF5 TCR Targets in Off-Target Tumors 
 In was interesting that the patterns of recognition against the MART-1 homologs 
and off-target tumors were not consistent amongst each of the different DMF5 TCRs. 
Thus, we began to hypothesize what targets these TCRs were recognizing on the off-
target tumor cells. First, we knew that they recognized specific peptides, or a class of 
peptides in the context of HLA-A2, because T2 cells loaded with negative control 
peptides and some of the MART-1 homolog peptides revealed no detectable reactivity. 
We refocused our attention on the human self-peptides, MART-1, human CD9, human 
elongation factor 1α, G-protein coupled receptor 3, and human receptor expression 
enhancing protein 5. We initially hypothesized it was possible that the T cells were 
recognizing one or more of these proteins on the off-target tumor cells.  
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Figure 42. Relative 2D Affinity of DMF5 TCRs. Adhesion frequencies of TCR 
transduced Jurkat E6.1 cells were determined using a two-dimensional micropipette 
adhesion frequency assay with TCR transduced Jurkat E6.1 cells expressing each 
DMF5 TCR and MART-1 10mer/HLA-A2-coated RBCs. Relative 2D affinities were 
calculated using the specific adhesion frequency (Pa) along with the surface pMHC (ml) 
and TCRβ (mr) densities, as determined by flow cytometry. For each TCR, 50 Jurkat 
E6.1 cell-RBC pairs were used to obtain Pa values from which the affinity was 
calculated as: AcKa = −ln [1−Pa(1)]/mrml. The geometric mean of affinities and 
normalized adhesion bonds are reported ± standard error of the mean. 2D affinity 
measurements were completed in the Evavold lab.   
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We utilized “The Human Protein Atlas” to determine if these proteins were expressed in 
the tissues from which our off-target tumors were derived. Aside from MART-1 
expression being limited to only melanocytes, the other four self-proteins were 
expressed either at high, medium, or low levels in a majority of tissues throughout the 
human body (Table 18). One caveat here is that we do not know the expression of the 
proteins in our specific tumors. However, these results implicated there was a possibility 
that some of these self-proteins could be expressed in the tumors. Since human CD9 is 
expressed on the cell surface, we immunofluorescently labeled the tumors with an anti-
CD9 mAb to determine if CD9 was expressed on the tumor cells. We confirmed 
expression of CD9 on all the tumor cell lines (Figure 43). Specifically, human CD9 
expression on the tumors ranged between 44% and 100%. Human elongation factor 1α, 
G-protein coupled receptor 3, and human receptor expression enhancing protein 5 are 
not expressed on the surface and thus, could not be immunofluorescently labeled. 
Other assays such as RT-PCR could confirm mRNA transcripts or western blot could 
confirm protein expression. However, once we knew the off-target tumors were CD9+, 
expression of one of more of the other three self-proteins would still not directly 
elucidate what antigens were being recognized. Although it was that plausible that CD9 
was being recognized on the off-target tumor cells by the DMF5 TCR transduced T 
cells, we believed we had thorough evidence to suggest the cross-reactivity was due to 
multiple different antigens, and was most likely DMF5 TCR dependent. Variability in the 
recognition of the off-target tumors between DMF5 TCRs, donors, and experiments 
indicated a few possibilities in regards to the antigens being recognized. 
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Table 18. Levels of MART-1 and Self-MART-1 Homolog Protein Expression in 
Normal Tissues. “X” indicates not expressed. These data were generated from The 
Human Protein Atlas. 
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Figure 43. Human CD9 Expression on Tumor Panel. 1x106 tumor cells were stained 
for surface expression of HLA-A2 and CD9. (a) PG13 cells (murine leukemia cell line) 
were used as a negative control. SAUJ tumor cells show an example of an HLA-A2-
CD9+ tumor line while A375 tumor cells (MART-1-) show an example of an HLA-
A2+CD9+ tumor line. (b) Summary of surface CD9 expression on tumor cell lines. Data 
represent the averages of two independent experiments and error bars indicate the 
standard error of the mean. 
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The highly cross-reactive TCRs (αD26Y TCR and αD26Y/βL98W TCR) could be 
eliciting low levels of cross-reactivity to numerous antigens being broadly recognized, or 
could be eliciting high levels of cross-reactivity to one or a few antigens. Variability in 
recognition of the different off-target tumors by even the same DMF5 TCR transduced T 
cell population indicated is it unlikely the off-target tumors are processing and 
presenting the same antigen or antigens. Furthermore, it is possible the DMF5 TCRs 
are recognizing the same set of antigens on the off-target tumor cells, just at different 
levels of magnitudes. Conversely, it is possible the DMF5 TCRs are each recognizing a 
completely different spectrum of antigens. In summary, it is possible that human CD9 
was recognized on the off-target tumor cells, but we believe this was not the sole 
potentially recognized antigen. 
We believed our data thus far indicated that T cells expressing each of the 
mutated DMF5 TCRs were recognizing multiple different peptides on the off-target 
tumors. Therefore, it was of interest to expand the number of targets, but also 
categorize the targets we were examining in order to narrow down potential targets. We 
elucidated potential targets by utilizing combinatorial peptide libraries in positional 
scanning format [440, 441]. In combinatorial peptide libraries in positional scanning 
format, each pool contains contain a mixture of peptides where one or more of the 
peptide residues’ is fixed at a specific amino acid and the remaining peptide residues 
include a mixture of amino acids. This method allowed us to examine reactivity against 
millions of peptides and highlight favorable amino acids at specific sites in the peptide 
for recognition. In this analysis we utilized TCR transduced Jurkat 76 cells to limit the 
donor variability observed in polyclonal T cell populations. The Jurkat 76 cell line is TCR 
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α-β- and therefore, we eliminated off-target recognition due to TCR chain mispairing in 
using this cell line. For this analysis, we compared Jurkat 76 cells expressing the WT 
DMF5 TCR with Jurkat 76 cells expressing the highly cross-reactive αD26Y/βL98W 
TCR, or Jurkat 76 cells expressing the unexpectedly, off-target tumor cross-reactive, 
αD26Y/αY50A/βL98W TCR (Figure 44) [350]. Jurkat 76 cells expressing the WT DMF5 
TCR exhibit recognition of nearly all the sub-libraries, supporting the notion that this WT 
DMF5 TCR is inherently cross-reactive. Jurkat 76 cells expressing the αD26Y/βL98W 
TCR exhibited enhanced recognition against the sub-libraries compared to the WT 
DMF5 TCR expressing Jurkat 76 cells. Lastly, Jurkat 76 cells expressing the 
αD26Y/αY50A/βL98W TCR exhibited a reduction in recognition against the sub-libraries 
compared to the WT DMF5 TCR expressing Jurkat 76 cells. Overall, these data support 
our conclusions based on the MART-1 homolog peptide data, where the αD26Y/βL98W 
TCR enhanced cross-reactivity and the αD26Y/αY50A/βL98W TCR reduced cross-
reactivity compared to the WT TCR.  
This approach of using a combinatorial peptide library, has been utilized to 
identify recognition of an off-target, altered-peptide ligand of an antigen specific TCR 
[442]. Albeit, in our model it would be difficult to identify important residues at specific 
peptide positions for antigen recognition because recognition generally occurred across 
all peptide pools with the WT TCR and αD26Y/βL98W TCR. However, the 
αD26Y/αY50A/βL98W TCR largely reduced Jurkat 76 cell potency against the peptide 
pools compared to the WT TCR and displayed a less permissive pattern of reactivity 
against the peptide pools. One notable difference was observed in the recognition of the 
peptide pool containing a fixed aspartic acid at position 5. 
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Figure 44. Combinatorial Peptide Library Scans. Combinatorial peptide library scans 
of WT (top), αD26Y/βL98W (middle), and αD26Y/αY50A/βL98W (bottom) TCRs. For 
each experiment, TCR transduced Jurkat 76 cells were incubated with equal numbers 
of T2 cells loaded with 152 sub-libraries where each position of the peptide (excluding 
primary anchors) was fixed with each of the naturally occurring amino acids (excluding 
cysteine). Reactivity was assessed by measuring IL-2 release in triplicate wells, as 
indicated by the heat map scales on the right. Results are the average of three 
independent experiments with each TCR. This experiment was completed in the Baker 
lab [350]. 
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Reactivity was about doubled with cells expressing the αD26Y/αY50A/βL98W TCR 
compared to Jurkat 76 cells expressing the WT DMF5 TCR. This suggested that despite 
generally reducing overall cross-reactivity compared to the WT DMF5 TCR, there were 
possibly a small number of peptides that elicited an increase in reactivity with Jurkat 76 
cells expressing the αD26Y/αY50A/βL98W TCR. This idea would support our findings 
as to why T cells expressing the αD26Y/αY50A/βL98W TCR were sometimes more 
cross-reactive against the off-target tumors than T cells expressing the WT DMF5 TCR. 
This pool (fixed aspartic acid at position 5) is also notable because it was demonstrated 
that the WT DMF5 TCR also recognizes epitopes containing a “DRG” charged core 
[404, 423]. In summary, the potential number of targets recognized on the tumor cells is 
seemingly vast, however, recognition via the αD26Y/αY50A/βL98W TCR could be the 
result of enhanced reactivity against a few targets compared to the WT TCR. 
In summary, in collaboration with the Baker’s laboratory, we have developed a 
novel structure guided approach to enhance antigen specificity and reduce cross-
reactivity. We generated five modified DMF5 TCRs and sought to determine how 
structure-guided mutations in the DMF5 TCR altered tumor lysis, polyfunctional T cell 
responses, cross-reactivity, antigen specificity, and recognition of processed antigens. 
When measuring polyfunctional T cell responses against a panel of MART-1 homologs, 
the structure guided approach appeared to be promising, with T cells expressing the 
αD26Y/αY50A/βL98W TCR exhibiting reduced percentages of MART-1 homolog 
reactive T cells compared to T cells expressing the WT TCR (Figure 20). Conversely, 
when observing T cell responses against processed antigens on a variety of different 
tissues, this trend did not remain consistent (Figure 40). Our results demonstrated that 
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sequence homology is not the sole factor in cross-reactivity, and 3D affinity against the 
“cognate” antigen is not always correlative to all-encompassing cross-reactivity. 
Furthermore, T cell responses vary due to biophysical properties/kinetics of the 
TCR/pMHC interaction and the polyclonal PBL-derived T cell population. Our structure-
based designed strategy could be utilized in the future, as it is more meticulous and 
specific than random mutation through yeast or phage display. Specifically, we also 
elucidated the critical role of the MHC weakening TCR mutation and how it could 
potentially be translatable to other TCRs. Overall, it is important to understand how 
alterations in the TCR/pMHC interface can affect functional T cell phenotypes to 
maximize the efficacy and safety of TCRs to be used in gene modified T cells in 
adoptive cell transfer. 
Second Round of DMF5 TCR Mutations 
The goal of designing the first round of DMF5 mutations (DMF5 TCRs described 
thus far) was to determine which TCR mutations enhanced MART-1 specificity while 
reducing off-target cross-reactivity. Our objective was to take the information we learned 
from the first generation of mutant DMF5 TCRs and subsequently optimize the results 
through the generation of a second round of mutant DMF5 TCRs. Based on information 
elucidated from the functional results, the Baker lab subsequently designed a second 
round of DMF5 TCRs. In αD26Y/αY50A/βL98W TCR expressing CD8+ T cells, a 
reduction in the percentage of MART-1 homolog reactive T cells was observed 
compared to T cells expressing the WT TCR, but a reduction in MART-1 potency was 
also observed. The objective with this next round of DMF5 TCRs was to better maintain 
MART-1 potency while also maintaining a reduction in cross-reactivity compared to the 
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WT TCR, similar to the level observed with the αD26Y/αY50A/βL98W TCR against the 
MART-1 homologs. Our results indicated the αY50 residue was critical for antigen 
recognition. Specifically, the alanine mutation was more effective than the valine 
mutation at reducing MART-1 reactivity and cross-reactivity. In collaboration with the 
Baker lab, we hypothesized the αY50 residue was too close to the MART-1 peptide 
(about 5 Ä away). Therefore, the mutation of a tyrosine to an alanine at position 50 in 
the TCR alpha chain weakened bonds with the MHC, but also likely weakened bonds 
with the MART-1 peptide. Specifically, it is possible that the αY50A TCR mutation may 
not be solely “MHC binding” specific. This could be an explanation for the reduction 
observed in MART-1 specific reactivity. Thus, we wanted to examine other TCR 
mutations at different TCR/MHC binding residues that might not interfere with MART-
1/TCR binding interactions. The Baker lab identified four residues in the DMF5 TCR that 
interacted with HLA-A2, but were more than 10 Ä away from the MART-1 peptide. 
These residues included αN52, αK68, βN52, and βT57 [443]. Each residue was 
mutated to an alanine because the alanine mutation in the αY50 mutations was more 
effective than the valine mutation. Four DMF5 TCRs were made: 
αD26Y/αN52A/βL98W, αD26Y/βN52A/βL98W, αD26Y/αK68A/βL98W, and 
αD26Y/βT57A/βL98W. Each new negative mutation replaced the previous αY50 
mutation. The second round of DMF5 TCRs was further used in functional T cell 
assays. 
The objective was to determine how this second round of DMF5 mutations 
altered MART-1 and MART-1 homolog reactivity compared to the WT TCR. However, 
findings from the first round of DMF5 TCR mutations demonstrated unexpected off-
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target tumor cross-reactivity that did not correlate with recognition of the MART-1 
homologs. Thus, we believed we should first examine recognition of our tumor panel 
before examining polyfunctional T cell responses. Our preliminary experiment in one 
donor is shown in Figure 59, in the appendix. T cells expressing the WT DMF5 TCR are 
cross-reactive against HLA-A2+ tumors as previously observed. We next determined 
how T cells expressing the newly designed mutant DMF5 TCRs altered the recognition 
of the off-target tumors compared to the WT TCR. T cells expressing each mutant 
DMF5 TCR exhibited more cross-reactivity against all the HLA-A2+ tumors compared to 
T cells expressing the WT TCR. The αD26Y/αN52A/βL98W, αD26Y/βN52A/βL98W, and 
αD26Y/βT57A/βL98W TCR expressing T cells were more reactive against MEL 624 
compared to T cells expressing the WT TCR, but were extremely more cross-reactive. 
Our previous findings indicated the presence of the αD26Y mutation in a mutant TCR 
enhanced cross-reactivity against the off-target tumors amongst all the DMF5 TCRs. It 
is possible that same phenomenon is occurring with these TCR mutations as well. 
These mutant DMF5 TCRs appear to be extremely cross reactive compared to the WT 
TCR, whereas the αD26Y/αY50A/βL98W TCR was mildly cross-reactive compared to 
the WT TCR. This indicated it was possible that the proximity of the αY50A mutation 
with the peptide was important to counterbalance the effects of the αD26Y mutation. 
Thus, these new negative mutations do not counterbalance the effect of the αD26Y 
mutation as efficiently. Overall, these results indicate this second round of TCR 
mutations did not reduce the cross-reactivity of the WT TCR.  
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In vivo Model 
All of the experiments thus far have examined antigen specificity and cross-
reactivity in vitro. It was important to next determine if these results were reproducible in 
vivo. However, in vitro findings do not always translate in vivo [444]. Therefore, we 
wanted to determine if the first round of DMF5 mutations could have anti-tumor activity 
in a murine model. Namely, we wanted to determine if the high affinity (3D) TCRs 
(αD26Y and αD26Y/βL98W) could control tumor growth better than the WT TCR and if 
the low affinity (3D) TCR (αD26Y/αY50A/βL98W) could control tumor growth. We chose 
to use a NSG A2+ mouse model for multiple reasons. First, an immunodeficient host 
allowed us to use a xenograft model. This was beneficial for examining the efficiency of 
human TCR transduced T cells against a human tumor in vivo [384, 445]. Furthermore, 
HLA-A2+ mice allowed us to examine any signs of autoimmunity due to the introduction 
of the TCR transduced T cells. Mice do not share complete homology with humans, 
however, three of the four self-MART-1 homologs in the peptide panel (CD9, elongation 
factor 1α, and receptor expression enhancing protein 5) are completely homologous in 
the mouse. In summary, we believed the NSG A2+ mice were an advantageous model 
to use to examine the anti-tumor efficacy of TCR transduced T cells and observe 
potential autoimmunity. 
Despite the advantages of the xenograft model, there are a few drawbacks. First, 
due to the lack of a host immune system, there is no cytokine or chemokine support to 
assist in T cell function, persistence, and trafficking to the tumor [446-448]. Furthermore, 
in our hands and in other studies, human T cells expressing the DMF5 TCR fail to 
control tumor growth in NSG mice [449]. Therefore, we explored additional mechanisms 
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to support the persistence, function and trafficking of the introduced TCR transduced T 
cells. Herein, those mechanisms included prior PBMC engraftment, cytokine support, 
and checkpoint blockade.  
The immunodeficiency of NSG mice is advantageous for xenograft models but 
disadvantageous for the support of the introduced human T cells. To overcome this, 
previous studies have generated humanized NSG mice in order to reconstitute a human 
immune system in the mice and support introduced T cells [450]. Thus, xenografts could 
be examined in the presence of a human immune system. This has been commonly 
done by engrafting human bone marrow-derived or umbilical cord blood-derived CD34+ 
hematopoietic stem cells into the mice [450-453]. We believed we could recapitulate this 
via the engraftment of human PBMCs. We first determined if human PBMCs could 
persist weeks after engraftment and determined if intraperitoneal or retro-orbital route of 
injection affected engraftment (Figure 60, in the appendix). These results indicated 
human CD3+ T cells could be detected in the blood of mice 72 days post engraftment. 
Furthermore, retro-orbital route of injection persisted better than the intraperitoneal 
route of injection, meaning the intravenous route of injection was superior for 
engraftment. Consistent with previous studies, mice demonstrated signs of GVHD 
around nine weeks post engraftment, indicating xeno-cross-reactivity occurred. In 
summary, these results indicated human T cells can persist 72 days post engraftment in 
the NSG A2+ mice.  
We confirmed engrafted human T cells could persist in the blood of NSG A2+ 
mice and retro-orbital route of injection was superior to intraperitoneal route of injection 
(Figure 60, in the appendix). We next determined if the engrafted T cells could support 
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the persistence and function of the introduced TCR transduced T cells. Mice were 
engrafted with human PBMC 7 days prior to MEL 624 tumor challenge (Figure 61, in the 
appendix). Mice were treated with TCR transduced T cells 17 days post tumor 
challenge. For this pilot experiment, we only used T cells transduced with either the WT 
TCR, the αD26Y TCR, or the αD26Y/αY50A/βL98W TCR. These results indicated that 
the engraftment prior to tumor challenge did not affect the anti-tumor activity of the TCR 
transduced T cells, as there were no differences between treated and untreated mice. 
Additionally, no signs of autoimmunity were observed in these mice throughout the 
duration of this experiment. This indicated that the introduced T cells did not elicit off-
tumor off-target damage that could be observed. To determine if engraftment supported 
the introduced T cells, we monitored the persistence of the TCR transduced T cells post 
injection. It was interesting that on day 13, no CD34+ T cells were found in the blood of 
treated mice, despite 66-76% CD34 expression amongst the TCR transduced T cell 
groups prior to injection (Figure 62, in the appendix). Specifically, in one mouse, only 
0.57% of cells in blood were CD3+CD34+. There was a large population of human CD3+ 
T cells in the blood, however, we are unable to distinguish engrafted T cells from T cells 
that have lost the CD34 transgene expression. Transgene expression has been shown 
to decrease over time in vivo but it has been shown that cytokines can help maintain 
transgene expression [275, 454]. Because the TCR transduced T cells are cultured ex 
vivo in IL-2 and IL-15, then enter the in vivo environment with no cytokine support, we 
hypothesized additional cytokine support would enhance the transgene expression and 
T cell function. 
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IL-2 and IL-15 are important for T cell activation, proliferation, and function [455-
460]. Furthermore, IL-2 and IL-15 have been shown to promote long-term survival and 
function of adoptively transferred T cells in vivo [461-466]. We therefore determined if 
IL-2 or IL-15 support would enhance the anti-tumor activity of TCR transduced T cells in 
vivo (Figure 63, in the appendix). In this pilot experiment, we compared T cells 
expressing the WT DMF5 TCR with untransduced T cells, with or without IL-2 or IL-15 
cytokine support. There were no differences between treatments with untransduced and 
WT TCR transduced T cells, with or without cytokine support. These results indicated 
that cytokine support did not enhance the anti-tumor activity of the TCR transduced T 
cells. Furthermore, on day 10 post therapy, there were no differences in the 
percentages of CD3+CD34+ human T cells in the blood of mice treated with IL-2 or IL-15 
(Figure 64, in the appendix). One mouse treated with WT TCR transduced T cells 
actually exhibited 1.88% CD3+CD34+ human T cells in the blood compared to 0.39% 
and 0.49% of IL-2 and IL-15 treated mice, respectively. These results indicated that 
cytokine support did not enhance transgene expression in vivo. One explanation for this 
could be that the TCR transduced T cells did not traffic to the tumor. To examine this, 
on day 16 post treatment, we determined if there were TCR transduced T cells in the 
tumor (Figure 65, in the appendix). Compared to untransduced T cells, there were no 
CD3+CD34+ T cells found in the tumors of mice treated with DMF5 WT TCR transduced 
T cells with or without IL-2 and IL-15. These results indicated that cytokine support did 
not enhance the trafficking of TCR transduced T cells to the tumor or the survival of 
TCR transduced T cell in the tumor. On day 16, we also determined if the TCR 
transduced T cells had homed and remained in the spleen (Figure 66, in the appendix). 
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No human CD3+ or human CD3+CD34+ T cells were found in the spleens of mice from 
each treatment group. Conclusively, our results suggested the introduced TCR 
transduced T cells were unable to survive in vivo despite IL-2 or IL-15 cytokine support.  
Our results thus far have demonstrated that engraftment of human T cells prior to 
treatment or cytokine support did not enhance the anti-tumor efficacy, persistence, or 
trafficking of TCR transduced T cells in vivo. The TCR transduced T cells underwent ex 
vivo activation for up to three weeks prior to injection in vivo and thus, exhaustion could 
be limiting their effector function in vivo [467-469]. Therefore, we determined if anti-PD-
1 treatment with adoptively TCR transduced T cells could enhance their anti-tumor 
efficacy [470, 471]. In this experiment, we compared the anti-tumor efficacy of 
untransduced or WT DMF5 TCR transduced T cells with or without anti-PD-1 (Figure 
67, in the appendix). These results indicated that treatment with anti-PD-1 did not 
enhance the anti-tumor efficacy of WT DMF5 TCR transduced T cells, as they did not 
control tumor growth better than no treatment or untransduced T cells. In summary, 
anti-PD-1 treatment did not enhance the anti-tumor efficacy of DMF5 TCR transduced T 
cells in vivo. 
Our in vivo data thus far suggested that TCR transduced T cells did not control 
MEL 624 tumor growth and were not found in the tumor after treatment. Furthermore, 
anti-PD-1 treatment did not affect the anti-tumor efficacy of the TCR transduced T cells, 
indicating that PD-1 dependent exhaustion was most likely not the sole reason. 
Conclusively, these results suggested loss of transgene expression and inability to 
traffic to the tumor potentially limited the TCR transduced T cells anti-tumor efficacy. To 
determine if inability of trafficking to the tumor was contributing to this, we performed an 
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in vivo cytotoxic T lymphocyte (CTL) assay [472]. This assay allowed us to determine if 
TCR transduced T cells could kill MART+ target cells in vivo without needing to traffic to 
the site of a tumor. A schematic of this assay is depicted in Figure 68, in the appendix. If 
DMF5 TCR transduced T cells killed MART-1 9mer pulsed PBMCs in vivo, we would 
expect to see an increase in the proportion of CFSE low (PBMCs) cells because the 
CFSE high cells (MART-1 9mer pulsed PBMCs) were killed. An example of the 
proportion of CFSE high and CFSE low cells from the spleen two days after injection is 
shown in Figure 69, in the appendix. In PBS treated mice, the proportion of CFSE high 
to CFSE lows cells remains even, at 7.04% high and 6.83% low, indicating no specific 
lysis occurred. In mice treated with WT DMF5 TCR transduced T cells, the proportion of 
CFSE high to CFSE low cells is skewed, at 11.8% low and 6.49% high. These results 
indicated that MART-1 9mer pulsed PBMCs (CFSE high) were killed. The % MART-1 
lysis is shown in Figure 70, in the appendix. These results indicated that WT DMF5 TCR 
transduced T cells killed about 41% of the MART+ target cells, compared to 5% with 
PBS treatment. These results suggested WT DMF5 TCR transduced T cells can kill 
MART+ targets in vivo. Since these T cells did not have to traffic to encounter these 
MART+ target cells in vivo, it is plausible that we previously did not observe anti-tumor 
activity of the TCR transduced T cells due to their inability to traffic to the site of the 
tumor or suppressive mechanisms in the tumor microenvironment.
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CHAPTER FOUR 
DISCUSSION 
Introduction 
 The use of TCR gene-modified T cells for adoptive T cell transfer is an evolving 
and promising form of immunotherapy. However, the use of TCRs that target self-
antigens involve the caveat of bearing a low affinity for the targeted antigen. TCR affinity 
enhancement via methods such as yeast or phage display have been utilized to 
enhance anti-tumor efficacy of TCR transduced T cells, but have resulted in patient 
fatalities [5, 6, 298, 299]. Therefore, reducing potential off-target cross-reactivity while 
maintaining or enhancing the anti-tumor activity of TCR gene-modified T cells is of 
upmost importance for both safety and efficacy. Herein, we developed a novel structure-
guided approach designed to fine-tune the antigen specificities of the DMF5 TCR. 
Numerous factors can impact the functional response of T cells. These factors include 
structural components in the TCR/pMHC interface, kinetic factors, and cellular factors. 
In this dissertation we focused on how these factors influence the on-target and off-
target responses of T cells engineered to express the WT or mutated DMF5 TCRs. 
Furthermore, our findings emphasize the importance of rigorous preclinical testing of 
modified TCRs and the need for advancement in modeling/prediction tools for protein 
interactions. Overall, this is important in order to better design TCRs that will be safe 
and more efficient in patients.
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How DMF5 Mutations Affect Recognition of MART-1 Homologs 
Correlation to Alanine Scan 
 The alanine scan method was utilized to determine that Titin was the target of the 
affinity enhanced MAGE-A3 TCR, causing lethal adverse events. Two sets of alanine 
substituted or glycine substituted peptide panels elucidated critical residues for 
recognition of MAGE-A3 by T cells expressing the affinity enhanced TCR. Searches for 
protein sequences with epitope homology resulted in three clinically relevant potential 
targets aside from MAGE: one was Titin, two were pathogenic [299]. Overall, this 
method was suitable for predicting a critical cross-reactive peptide with this modified 
TCR, and if completed prior to therapeutic treatments, the authors could have identified 
the target that led to lethal adverse events.  
We utilized a panel of MART-1 nonameric alanine substituted peptides to 
determine how mutations in the DMF5 TCR affected recognition of a structurally altered 
MART-1 peptide. The alanine scan method can be a suitable method for making a 
general prediction about the importance of an individual residue in the peptide for 
recognition, and furthermore, it was an adequate tool for predicting the lethal off-target 
peptide in the MAGE-A3 clinical trial. However, our results indicated that this method is 
not always an adequate predictor for potential off-target, altered-peptide ligand 
reactivity. Since the alanine scan data were generated in TCR transduced CD8- Jurkat 
E6.1 cells, the results must be compared with the reactivity of TCR transduced CD4+ T 
cells. Specifically, the alanine scan demonstrated the importance of positions 4 and 6 in 
the MART-1 9mer peptide for recognition by αD26Y TCR expressing cells. However, 
αD26Y TCR expressing CD4+ T cells recognized all of the seven MART-1 homologs 
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that did not display sequence homology with the MART-1 9mer peptide at position 4 
and/or position 6. The alanine scan is a low throughput screen that only allows for 
determination of a residue’s importance for TCR recognition when mutated to an 
alanine, and when mutated individually. Therefore, this method lacks the ability to 
account for the effects of non-alanine mutations in the peptide and the effects of 
multiple mutations in the peptide. 
It has been shown that the conformational adaptability of TCRs is important for 
the ability to recognize multiple different ligands [473, 474]. As a result, recognition of a 
peptide is more dependent upon the net effect of all the individual residues and the 
TCR’s ability to conform to that pMHC structure. For instance, one amino acid 
substitution could result in an unfavorable interaction with the TCR, but another amino 
acid substitution elsewhere, in the same peptide, could result in a favorable interaction 
with the TCR. Therefore, different interactions between the peptide and the MHC and 
between the peptide and the TCR can offset each other differently. These interactions 
will be both ligand and TCR dependent. In summary, recognition of the alanine 
substituted MART-1 peptides did not entirely predict recognition of different MART-1 
homologs because each amino acid in a given peptide will contribute differently to 
binding in the MHC and to binding with the TCR to subsequently affect T cell activation 
and T cell function. 
Correlation to Structure 
 Our results indicated that the structural effects of the introduced DMF5 TCR 
mutations did not always correlate to the predicted recognition of MART-1 homologs. 
The αD26Y TCR mutation was designed to enhance charge complementarity with the 
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N-terminal region of the MART-1 peptide, as previously described in Chapter Three 
[350, 351]. However, this TCR mutation also eliminated charge repulsion with a 
negatively charged glutamic acid in the HLA-A2 α1 helix [349]. This illustrates the 
difficulty associated with identifying TCR residues that will only impact binding with the 
peptide when mutated to a different amino acid. With the αD26Y TCR mutation, it is not 
easy to distinguish the influence of the favorable HLA-A2 binding interaction with the 
influence of the favorable peptide binding interaction. It is plausible that both factors 
were contributing to the enhanced cross-reactivity.  
Our data suggested that the tyrosine mutation at position 26 in the TCR alpha 
chain non-specifically enhanced recognition of the MART-1 homologs. We will again 
focus on the CD4+ T cells for this part of the discussion because the structure-guided 
mutations were designed in the absence of CD8. Although not statistically significant, 
the percentages of MART-1 9mer and 10mer reactive T cells was modestly enhanced 
with T cells expressing the αD26Y TCR vs. the WT TCR, as predicted (Figure 19). The 
percent reactive CD4+ T cells was enhanced against every MART-1 homolog (reaching 
statistical significance in two) in αD26Y expressing T cells compared WT expressing T 
cells (Figure 19). The replacement of a charged aspartic acid with a bulky and 
amphipathic tyrosine enhances surface area and allows for increased involvement in 
van der Waals forces [395]. Therefore, the αD26Y TCR mutation seemingly enhanced 
non-specific binding to nonpolar, hydrophobic residues at position 2 in the 9mer 
peptides. In the MART-1 homologs, all residues at position two are a hydrophobic 
amino acid, except for in one MART-1 homolog. In ADP-ribose diphosphatase there is a 
charged aspartic acid at position two. ADP-ribose diphosphatase was minimally 
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recognized by T cells expressing the WT TCR (1.67%) but there was a stark increase in 
the percentage of αD26Y TCR expressing reactive T cells (16.47%). This result was 
most likely due to the elimination of the charge repulsion between the negatively 
charged aspartic acids associated with the WT DMF5 TCR and ADP-ribose 
diphosphatase by the tyrosine TCR alpha chain mutation. There is no clear importance 
or ranking of preferred hydrophobic residues at position two in the peptide with the 
αD26Y TCR. This suggested that the tyrosine mutation enhanced non-specific binding. 
Overall, the αD26Y TCR mutation resulted in non-specific cross-reactivity with all the 
MART-1 homologs, indicating its lack of specificity for the MART-1 peptide. 
The second MART-1 targeting TCR mutation, βL98W, was designed to enhance 
shape complementarity with the leucine at position 7 in the MART-1 9mer peptide, as 
previously described in Chapter Three [350, 351]. Although not statistically significant, 
the percentages of MART-1 9mer and 10mer reactive CD4+ T cells was modestly 
enhanced with T cells expressing the βL98W TCR vs. the WT TCR, as predicted 
(Figure 19). There were only minor increases observed (averaging between 0.64% and 
4.3%) in the percentages of MART-1 homolog reactive CD4+ T cells between the WT 
TCR and βL98W TCR, with none reaching statistical significance (Figure 19). Although 
the βL98W TCR mutation enhanced binding to the MART-1 9mer via the leucine at 
position 7, increased percentages of reactive βL98W TCR expressing CD4+ T cells 
were only notable against one out of the four MART-1 homologs that contained a 
leucine at position 7, ADP-ribose diphosphatase (5.9% vs. 1.6%) (Figure 19). This could 
also be due to the valine N-terminal anchor in this peptide, as valines are superior HLA-
A2 anchors [404]. Like tyrosine, tryptophan is also commonly used to enhance binding 
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due to their rigid, bulky, and amphipathic nature [72]. Position 7 in other MART-1 
homologs is generally also very hydrophobic, and thus the tryptophan mutation 
seemingly remains unable to discern differences between the hydrophobic residues. 
There is also no pattern in preference for specific residues at position 7 in the peptide 
with the βL98W TCR. In conclusion, the tryptophan TCR mutation at position in 98 in 
the TCR beta chain was not entirely specific for the MART-1 peptide, but was more 
specific than the αD26Y TCR mutation. 
The field generally considers high affinity TCRs are optimal for T cell function and 
therapeutic efficacy [180, 396]. However, our results did not entirely correlate with this 
assumption when combining the αD26Y TCR and βL98W TCR mutations. The 
correlation with affinity will be discussed in the next section. CD4+ T cells expressing the 
αD26Y/βL98W TCR starkly reduced the percentage of MART-1 9mer and 10mer 
reactive T cells compared to T cells expressing the WT TCR (Figure 19). This results 
indicated that the combination of the two MART-1 targeting mutations was not additive, 
although affinity is dramatically increased. T cells expressing the αD26Y/βL98W TCR 
exhibited in a trend towards an increase in the percentages of MART-1 homolog 
reactive T cells compared to T cells expressing the WT TCR, with statistical significance 
reached with two MART-1 homologs (Figure 19). We would have expected to see more 
considerable differences in the recognition of the MART-1 homologs, based upon the 
recognition of the MART-1 homologs by T cells expressing the αD26Y TCR. Therefore, 
these results were most likely due to the supraphysiological high affinity of the 
αD26Y/βL98W TCR. This will be discussed in the next section. Consequently, it is 
difficult to accurately determine the structural effects of the αD26Y/βL98W TCR on 
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recognition of MART-1 and the MART-1 homologs since the affinity of this TCR most 
likely affected T cell function. Overall, the combination of the αD26Y TCR mutation and 
the βL98W TCR mutation in the αD26Y/βL98W TCR did not enhance MART-1 
specificity.  
Our positive and negative design strategy hypothesized that introduction of a 
TCR mutation that weakened TCR binding with the MHC would reduce off-target cross-
reactivity. As predicted, the addition of the αY50A mutation to the αD26Y/βL98W TCR 
reduced the percentages of MART-1 homolog CD4+ reactive αD26Y/αY50A/βL98W 
TCR expressing T cells compared to αD26Y/βL98W TCR expressing T cells (Figure 
19). However, compared to the T cells expressing the WT TCR, the percentages of 
MART-1 9mer and 10mer CD4+ reactive αD26Y/αY50A/βL98W TCR expressing T cells 
was significantly reduced (Figure 19). These results indicated that even though MART-1 
homolog recognition was comparable, MART-1 specific reactivity was reduced. 
However, these results were different with the introduction of a different MHC 
weakening TCR mutation, αY50V. T cells expressing the αD26Y/αY50V/βL98W TCR 
exhibited comparable percentages of MART-1 9mer and 10mer reactive CD4+ T cells 
compared to T cells expressing the WT TCR (Figure 19). Also, there were no significant 
changes in the percentages of MART-1 homolog reactive T cells, however, minor 
increases were observed. These results indicated the introduction of a valine mutation 
at position 50 in the TCR alpha chain could offset the effects of the αD26Y/βL98W TCR 
and restore MART-1 reactivity to similar levels observed with the WT TCR. These 
results also indicated the importance of eliminating contact with positions 154, 155, and 
158 in the HLA-A2 with the alanine mutation, to result in reduced T cell reactivity 
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compared to the WT TCR levels. Overall, these results demonstrated the combination 
of the MHC weakening TCR mutations with peptide binding TCR mutations could alter 
on-target and off-target antigen recognition. 
The effects of these structure-guided TCR mutations are generally described in a 
very linear fashion, based on their impact on the MART-1 decamer/HLA-A2 complex. 
However, the TCR/pMHC interaction includes only a small subset of all the membrane-
bound proteins on a T cell and the APC. Thus, this interaction is very dynamic and fluid 
complex. It is clear from our data that structural predictions based on this complex, do 
not always directly correlate with recognition of altered-peptide ligands and cross-
reactive peptides. This is likely due to multiple factors involved in the TCR/pMHC 
interaction. For example, it has been shown that anchor residues can alter TCR binding 
and specificity [475-478]. Therefore, it is possible that a peptide with little core sequence 
homology but an optimal anchor residue could impact TCR binding and recognition 
differently than a peptide with more core sequence homology but a suboptimal anchor 
residue. Specifically, it has been demonstrated that different anchor modifications of the 
MART-1 9mer and 10mer peptides elicited different cytokine responses [479]. Also, as 
already mentioned above, multiple favorable and non-favorable interactions within the 
TCR/pMHC complex will affect binding and subsequent signaling. These interactions 
will be different with each TCR and each ligand. Overall, these results emphasized the 
idea that the net effect of individual interactions within the TCR/pMHC complex dictates 
binding and peptide recognition.  
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Correlation to 3D Affinity 
 The structure-guided DMF5 TCR mutations altered the binding affinity compared 
to the WT DMF5 TCR. The DMF5 TCR 3D affinity measurements generally correlated 
to the percentages of reactive CD4+ T cells against MART-1 and the MART-1 
homologs. One exception is the comparable percentages of reactive T cells between 
the WT TCR and αD26Y/αY50V/βL98W TCRs despite the αD26Y/αY50V/βL98W 
harboring a much lower affinity. Albeit, this result coincided with our goal in that using 
this strategy was not necessarily to enhance TCR affinity, but rather to redistribute the 
TCR’s free binding energy. Moreover, these results begin to elucidate the limitations 
associated with using the 3D affinity measurement against the target antigen as a 
predictor for cross-reactivity against altered-peptide ligands. For example, 4.9% of CD4+ 
T cells expressing the αD26Y/αY50V/βL98W recognized the MART-1 homolog, HREEP 
5, whereas only 2.5% of T cells expressing the βL98W TCR recognized HREEP5. Their 
3D affinities with the MART-1 9mer are 140 μM and 12 μM, respectively. Despite the 
decrease in 3D affinity against the MART-1 9mer, the structural interaction between the 
αD26Y/αY50V/βL98W TCR and the HREEP 5/HLA-A2 complex elicited a better T cell 
response than with the βL98W TCR. The 3D affinity measurement is based upon the 
net interaction between the TCR/pMHC. However, it is possible that strongly enhanced 
binding, or strong favorable interactions at certain TCR/pMHC residues can heavily 
influence a T cell response, despite the presence of unfavorable interactions at other 
TCR/pMHC residues. Specifically, the net interactions will influence 3D affinity, but 
interactions at different TCR/pMHC residues could differentially influence 
conformational changes within the TCR/CD3 complex and subsequent signaling and T 
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cell function. In summary, the 3D affinity measured with the targeted ligand can 
correlate to functional outcomes with the targeted ligand and with altered-peptide 
ligands, but as demonstrated here, that is not always the case.  
 The field generally considers high affinity TCRs are optimal for T cell function and 
therapeutic efficacy. However, more recently it has been demonstrated when TCR 
affinity is too high, reduced T cell function is observed [146, 480-483]. This was 
exhibited in T cells expressing the αD26Y/βL98W TCR, as high TCR 3D affinity does 
not always yield enhanced T cell function. The lack of rational correlation between 3D 
affinity and T cell function in T cells expressing the αD26Y/βL98W TCR can be 
attributed to its supraphysiological high affinity. It has been demonstrated when a TCR’s 
3D affinity approaches 5 - 1 μM, a decline in TCR signaling, in expression of activating 
and co-stimulatory molecules, and in T cell function is observed [146, 480-483]. SHP-1 
negatively regulates TCR signaling and has been shown to be upregulated in an affinity-
dependent manner [419, 484]. The highest levels of SHP-1 have been observed in T 
cells with supraphysiological TCR affinities [419]. Therefore, it would be of interest to 
determine the levels of SHP-1 in T cells expressing the αD26Y/βL98W TCR in response 
to MART-1 and the MART-1 homologs compared to T cells expressing the other DMF5 
TCRs. Additionally, prolonged half-lives of TCRs have also been associated with a 
decrease in T cell function [485-488]. Serial triggering is important for full T cell 
activation and can be limited by prolonged half-lives [147]. It has also been shown that 
dissociation rates better correlate to T cell potency than TCR affinity [489-491]. Kon and 
Koff rates of the αD26Y/βL98W TCR could help elucidate some of the kinetic factors 
attributing to the observed decline in on-target T cell function. Additionally, we might 
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expect stark enhancements in the percentages of MART-1 homolog reactive 
αD26Y/βL98W TCR expressing T cells compared to the αD26Y TCR if we used 3D 
affinity as a predictor. Lastly, the 3D affinity measured with the αD26Y/βL98W TCR and 
the MART-1 decamer/HLA-A2 was in the nM affinity range. Therefore, MART-1 
homologs harboring a superior anchor residue or other favorable interactions could 
again, result in an attenuated T cell responses with a high affinity TCR. In conclusion, 
these results suggested the supraphysiological 3D affinity of the αD26Y/βL98W TCR 
attenuated its on-target, and possibly off-target T cell potency in αD26Y/βL98W TCR 
expressing T cells. 
 It is well appreciated that higher affinity TCRs can be more cross-reactive [179, 
483]. High affinity TCRs can tolerate significant changes in the peptide and still induce T 
cell activation, whereas these peptide changes with a lower affinity TCR could result in 
the loss of T cell activation [148]. This was exemplified in the MAGE-A3/Titin story. The 
affinity enhanced MAGE-A3 TCR recognized MAGE-A3 and Titin very similarly despite 
differences in the peptide core sequences [298]. This was also exemplified in our 
hands, with the αD26Y/βL98W DMF5 TCR. The αD26Y/βL98W TCR modeled with the 
MART-1 9mer peptide, HSV-1 glycoprotein III peptide, and M. tuberculosis protein I 
peptide indicated no substantial changes to the TCR CDR loops and side chains in the 
three different models [350]. The HSV-1 glycoprotein III peptide differs from the MART-1 
9mer peptide in three residues and the M. tuberculosis protein I peptide differs from the 
MART-1 9mer peptide in seven residues, even in the peptide core. This demonstrated 
how the high affinity TCR accommodates structural differences in the peptide. In 
summary, 3D affinity can generally predict overarching patterns of antigen specificity 
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and cross-reactivity in CD4+ T cells, however, this is not always the case, and is TCR 
and ligand-dependent.  
Contribution of CD4 and CD8 
 Another factor that affects antigen specificity and cross-reactivity is the CD4 and 
CD8 co-receptors. Our data indicated the presence of the CD8 co-receptor increased 
the percentage of cross-reactive T cells compared to CD4+ T cells (Figures 19-20). This 
is not surprising due to the functional role of CD8 [92], and previous studies describing 
CD8’s role in cross-reactivity [148, 368]. CD8 stabilizes the TCR/pMHC interaction and 
furthermore, has the ability to influence Kon and Koff rates [421, 422, 492-494]. 
Specifically, CD8 has been shown to strengthen binding of TCR/pMHC by 3- to 4-fold 
[422, 494, 495]. Therefore, stabilization of low affinity interactions via CD8, with the aid 
in Lck recruitment, could induce T cell activation and T cell responses. This was 
apparent in the enhanced percentages of MART-1 homolog reactive WT TCR 
expressing CD8+ T cells compared to the CD4+ T cells. However, the specific role of 
CD8 becomes more complex within different TCR and ligand interactions. For example, 
CD8’s role in both TCR/pMHC stabilization and Lck localization have been implicated 
important for T cell function in lower affinity interactions, whereas only the role in Lck 
localization was important for T cell function in higher affinity interactions [439, 496]. 
Furthermore, we did not observe notable differences in the percentages of MART-1 and 
MART-1 homolog reactive CD4+ and CD8+ T cells expressing the high affinity 
αD26Y/βL98W TCR. There are two plausible explanations for this result. First, CD8 
stabilization of a high affinity interaction could prolong the dissociation rate and reduce 
serial triggering, resulting in reduced T cell function or partial activation. Secondly, a 
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high affinity TCR, 17 μM, previously demonstrated comparable T cell function with and 
without the CD8 co-receptor [439]. Thus, implicating in a high affinity interaction, CD8 
does not affect T cell function. However, the 3D affinity measurement of the βL98W 
TCR with the MART-1 9mer was 12 μM and exhibited notable differences between the 
percentages of MART-1 9mer CD4+ (25.9%) and CD8+ (41.9%) reactive T cells. This 
suggests the specific role of CD8 is TCR and ligand dependent.  
 The effect of the MART-1 targeting TCR mutations, αD26Y and βL98W, on 
MART-1 recognition was also different in CD4+ and CD8+ T cells. Although not 
significant, T cells expressing the αD26Y TCR and βL98W TCR did enhance the 
percentages of MART-1 reactive T cells in CD4+ T cells compared to T cells expressing 
the WT TCR but not in CD8+ T cells. These results indicated that the effect of the 
binding enhancement on MART-1 due to these TCR mutations was potentially 
overshadowed in the presence of the CD8 co-receptor. These results indicated that this 
structure-guided mutation strategy could have different implications in CD4+ and CD8+ T 
cells. For example, the positive and negative design worked in CD8+ T cells for reducing 
cross-reactivity, as T cells expressing the αD26Y/αY50A/βL98W exhibited a reduction in 
the percentage of MART-1 homolog reactive T cells compared to T cells expressing the 
WT TCR. However, WT TCR expressing T cells were barely reactive against the MART-
1 homologs in the CD4+ T cells. Furthermore, MART-1 potency was significantly 
reduced in αD26Y/αY50A/βL98W TCR expressing CD4+ T cells compared to with the 
WT TCR. Therefore, the positive and negative design could be more important for 
reducing cross-reactivity in CD8+ T cells. Alternatively, although not significant, CD4+ T 
cells expressing the βL98W TCR enhanced the percentage of MART-1 reactive T cells 
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compared to the WT TCR, with some minor increases in the percentages MART-1 
homolog reactive T cells. This enhanced percentage of MART-1 reactive T cells was not 
observed in the CD8+ T cells between the two TCRs. These results suggest that in 
CD4+ T cells, positive design could be more important in enhancing on-target potency, 
but most importantly, if the introduced TCR mutations do not, or very minimally, affect 
off-target recognition. In summary, CD8 augments cross-reactivity and masks the 
potential effect of peptide targeting mutations in the enhancement of antigen specific T 
cell potency. Therefore, the positive and negative design approach could have different 
therapeutic implications in CD4+ and CD8+ T cells.  
Cytotoxicity vs. Cytokine Expression 
 It was notable that cytotoxicity against the HLA-A2+ melanoma tumor, MEL 624, 
did not correlate with 3D TCR affinity or polyfunctionality. Using 3D TCR affinity as a 
predictor, we would have expected T cells expressing the αD26Y/αY50A/βL98W or 
αD26Y/αY50V/βL98W TCRs to elicit reduced targeted melanoma killing compared to T 
cells expressing the WT TCR. However, T cells expressing the αD26Y/αY50A/βL98W 
TCR or the αD26Y/αY50V/βL98W TCR exhibited comparable or a trend towards better 
killing, respectively, compared to T cells expressing the WT TCR. If cytotoxicity directly 
correlated with CD107A and cytokine expression, we also would not have expected this 
based upon the total percentages of functional (CD107A and or/cytokine expression) T 
cells elicited against the MART-1 9mer.  
 There is evidence in the literature that explains how TCR affinity and T cell 
cytokine production do not always correlate with cytotoxicity. Initially, it had been shown 
that it is possible for just one TCR/pMHC interaction to induce a cytolytic T cell 
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response [151, 497] . Subsequent studies indicated three TCR/pMHC interactions 
elicited targeted cell death [498]. This is thought to be important for efficient immunity 
because a small number of antigenic pMHC complexes can be expressed on a target 
cell. Thus, cytotoxicity was determined to be the most antigen sensitive effector T cell 
response [499]. It was also demonstrated that using TCRs that varied in affinity, by up 
to 9-fold, resulted in similar killing. Furthermore, the induced cytotoxicity was elicited in 
transient immune synapse formation and reduced calcium flux [498]. This is suggests 
that T cell targeted killing is less dependent upon affinity and can occur in the absence 
of full T cell activation [500]. These findings coincide with our findings. Even though T 
cells expressing the two highest 3D affinity TCRs (αD26Y and αD26Y/βL98W) did 
significantly elicit a higher percentage of tumor killing compared to T cells expressing 
the WT TCR, cytotoxicity was comparable with the other higher and the lower affinity 
TCRs. Overall, these results indicate that 3D affinity does not always correlate to 
cytotoxicity.  
 Our cytotoxicity results also did not directly correlate with the observed 
polyfunctional T cell responses. It has been shown that cytokine production is more 
dependent upon kinetic factors. Cytokine production requires sustained signaling and 
maintenance at the immunological synapse for maximum effect [501, 502]. Altered-
peptide ligands can also act as agonists, partial agonists, or antagonists to elicit 
different T cell responses. For example, lower affinity interactions have been shown to 
elicit cytokine production, but not T cell proliferation [150, 503]. Partial agonistic 
peptides have been demonstrated to elicit cytotoxicity and/or release of IFN-γ and TNF-
α, but not IL-2 [328]. Partial agonists and antagonists tend to have shorter half-lives and 
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thus, potentially dissociate from the TCR before full T cell activation is achieved [79, 
487, 489, 504]. It has been demonstrated that half-lives between 8 and 12 seconds 
allow all six tyrosines on the ITAMS to be phosphorylated, whereas half-lives between 3 
and 8 seconds only allow enough time for a subset of the ITAMS to be phosphorylated, 
resulting in partial T cell activation [505]. In summary, the release of lytic granules and 
the expression of cytokines are governed by different mechanisms in T cells [506]. 
Based on the percentage of MART-1 reactive T cells, our results suggest that T cells 
expressing the αD26Y/αY50A/βL98W TCR could result in partial activation. Coinciding 
with our results, cytokine production is more correlated to 3D affinity and kinetic 
TCR/pMHC parameters, where cytotoxicity is less dependent upon TCR affinity.  
 Lastly, our results indicated that the percentages of CD107A+ T cells in response 
to the MART-1 9mer (Figures 35-36) generally correlated with cytotoxicity. The one 
exception to this correlation was observed with T cells expressing the αD26Y/βL98W 
TCR. Specifically, compared to T cells expressing the WT TCR, αD26Y/βL98W TCR 
expressing T cells exhibited a statistically significant increase in MEL 624 killing (Figure 
17), but a statistically significant decrease in the percentage of CD107A+ CD8+ MART-1 
9mer reactive T cells and a comparable percentage of CD107A+ CD4+ MART-1 9mer 
reactive T cells (Figure 36). It was notable that the drastic lack in correlation was 
observed with the TCR with the supraphysiological affinity. These results suggested at 
this level of affinity, CD107A expression is not correlative to lysis and/or CD107A 
expression is antigen density dependent. Following the results obtained from the off-
target tumor panel, it is plausible to hypothesize that T cells expressing the modified 
DMF5 TCRs were exhibiting lysis in response antigens other than MART-1 on MEL 624 
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cells. However, the patterns in recognition of MEL 624 in terms of IFN-γ production, 
generally correlated with patterns observed in the percentages of MART-1 9mer 
reactive CD8+ T cells in Figure 20. It is possible the DMF5 TCRs recognized other 
antigens on MEL 624, however, these results implicated that was not the likely or sole 
justification. We would have to knockout MART-1 in MEL 624 tumor cells to determine 
the level of recognition due to other antigens. Overall, lysis broadly correlated to 
expression of CD107A except in T cells harboring a TCR with supraphysiological 
affinity. 
Polyfunction and Donor Variability 
 Another factor that affects T cell responses is the donor in which T cells were 
derived. Our results indicated that T cells expressing the same TCR elicited different 
polyfunctional T cells responses in different donors even when seeing the same ligand. 
This was not surprising, as there are several factors that contribute to the T cell 
response. The structure of the TCR/pMHC interaction affects numerous biophysical 
parameters (i.e. affinity, on-rate, off-rate, t1/2, serial triggering, force) and then the 
combination with numerous cellular parameters (CD4/CD8, co-stimulatory molecules, 
ligand density, receptor density, activation status, exhaustion status, signaling 
molecules, TCR mispairing) subsequently dictates a polyfunctional response by a T cell. 
The T cell response is initiated by the TCR/pMHC interaction. Thus, the first variable 
here is the structure of the TCR/pMHC tri-molecular complex. This interaction affects 
numerous biophysical/kinetic parameters such as affinity, on-rate, off-rate, t1/2, serial 
triggering, and force. How these parameters can affect T cell function has been 
described in previous sections. The ability of a mutated TCR to alter T cell responses 
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compared to the WT TCR has also been previously demonstrated [507]. However, the 
kinetic factors are not the sole contributor to T cell function. There are numerous cellular 
factors that affect T cell function as well (CD4/CD8, co-stimulatory molecules, ligand 
density, receptor density, activation status, exhaustion status, signaling molecules, TCR 
mispairing).  
 First, a heterogeneous T cell population was used for generating TCR 
transduced T cells. This included T cells of various functional subsets and numerous 
specificities [508]. This can affect the T cell response for a number of reasons. For 
example, T cells exhibiting a stem cell memory or central memory phenotype 
demonstrated a more potent antigen response than effector memory T cells and long-
term immune responses [509, 510]. Efficacy of CAR T cell therapy has also been 
associated with the proportion of naïve vs. effector T cells in the final product [511]. 
Furthermore, memory T cells have been shown to be stimulated by significantly lower 
peptide concentrations than naïve T cells, and have demonstrated faster and more 
efficient T cell function than naïve T cells [130, 512]. Therefore, the proportions of these 
T cell subtypes in different donors could affect their polyfunctional T cell response. An 
analysis of PBL from healthy patients demonstrated the percentage of naïve and 
memory CD8+ T cells varied widely among patients [513]. Different subsets of T cells 
express varying levels of activation and co-stimulatory molecules [514]. Additionally, 
one study demonstrated the donor variation in immune cell subpopulations as well as 
signaling responses in 60 healthy donors. Specifically, this study showed that IL-2 
responses in naïve CD4+ T cells varied widely among the healthy donors [515]. Lastly, 
one study of 123 healthy donors indicated donors over the age of 40 exhibited lower 
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activation markers on CD8+ T cells and lower naïve and central memory CD8+ T cells 
compared to donors under the age of 40 [516]. These results illustrate the wide potential 
for donor variability associated with a heterogeneous PBL population.  
 Donor variability has been exemplified in numerous clinical trials both in terms of 
clinical responses and adverse events. When the WT DMF5 TCR was used clinically, 
objective cancer regressions were seen in 30% of the patients. Furthermore, on-target, 
off-tumor adverse events of varying degrees were seen in 16/20 patients [288]. If the T 
cells all were transduced the same way the same TCR, why didn’t every patient exhibit 
a clinical response or toxicities? Or why were they exhibited at different levels? In the 
MAGE-A3 clinical trial that resulted in lethal neurological toxicities, two out of nine 
patients died. However, five patients did not exhibit any neurological toxicities. Two 
patients exhibited neurological toxicities that were not lethal. Additionally, one patient 
exhibited a complete response and four patients exhibited a partial response [5]. In a 
clinical trial using NY-ESO-1 specific TCR engineered T cells, 16 out of 20 treated 
patients exhibited clinical responses [302]. These are a few examples of results that 
demonstrated the variety of T cell responses that can occur in different donors despite 
expressing the same introduced TCR. In summary, the structure of the TCR/pMHC 
impacts numerous kinetic factors that influences T cell function. However, numerous 
cellular factors further dictate the T cell response. Overall, donor variability and 
experimental variability occur for numerous reasons, therefore, it is not feasible to 
predict or associate a polyfunctional phenotype with a specific structural TCR/pMHC 
interaction. 
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Importance of MHC Weakening Site 
 One of the unique aspects of this project is combining TCR mutations that target 
the peptide, with TCR mutations that weaken binding with the MHC. Although peptide 
targeting TCR mutations would be ligand-dependent and thus TCR specific, the MHC 
targeting TCR mutations could be translatable to other TCRs. Our results indicated the 
translatability of the CDR2 region mutation in the TCR alpha chain that weaken binding 
with the MHC. More specifically, TCR mutation weakened or eliminated binding with 
positions 154, 155, and 158 in the HLA-A2 α2 helix with a valine or alanine mutation, 
respectively [350]. Residues at position 50 the CDR2 TCR alpha chain make one of the 
most frequent contacts between TCRs and MHC class I [37, 398]. These single TCR 
mutations in the DMF5 TCR eliminated all detectable reactivity against MART-1 loaded 
targets, further supporting the importance of this residue in pMHC binding and their 
evolutionarily selection. In the HCV 1406 TCR, alanine mutation at the same TCR 
contact site eliminated all detectable reactivity against the WT NS3 peptide loaded 
targets. However, the valine mutation eliminated all detectable reactivity against some 
of the mutant NS3 epitope loaded targets and reduced reactivity against other mutant 
NS3 epitopes and the WT NS3 peptide loaded targets compared to the WT TCR. These 
results indicated that these mutations impact HLA-A2 restricted TCRs differently, but 
yield a similar trend in eliminating or reducing off-target peptide recognition. Therefore, 
this conserved TCR alpha chain residue could be mutated in high affinity and/or 
potentially cross-reactive TCRs to reduce HLA-A2 restricted cross-reactivity. More 
importantly, this strategy could again be implemented in the positive/negative design 
strategy with other TCRs. This contact site has been broadly implicated in MHC class I 
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interactions, and not just limited to specifically HLA-A2. Furthermore, the alanine 
substitution had more of an impact than the valine substitution. Therefore, it is feasible 
to hypothesize that a smaller amino acid substitution, such as a glycine, would have 
even more of an impact than the alanine substitution. It would be interesting to 
determine how mutation in the TCR at this contact site in the MAGE-A3 affinity 
enhanced TCR would affect cross-reactivity with Titin, even though this TCR is HLA-A1 
restricted. Furthermore, similar residues have been identified for MHC class II binding, 
indicating this strategy could be implemented in TCRs in CD4+ T cells as well [37]. Even 
though peptide targeting mutations would be TCR and ligand specific, this TCR alpha 
chain residue is seemingly broadly applicable to MHC class I restricted TCRs. In 
summary, this CDR2 TCR alpha chain residue could be translatable to other TCRs as a 
strategy to reduce potential cross-reactivity. Importantly, the unique role of the negative 
design in this novel positive and negative design strategy can be implemented in other 
TCRs. 
How DMF5 Mutations Affect Recognition of Processed Antigens 
Correlation to MART-1 Homologs 
 It is important to also observe recognition of processed antigens because 
exogenous peptide loaded T2 cells are not entirely biologically relevant. Furthermore, 
many peptide reactive T cells do not recognize processed antigen. The patterns of T 
cell reactivity against the MART-1 homologs by T cells expressing each of the different 
DMF5 TCRs did not directly correlate with their cross-reactivity against off-target 
tumors. These results exemplify the differences in conclusions that can be obtained 
when observing cross-reactivity via two distinct methods. 
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It is evident that utilizing peptides derived from a sequence homology search with 
the target ligand are not always adequate in assessing inclusive cross-reactivity. T cell 
cross-reactivity has been described based upon peptides with sequence homology, 
peptides with very minimal sequence homology but also, with unrelated peptides [517]. 
It is known that TCRs can recognize divergent peptides that would not be found in 
homology searches [350, 518]. Estimations suggest that one TCR can recognize one 
million different peptides [519]. This is possible due to their inherent plasticity in the 
CDR loops. TCR protein adaptability has been described and is critical for recognition of 
diverse peptides [474, 520]. Therefore, it is thought that cross-reactivity is not due to 
recognizing numerous unrelated peptides, but rather the tolerance of peptide 
alterations, and conservative alterations at residues that contact the TCR CDR loops 
[521]. These principles highlight the pitfalls associated with focusing solely on sequence 
homology as a predictor for cross-reactivity. An example of this was exemplified in our 
data. T cells expressing the αD26Y/αY50A/βL98W TCR did reduce cross-reactivity 
against the MART-1 homologs compared to T cells expressing the WT TCR. However, 
recognition of the off-target tumors was either comparable or enhanced with T cells 
expressing the αD26Y/αY50A/βL98W TCR compared to T cells expressing the WT 
TCR. In conclusion, we observed two very different results dependent upon the method 
in which we examined cross-reactivity. These results highlight the importance of 
addressing cross-reactivity in an inclusive manner. 
Multiple studies indicated molecular mimicry could occur with structural and 
chemical similarities and not sequence similarities, thus implicating the importance of 
the antigenic peptide surface [517, 522-525]. Moreover, TCR recognition can rely on 
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sequence similarities in few regions of the peptide while tolerating vast diversity 
elsewhere in the peptide [369, 521, 526]. Specifically, it has been shown that just one 
conserved residue in the peptide can still result in partial T cell activation [527]. If T cells 
are estimated to recognize up to one million peptides, focusing on epitopes that have 
homology with only one of those potential million recognized peptides, is actually a very 
incomplete pool of potentially recognized targets. Based on what is known about TCR 
cross-reactivity and recognition of sequence dissimilar epitopes, it is understandable 
how focusing on MART-1 homologs, selected upon sequence homology, did not 
correlate to cross-reactivity against an abundant number of antigens on the off-target 
tumor cell lines. Furthermore, the TCRs harboring the structure-guided mutations did 
not always directly correlate to recognition of MART-1 homologs according to their 
sequence and the proposed structural effect of the specific TCR mutation. In summary, 
this inconsistency can be explained by the idea of TCRs recognizing structural mimicry 
as well as sequence mimicry. 
 The DMF5 TCR was identified based upon its recognition of MART-1. 
Accordingly, peptides in the MART-1 homolog peptide panel were selected based upon 
sequence homology with MART-1. However, the DMF5 TCR actually commonly 
recognizes two distinct classes of epitopes. One class is the hydrophobic motif, GIG, in 
the peptide core, and the second class is a central core consisting of charged amino 
acids [404, 423]. The DMF5 TCR tolerates such different antigenic surfaces by rotating 
its side chains to optimize electrostatic interactions [404]. Other TCR adaptability 
mechanism can involve CDR loop conformational changes or TCR repositioning [528-
530]. The lack of conformational changes or repositioning indicates the DMF5 TCR 
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requires minimal alterations to accommodate divergent changes in the peptide core. 
MART-1 and the MART-1 homologs used in these studies fall into the peptide class with 
a hydrophobic motif in the peptide core. It would have been of interest to also 
investigate how each of the DMF5 TCRs recognize peptides in the second peptide 
class, consisting of central cores dominated by charged amino acids. The structure-
guided mutations were designed based on the hydrophobic MART-1 peptide with the 
GIG peptide core, and thus, we are unsure of how these mutations in the DMF5 TCR 
would affect recognition of this other class of peptides. Therefore, antigens in this class 
of peptides, with a central charged core, could be expressed on the off-target tumors 
and were potentially recognized targets, however, we are unaware of how the different 
DMF5 TCRs recognize them. 
 Notably, our data generated by the combinatorial peptide libraries indicated 
enhanced recognition of peptides containing an aspartic acid at position 5 by cells 
expressing the αD26Y/αY50A/βL98W TCR compared to the WT TCR. Furthermore, this 
pool is recognized starkly more than all the other pools by cells expressing the 
αD26Y/αY50A/βL98W TCR. These results indicated that the αD26Y/αY50A/βL98W 
TCR might easily conform to or even prefer peptides with this antigenic surface. It is 
possible that the αD26Y mutation in this TCR removes an unfavorable interaction 
between the two negative charges that is present with the WT TCR. Furthermore, the 
removal of this repulsion is strong enough to not be offset by the αY50A mutation. T cell 
potency against this pool is enhanced with cells expressing the αD26Y/βL98W TCR 
compared to cells expressing the WT TCR. However, the addition of the αY50A 
mutation to the αD26Y/βL98W TCR was not enough to restore T cell reactivity to the 
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level observed with the WT TCR. Consequently, it is possible that peptides that conform 
to structures like the peptides in this specific pool, with an aspartic acid at the core of 
the peptide, could be presented on the off-target tumor lines. This would explain why T 
cells expressing the αD26Y/αY50A/βL98W TCR were more cross-reactive against some 
of the off-target tumors than T cells expressing the WT TCR.  
 It was demonstrated that the WT DMF5 TCR does exhibit a conserved 
interaction upon binding a peptide with the hydrophobic GIG core and a peptide with the 
charged core. This conserved interaction consisted of the CDR1 loop in the TCR alpha 
chain and the peptide backbone near the N-terminus [404]. This is interesting because 
the αD26Y mutation was made in the CDR1 loop targeting the N-terminal region of the 
peptide. Furthermore, TCRs containing this mutation were the most cross-reactive 
against the off-target tumors amongst the mutated DMF5 TCRs, with the βL98W TCR, 
the only mutated TCR lacking the αD26Y mutation, being the least cross-reactive. 
These results suggest an important role of this mutation. If the interaction between the 
CDR1 TCR alpha chain loop and the N-terminal region of the peptide is conserved 
despite divergent peptides in the HLA-A2 complex, then the αD26Y mutation would be 
in the same conformation in every interface, and thus, could non-specifically enhance 
binding to any peptide. Our results suggested the structural role of the αD26Y mutation, 
in a conserved interaction, could be contributing the unpredicted off-target recognition of 
the off-target tumor lines. 
It is possible for mutated TCRs to exhibit one pattern of cross-reactivity against 
certain classes of peptides while displaying a different pattern of cross-reactivity against 
a different class of peptides. This is most likely the reason why our results using the 
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MART-1 homologs did not directly align with reactivity against processed antigens on 
off-target tumor lines. Our results and other studies demonstrated valuable information 
that can be revealed using combinatorial peptide libraries. This will be discussed in a 
later section. In summary, when assessing TCR cross-reactivity, the sole use of 
peptides with sequence homology is not always a completely sufficient method.  
3D Affinity vs. 2D Affinity 
 Our results indicated that 3D measurements better correlated with cross-
reactivity against the MART-1 homologs, or with sequence homology, whereas 2D 
measurements better correlated with cross-reactivity against off-target tumor cells. 
There are numerous reasons why the 2D affinity measurements might better correlate 
to the more biologically relevant system. 2D measurements take into account the 
geometric and physical constraints involved in membrane-bound interactions, where 3D 
measurements do not [156, 166]. Thus, there are many intrinsic T cell factors such as 
membrane organization and orientation, membrane anchor, cytoskeleton regulation, 
and TCR structure in the CD3 complex that are involved in 2D measurements [380, 
531-534]. Additionally, proteins in 3D SPR are in solution, whereas in the 2D 
micropipette frequency assay, the pMHC and TCR are directly, and head on, brought 
into contact. This affects how the TCR and pMHC come in contact with each other and 
thus how they bind together. Our results begin to illuminate the caveat with predicting T 
cell function and cross-reactivity based on 3D affinity measurements [168]. 
 3D affinity measures the in vitro molecular binding properties, while 2D affinity 
measures physiological in situ kinetics [534]. Thus, our data highlight the differences 
between binding specificity and functional specificity in regards to 3D affinity and 2D 
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affinity. Specifically, 3D affinity measurements better correlated with recognition of 
MART-1 and the MART-1 homologs. For example, compared to the WT TCR, T cells 
expressing the αD26Y/αY50A/βL98W TCR reduced T cell potency against MART-1 and 
the MART-1 homologs, aligning with a reduction in this TCR’s 3D affinity. However, 
when observing recognition of off-target tumors, the overall functional specificity of T 
cells expressing the αD26Y/αY50A/βL98W TCR better correlated to its 2D affinity, in 
relation to the WT TCR. Figure 45 depicts the rankings of cross-reactivity with the 
different DMF5 TCRs in regards to the MART-1 homologs and the off-target tumor 
panel and their correlation with 3D and 2D affinity. The ranking of MART-1 homolog 
cross-reactivity in Figure 45A is based up the results calculated in Table 7. It is evident 
that reactivity against the MART-1 homologs followed the pattern of enhanced 3D 
affinity, enhanced cross-reactivity. Exceptions are the αD26Y/βL98W TCR, due to 
supraphysiological high affinity, and the αD26Y/αY50V/βL98W TCR being comparable 
to the WT TCR in terms of cross-reactivity but not 3D affinity. The ranking of off-target 
tumor cross-reactivity in Figure 45B is based up the results calculated in Figure 41. 
DMF5 TCR ranking in regards to the cross-reactivity against the off-target tumors lines 
is different than with the MART-1 homologs, but directly aligns with the measured 2D 
affinity. As mentioned previously, 2D affinity measurements have been better correlated 
with T cell function. An example of this has also been demonstrated in the clinic, where 
the 2D affinity of TCR transduced T cells correlated to clinical outcomes in a small 
sample set of patients [290]. Specifically in three patients, patient one exhibited no 
clinical response to treatment and their TCR transduced T cells exhibited the lowest 2D 
affinity measurement against the targeted ligand [290].   
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Figure 45. Cross-Reactivity Rankings of TCRs in Relation to 3D and 2D Affinity. 
(a) Ranking of TCRs in regards to cross-reactivity against the MART-1 homologs 
(based on Table 7). 3D affinity measurements are shown above the TCRs, respectively. 
(b) Ranking of TCRs in regards to cross-reactivity against the tumor panel (based on 
Figure 41). 2D affinity measurements are shown above the TCRs, respectively 
 
Moreover, the other two patients exhibited clinical and biological responses and their 
TCR transduced T cells exhibited a statistically significant increase in their 2D affinity 
measurements [290]. These results indicated that donor variability is a factor in 2D 
affinity and can have implications in clinical outcomes. Overall, observing general 
reactivity against only one peptide, specifically with sequence homology to the targeted 
peptide, better correlated to 3D affinity. Conversely, observing reactivity in the presence 
of numerous peptides better correlated to 2D affinity and can be associated with 
functional specificity.  
Potential Tumor Targets 
 Based on our data, and what we know about T cell cross-reactivity, we believe 
the mutated DMF5 TCRs were capable of recognizing multiple different peptides that fit 
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an antigenic structure that is tolerated by the TCRs. First, we can eliminate TCR chain 
mispairing as the sole cause because Jurkat 76 cells expressing the WT and modified 
TCRs still recognized some of the tumors (data not shown – experiments completed by 
our collaborators in the Baker lab, results obtained through personal communication). 
Jurkat 76 cells lack an endogenous TCR and thus, any expressed TCR is the properly 
paired introduced TCR. Although TCR chain mispairing is always a potential cause of 
autoimmunity, these results demonstrated that cross-reactivity was not exclusively due 
to mispairing.  
In the combinatorial peptide library data, the abundant recognition of nearly all 
the pools by the αD26Y/βL98W TCR supports the theory of plausible recognition of 
multiple peptides. Additionally, our results from the alanine scan also provided insight 
into the potential number of targets the mutated DMF5 TCRs could recognize (Figure 
16). As mentioned previously, Titin was identified as the cross-reactive peptide with the 
affinity enhanced MAGE-A3 TCR. This was identified by fixing residues important for 
recognition based on an alanine scan, and searching for homologous epitopes in 
proteins [299]. When we performed a similar search based upon our alanine scan data, 
the results are far more extensive. For instance, with the αD26Y TCR, positions 4 and 6 
in the MART-1 9mer peptide appeared important for recognition of the MART-1 9mer 
(Figure 16). When we fixed position 4 and position 6 and used the ScanProsite tool to 
search the UniProtKB/Swiss database for XXXIXIXXX motifs in proteins in Homo 
sapiens (including splice variants), 6,391 matches are found. When we performed the 
same search for the MAGE-A3 motif based upon the authors alanine scan results 
(EXDPIXXXY), only 17 matches were found in Homo sapiens (including splice variants) 
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[299]. Albiet, this does not mean all 6,391 epitopes are presented on HLA-A2. Recent 
advancements in modeling, bioinformatics, and epitope-mapping have been made in 
order to better predict epitope presentation by MHC class I and MHC class II [535-542]. 
Nonetheless, this drastic difference illuminates the vast potential of targets that these 
modified DMF5 TCRs are recognizing. Furthermore, this does not even begin to 
address the potential recognized epitopes that do not follow MART-1 sequence 
homology. In summary, our results indicated mutations in the DMF5 TCR allowed the 
TCRs to be more permissive in their recognition and allowed for non-specific recognition 
of multiple different peptides.  
 There are a few methods that could be utilized to determine the recognized 
targets on the off-target tumor cells lines. One potential approach to determine the 
recognized targets would be acid eluting off the peptides from the HLA-A2 complexes 
[543-546]. Following elution, peptide extracts would be fractionated by reverse phased 
high-performance liquid chromatography (HPLC). Cytotoxicity assays would be 
performed with T2 cells loaded with peptide fractions and effector T cells. Further 
fractionation of reactive peaks would narrow down the number of potential peptides. 
Lastly, mass spectrometry would determine the sequence of peptides, and all potential 
peptides would be made and put in final functional assays. This approach has been 
utilized to identify an antigenic peptide (YXEPGPVTA) for melanoma specific T cell 
clones [546]. A second approach is using combinatorial peptide libraries in a positional 
scanning format [547-550]. A scoring matrix is generated based upon lysis of the 
specific amino acids at each residue. This matrix is then implemented with protein 
databases to predict stimulatory scores for epitopes present in proteins. This approach 
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was utilized to predict off-target reactivity of the 7B5 TCR (HLA-A2 restricted, 
recognizes the HA-2 peptide), and even identified a cross-reactive peptide. Notably, this 
study demonstrated that results from their alanine scan assay were insufficient for 
identifying this cross-reactive peptide [442]. However, these approaches might be 
impractical for identifying the recognized peptides on the off-target tumor cells in this 
study. We have already partially completed the combinatorial peptide library approach, 
and results indicated recognition of nearly all the pools by the WT and αD26Y/βL98W 
TCR, suggesting the extensive number of potential targets with a wide variety of 
potential sequences (Figure 44). Nonetheless, when used clinically, the DMF5 WT TCR 
did not cause adverse events due to off-target autoimmunity [332]. These results 
indicated that despite observation of off-target cross-reactivity in vitro, it was not 
observed in a human. Therefore, there could be a “cut off” point or range in which 
autoimmunity might occur in vivo. Based on what we know about donor variability, this 
cut off is not likely to be highly definitive. Furthermore, it is plausible that the threshold 
for causing off-target autoimmunity in vivo is TCR and ligand dependent. Albeit, the 
peptide elution or combinatorial peptide library approaches could be more practical for 
identifying the off-target peptides for the αD26Y/αY50A/βL98W TCR. Results from the 
combinatorial peptide library with this TCR, indicated far fewer peptide pools that 
elicited discernable reactivity, and thus, could be parsed apart more easily. Taken 
together, our results suggested the number of peptides recognized on the off-target 
tumor cells was potentially very extensive for the highly cross-reactive DMF5 TCRs 
(αD26Y TCR, αD26Y/βL98W TCR, and αD26Y/αY50V/βL98W TCR) but limited for the 
αD26Y/αY50A/βL98W TCR. 
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Implications for Future Use of Structure-Guided Design Strategy 
 The results from our studies have critical implications for future utilization of this 
structure-guided design strategy for manipulating TCR specificity. Some of our findings 
were expected. However, our results do not undervalue the structure-guided design 
strategy and its implications for future use. Importantly, our results provided critical 
insight for the field in terms of modifying TCRs and addressing cross-reactivity. 
We initially thought the DMF5 TCR/MART-1 peptide model would be useful to 
study the cross-reactive properties of TCRs. This was based upon the reports of high 
frequencies of MART-1 reactive T cells in the blood of cancer patients and healthy 
donors [323, 327, 551], and the evidence that MART-1 “like” epitopes recurrently 
appear among self and non-self-proteins [327]. However, the inherent nature of this 
TCR and its ligand, could have exacerbated some of the findings compared to if a 
different TCR and ligand were used. For example, MART-1 9mer is extremely 
hydrophobic, being all hydrophobic except for the neutral threonine at position 8. Since 
immunogenicity and hydrophobicity have been directly correlated [68], it makes sense 
the DMF5 TCR is cross-reactive. However, recognition of hydrophobic peptides is 
already preferred by TCRs, compared to more polar peptides, because there is less 
defined geometry for the CDR loops to match [72]. Herein, we made peptide enhancing 
mutations to a TCR that was already very permissive in terms of cross-reactivity of 
sequence homologous and non-sequence homologous epitopes. One of the main 
challenges associated with the MART-1 peptide for our approach was that there are no 
unique residues to target that could be considered relatively MART-1 “specific”. 
Therefore, the combination with negative, MHC weakening, TCR mutation did not offset 
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the positive, MART-1 targeting, TCR mutation enough to prevent cross-reactivity 
against all potential targets. That being said, this positive and negative design strategy 
could be implemented in other TCRs and perceivably yield different results. This 
concept of the MART-1 9mer being very hydrophobic and “featureless” relates to the 
commonly described features of a “vanilla” peptide or a “spicy” peptide [552]. Spicy 
peptides are described as having a prominent feature exposed to the TCR, whereas 
vanilla peptides are described as being featureless. Thus, others have hypothesized 
that TCRs that recognize a spicy peptide should be less cross-reactive because most 
other peptides would lack the defining peptide feature. Conversely, TCRs that target a 
vanilla peptide should be more cross-reactive because peptide features are more 
shared amongst other peptides [552]. Our studies with the DMF5 TCR and other studies 
with MART-1 reactive T cells exemplify this hypothesis [327, 350]. Consequently, in 
TCRs that recognize less hydrophobic peptides, there could be more distinct peptide 
residues to target for positive TCR mutation. Thus, introduction of a TCR mutation that 
enhances binding to that distinct peptide feature, could further enhance antigen 
specificity. Subsequent addition of a negative, MHC weakening, TCR mutation, could 
then reduce any remaining potential off-target cross-reactivity. Every TCR/pMHC ligand 
will be different, but these results outlined preliminary stipulations to bear in mind when 
mutating TCRs and altering their functional specificities. In summary, it is plausible that 
this structure-guided strategy would yield different results with another TCR and ligand. 
 Our results also highlight the importance, but difficulty, in the introduction of a 
peptide targeting TCR mutation that only impacts on binding with the peptide and not 
the MHC. Specifically, our results indicated that the αD26Y mutation was most likely 
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driving off-target cross-reactivity and the structural effect of this mutation was too 
impactful to be completely countered balanced by the negative mutation. This was 
demonstrated in the both the first and the second round of DMF5 TCR mutations, where 
every mutant DMF5 TCR containing the αD26Y TCR mutation enhanced recognition of 
the off-target tumors, compared to mutant DMF5 TCRs that did not contain the αD26Y 
TCR mutation. As mentioned previously, we cannot discern the impact of the MART-1 
enhancement of this mutation versus the MHC enhancement, but it could be imperative 
for future mutations to avoid also enhancing binding with the MHC molecule. 
Unfortunately, this is easier said than done, as TCR contact with the MHC accounts for 
75-80% of the TCR/pMHC interaction, and the peptide and MHC are closely packed 
together [71, 349]. Furthermore, the impact of binding enhancement with the MHC could 
be TCR and ligand dependent. Specifically, it is possible that the removal of the charge 
repulsion between the HLA-A2 and the DMF5 TCR with the αD26Y TCR mutation was 
important for the observed enhancement in cross-reactivity. Conversely, it is possible 
that the introduction of a favorable interaction between the TCR and MHC in a different 
model would have a minor effect on cross-reactivity. A future strategy for this DMF5 
TCR would be remove the αD26Y mutation from the αD26Y/αY50A/βL98W TCR and 
replace it with possibly another CDR3 region mutation that targets the core of the 
peptide. Overall, the goal of the positive design strategy was to introduce mutations that 
only impact peptide binding. Furthermore, this can be a difficult task, and implications 
are likely to be TCR and ligand dependent. 
It was very interesting that just one or two mutations in the DMF5 TCR (αD26Y or 
αD26Y/βL98W) frequently elicited recognition of the off-target HLA-A2+ tumors in our 
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panel. We believe that in the proper system, these TCRs could potentially be 
therapeutic. This system would be an off the shelf reagent of TCR transduced 
allogeneic T cells for intra-tumoral injection in an HLA-A2+ tumor (E. Fleming-Trujillo, et. 
al. unpublished). First, the TCR transduced T cells have to be allogeneic because, 
activated TCR transduced HLA-A2+ T cells commit fratricide. Secondly, it would have to 
be an intra-tumoral injection because it could be detrimental to systemically inject 
allogenic T cells expressing a highly cross-reactive TCR. The TCR transduced 
allogeneic T cells could also be irradiated to limit any potential damage. Furthermore, 
intra-tumoral injection of irradiated TCR transduced allogeneic T cells has already been 
demonstrated as feasible and safe, with the potential to elicit regression of untreated 
tumors [331]. In summary, we believe the off-target cross-reactive properties of the 
αD26Y and αD26Y/βL98W TCRs could be widely therapeutic as an off the shelf reagent 
for treatment of HLA-A2+ tumors, if implemented in the proper and safe system. 
The results of this dissertation highlight the need for the advancement in 
modeling and prediction tools for protein interactions, specifically in the area of cross-
reactivity. We demonstrated that when examining potential cross-reactivity, sequence 
homology searches are not always adequate, and furthermore, our panel of tumors did 
not encompass every tissue. Addressing cross-reactivity in murine models is also not 
completely sufficient, due to lack of complete homology between the mouse and 
human. At this point, there is no better model than a human to fully examine potential 
cross-reactivity, and even then, results are not identical. Immunogenicity predictions 
tools such as the Immune Epitope Database, are a step in the right direction to better 
predict and characterize B cell and T cell epitopes involved in disease, autoimmunity, 
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allergy, and transplant [541]. In summary, the advancements in modifying TCRs and 
their antigen specificities should coexist with the advancements in modeling and 
prediction tools. 
In vivo Future Directions 
 Our data demonstrated some of the challenges associated with using xenograft 
in vivo models for our studies. Our results suggested that human TCR transduced T 
cells had difficulty trafficking to the site of the tumor, most likely due to the 
immunodeficient nature of the NSG mouse model and the lack of human environment. 
Aside from what was examined in these studies, there are other methods of trying to 
enhance T cell persistence and trafficking to the tumor that could be explored in the 
future. For example, IL-7 is important for T cell survival and differentiation. IL-7 has 
been shown to enhance adoptive T cell therapy, and more specifically, the combination 
of IL-7 and IL-15 [460, 553-556]. Thus, it would be of interest to determine how IL-7 or 
how the combination of IL-7, IL-15, and IL-2 affect the persistence and anti-tumor 
activity of the introduced TCR transduced T cells. In our engraftment model, engrafted T 
cells did persist, but did not enhance the anti-tumor activity of the introduced TCR 
transduced T cells. It is plausible that engraftment of whole hematopoietic stem cells 
would better recapitulate a human immune system than engrafted PBMCs due to the 
multiple hematopoietic lineages. Therefore, they might better support to persistence of 
the introduced T cells [385, 557-561]. Lastly, another option would be to murinize the 
TCR constant regions of DMF5 TCRs and transduce murine T cells. These TCR 
transduced murine T cells could be used in immunocompetent mice for analysis of anti-
tumor activity. In conclusion, different cytokine support, humanized NSG mice, or 
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switching mouse models to immunocompetent mice are a few examples of alternative 
strategies to enhance the in vivo anti-tumor efficacy and analysis of TCR transduced T 
cells in these studies. 
Concluding Remarks 
In these studies we developed and implemented a novel structure-guided 
approach to enhance antigen specificity and reduce off-target cross-reactivity. We 
sought to determine how structure-guided mutations in the DMF5 TCR altered tumor 
lysis, polyfunctional T cell responses, on-target specificity, and recognition of processed 
antigens. When measuring polyfunctional T cell responses against a panel of MART-1 
homologs, the structure guided approach appeared to be promising, with T cells 
expressing the αD26Y/αY50A/βL98W TCR exhibiting reduced percentages of MART-1 
homolog reactive T cells compared to T cells expressing the WT TCR. However, when 
T cell responses were measured against processed antigens on a variety of different 
tissues, large off-target cross-reactivity was observed. Our results demonstrate that 
sequence homology is not the sole factor in cross-reactivity, and that 3D affinity against 
the “cognate” antigen is not always correlative to broad cross-reactivity. Furthermore, T 
cell responses vary due to biophysical properties/kinetics of the TCR/pMHC interaction 
and how structural changes in the interface affect these properties and consequent 
downstream T cell function is not feasibly predictable. Despite this, our structure-based 
designed strategy could be utilized in the future, as it is more meticulous and specific 
than random mutation through yeast or phage display. It important to understand how 
alterations in the TCR/pMHC interface can affect functional T cell phenotypes to 
maximize the efficacy and safety of TCRs to be used in gene modified T cells in 
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adoptive cell transfer. In conclusion, when altering TCRs for therapeutic use, safety 
should be of the utmost importance and herein, we emphasize the importance of 
rigorous preclinical testing of modified TCRs and the need for advancement in 
modeling/prediction tools for protein interactions. 
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Figure 46. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on 
Polyfunctional Responses against MART-1 (Donor One). The data indicate reactivity 
against T2 cells loaded with the MART-1 9mer peptide in donor one, experiment two. 
“Cool plots” were generated to include any functional phenotype present over 0.1%. In 
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates 
negative for the marker. As described in Chapter Two, reactivity is defined after 
background subtraction and specifically, any phenotype expressed by over 0.1% of 
TCR transduced T cells (subtraction of the background immunofluorescence observed 
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool 
plot” correlates to the scale on the right. An “X” indicates no T cells were positive 
(<0.1% after background subtraction) for given functional phenotype. The color white for 
a given functional phenotype indicates a percentage less than 0.2%.  
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Figure 47. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on 
Polyfunctional Responses against MART-1 (Donor Two). The data indicate reactivity 
against T2 cells loaded with the MART-1 9mer peptide in donor two, experiment two. 
“Cool plots” were generated to include any functional phenotype present over 0.1%. In 
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates 
negative for the marker. As described in Chapter Two, reactivity is defined after 
background subtraction and specifically, any phenotype expressed by over 0.1% of 
TCR transduced T cells (subtraction of the background immunofluorescence observed 
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool 
plot” correlates to the scale on the right. An “X” indicates no T cells were positive 
(<0.1% after background subtraction) for given functional phenotype. The color white for 
a given functional phenotype indicates a percentage less than 0.2%.  
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Figure 48. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on 
Polyfunctional Responses against MART-1 (Donor Three). The data indicate 
reactivity against T2 cells loaded with the MART-1 9mer peptide in donor three, 
experiment two. “Cool plots” were generated to include any functional phenotype 
present over 0.1%. In the functional phenotypes listed, “+” indicates positive for the 
marker and “-“ indicates negative for the marker. As described in Chapter Two, 
reactivity is defined after background subtraction and specifically, any phenotype 
expressed by over 0.1% of TCR transduced T cells (subtraction of the background 
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide). 
The color depicted in the “cool plot” correlates to the scale on the right. An “X” indicates 
no T cells were positive (<0.1% after background subtraction) for given functional 
phenotype. The color white for a given functional phenotype indicates a percentage less 
than 0.5%.  
  
[259] 
 
 
Figure 49. Impact of DMF5 Mutations in TCR Transduced CD8+ T cells on 
Polyfunctional Responses against MART-1 (Donor One). The data indicate reactivity 
against T2 cells loaded with the MART-1 9mer peptide in donor one, experiment two. 
“Cool plots” were generated to include any functional phenotype present over 0.1%. In 
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates 
negative for the marker. As described in Chapter Two, reactivity is defined after 
background subtraction and specifically, any phenotype expressed by over 0.1% of 
TCR transduced T cells (subtraction of the background immunofluorescence observed 
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool 
plot” correlates to the scale on the right. An “X” indicates no T cells were positive 
(<0.1% after background subtraction) for given functional phenotype. The color white for 
a given functional phenotype indicates a percentage less than 0.5%. Five prominent 
phenotypes are highlighted with red boxes.  
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Figure 50. Impact of DMF5 Mutations in TCR Transduced CD8+ T cells on 
Polyfunctional Responses against MART-1 (Donor Two). The data indicate reactivity 
against T2 cells loaded with the MART-1 9mer peptide in donor two, experiment two. 
“Cool plots” were generated to include any functional phenotype present over 0.1%. In 
the functional phenotypes listed, “+” indicates the positive for marker and “-“ indicates 
negative for the marker. As described in Chapter Two, reactivity is defined after 
background subtraction and specifically, any phenotype expressed by over 0.1% of 
TCR transduced T cells (subtraction of the background immunofluorescence observed 
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool 
plot” correlates to the scale on the right. An “X” indicates no T cells were positive 
(<0.1% after background subtraction) for given functional phenotype. The color white for 
a given functional phenotype indicates a percentage less than 0.5%. Five prominent 
phenotypes are highlighted with red boxes.  
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Figure 51. Impact of DMF5 Mutations in TCR Transduced CD8+ T cells on 
Polyfunctional Responses against MART-1 (Donor Three). The data indicate 
reactivity against T2 cells loaded with the MART-1 9mer peptide in donor three, 
experiment two. “Cool plots” were generated to include any functional phenotype 
present over 0.1%. In the functional phenotypes listed, “+” indicates positive for the 
marker and “-“ indicates negative for the marker. As described in Chapter Two, 
reactivity is defined after background subtraction and specifically, any phenotype 
expressed by over 0.1% of TCR transduced T cells (subtraction of the background 
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide). 
The color depicted in the “cool plot” correlates to the scale on the right. An “X” indicates 
no T cells were positive (<0.1% after background subtraction) for given functional 
phenotype. The color white for a given functional phenotype indicates a percentage less 
than 0.5%. Five prominent phenotypes are highlighted with red boxes.  
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Figure 52. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue 
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were 
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release 
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all 
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed. 
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive 
TCRs compared to the WT TCR. One representative experiment and donor is shown. 
Reactivity is defined as a T cell culture that secretes twice background, or twice the 
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor 
1, experiment 2. 
 
[263] 
 
 
 
Figure 53. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue 
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were 
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release 
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all 
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed. 
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive 
TCRs compared to the WT TCR. One representative experiment and donor is shown. 
Reactivity is defined as a T cell culture that secretes twice background, or twice the 
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor 
2, experiment 1. 
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Figure 54. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue 
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were 
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release 
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all 
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed. 
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive 
TCRs compared to the WT TCR. One representative experiment and donor is shown. 
Reactivity is defined as a T cell culture that secretes twice background, or twice the 
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor 
2, experiment 2. 
[265] 
 
 
 
Figure 55. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue 
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were 
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release 
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all 
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed. 
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive 
TCRs compared to the WT TCR. One representative experiment and donor is shown. 
Reactivity is defined as a T cell culture that secretes twice background, or twice the 
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor 
3, experiment 1. 
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Figure 56. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue 
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were 
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release 
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all 
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed. 
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive 
TCRs compared to the WT TCR. One representative experiment and donor is shown. 
Reactivity is defined as a T cell culture that secretes twice background, or twice the 
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor 
3, experiment 2. 
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Figure 57. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue 
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were 
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release 
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all 
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed. 
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive 
TCRs compared to the WT TCR. One representative experiment and donor is shown. 
Reactivity is defined as a T cell culture that secretes twice background, or twice the 
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor 
4, experiment 1. 
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Figure 58. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue 
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were 
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release 
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all 
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed. 
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive 
TCRs compared to the WT TCR. One representative experiment and donor is shown. 
Reactivity is defined as a T cell culture that secretes twice background, or twice the 
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor 
4, experiment 2. 
[269] 
 
 
Figure 59. Impact of Second Round of DMF5 Mutations on Cross-Reactivity Using 
Multi-Tissue Tumor Panel. Human T cells expressing either WT or mutant DMF5 TCR 
were stimulated with tumor cell lines for 18 hours (see Table 2 – Chapter Two, 
Methods). IFN-γ release was measured by ELISA in triplicate wells Reactivity is defined 
as a T cell culture that secretes twice background, or twice the amount of IFN-γ 
produced as against MEL 624-28, and greater than 200 pg/mL. 
  
[270] 
 
 
Figure 60. Engraftment of PBMCs in NSG A2+ Mice. (a) Schematic of experimental 
design is depicted. (b) Persistence of human CD3+ T cells in the blood of non-engrafted 
and engrafted mice on day 72 post engraftment of human PBMCs. Cells were 
immunofluorescently labeled with a human anti-CD3 mAb. Each group consisted of 3 
mice. One representative mouse per group is shown. 
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Figure 61. Effect of Engraftment on Therapeutic Efficacy of TCR Transduced T 
cell Treatment. (a) Schematic of experimental design is depicted. Mice were engrafted 
with PBMC on day -7 via retro-orbital injection. Mice were tumor challenged on day 0 
with MEL 624 tumor cells. Mice were treated on day 17 with untransduced, WT DMF5 
TCR transduced, αD26Y TCR, or αD26Y/αY50A/βL98W TCR T cells via retro-orbital 
injection. (b) Tumor growth of MEL 624. N = 3 mice/group. Data represent the mean + 
standard deviation.  
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Figure 62. CD34 Expression Prior and Post in Vivo Injection. (a) Human 
untransduced, WT TCR expressing, αD26Y TCR, and αD26Y/αY50A/βL98W TCR 
expressing T cells were labeled with an anti-CD34 mAb 12 days after REP and 1 day 
prior to in vivo injection. (b) Persistence of human CD3+CD34+ TCR transduced T cells 
in the blood of treated and untreated mice on day 13 post therapeutic TCR transduced 
T cell injection. Cells were immunofluorescently labeled with human anti-CD3 and anti-
CD34 mAbs. Each group consisted of 3 mice. One representative mouse per group is 
shown. 
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Figure 63. Effect of Cytokine Support on Therapeutic Efficacy of TCR Transduced 
T cell Treatment. (a) Schematic of experimental design is depicted. Mice were tumor 
challenged on day 0 with MEL 624 tumor cells. On day 17, mice were treated with 
untransduced or WT DMF5 TCR transduced T cells via retro-orbital injection. Beginning 
on day 17, cytokine treatment groups of mice were treated with 2.5 μg rhIL-15 every 3 
days or 60,000 IU rhIL-2 twice a day for four days, then every 3 days via intraperitoneal 
injection. (b) Tumor growth of MEL 624. N = 3 mice/group. Data represent the mean + 
standard deviation.  
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Figure 64. CD34 Expression Of Injected T Cells 10 Days Post In Vivo Injection. 
Persistence of human CD3+CD34+ TCR transduced T cells in the blood of mice treated 
with untransduced or WT TCR transduced T cells, with or without IL-2 or IL-15 cytokine 
support on day 10 post therapy. Cells were immunofluorescently labeled with human 
anti-CD3 and anti-CD34 mAbs. Each group consisted of 3 mice. One representative 
mouse per group is shown. 
  
[275] 
 
 
Figure 65. TCR Transduced T cells in the Tumor on Day 16 Post Treatment. On 
day 16 post treatment, tumors were harvested and processed from one mouse per 
group. Cells were immunofluorescently labeled with human anti-CD3 and anti-CD34 
mAbs. 
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Figure 66. TCR Transduced T cells In the Spleen on Day 16 Post Treatment. On 
day 16 post treatment, spleens were harvested and processed from one mouse per 
group. Cells were immunofluorescently labeled with human anti-CD3 and anti-CD34 
mAbs. 
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Figure 67. Effect of Anti-PD-1 on Therapeutic Efficacy of TCR Transduced T cell 
Treatment. (a) Schematic of experimental design is depicted. Mice were tumor 
challenged on day 0 with MEL 624 tumor cells. On day 17, mice were treated with 
untransduced or WT DMF5 TCR transduced T cells via retro-orbital injection. Beginning 
on day 17, anti-PD-1 groups of mice were treated with 0.25 mg of anti-PD-1 every 3 
days via intraperitoneal injection. (b) Tumor growth of MEL 624. N = 3 mice/group. Data 
represent the mean + standard deviation. 
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Figure 68. Schematic Of In Vivo CTL Assay. On day 0, PBS or effector T cells were 
injected via retro-orbital route. On day 1, 6x106 MART-1 9mer HLA-A2+ PBMCs labeled 
with a high concentration of CFSE and 6x106 HLA-A2+ PBMCs labeled with a low 
concentration of CFSE were injected via retro-orbital route. On day 3, spleens were 
harvested and processed and analyzed via flow cytometry for CFSE cells.  
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Figure 69. Example of CFSE Cells in the Spleen of PBS and WT DMF5 TCR 
Transduced T cell Treated Mice. Splenocytes from each group were analyzed via flow 
cytometry. Splenocytes were first gated on HLA-A2+ cells to differentiate the target cells 
from any murine splenocytes. Cells were then gates on SSC and CFSE. Depicted 
above is an example of CFSE low and high cells in a PBS treated mouse and CFSE low 
and high cells in a WT DMF5 TCR transduced T cell treated mouse. 
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Figure 70. MART-1 Specific Lysis by WT DMF5 TCR Transduced T Cells. One day 
post PBS or WT DMF5 TCR transduced T cell treatment, mice were treated with 6x106 
MART-1 pulsed [0.5 μM] and 6x106 [5 μM] CFSE labeled HLA-A2+ PBMCs. Two days 
after injection of CFSE labeled target cells, spleens were harvested and processed. 
Proportions of CFSE labeled cells in the spleen were analyzed via flow cytometry. Data 
represent the mean + the standard error of the mean. N = 5 mice/group. 
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